Roles O O
of O O
fetal O O
G O O
gamma O O
- O O
globin O O
promoter O O
elements O O
and O O
the O O
adult O O
beta O O
- O O
globin O O
3 O O
' O O
enhancer O O
in O O
the O O
stage O O
- O O
specific O O
expression O O
of O O
globin O O
genes O O
. O O
Roles O O
of O O
fetal O O
G O O
gamma O O
- O O
globin O O
promoter O O
elements O O
and O O
the O O
adult O O
beta O O
- O O
globin O O
3 O O
' O O
enhancer O O
in O O
the O O
stage O O
- O O
specific O O
expression O O
of O O
globin O O
genes O O
. O O

The O O
human O O
fetal O O
G O O
gamma O O
- O O
globin O O
and O O
adult O O
beta O O
- O O
globin O O
genes O O
are O O
expressed O O
in O O
a O O
tissue O O
- O O
and O O
developmental O O
stage O O
- O O
specific O O
pattern O O
in O O
transgenic O O
mice O O
: O O
the O O
G O O
gamma O O
gene O O
in O O
embryonic B-CellLine B-CellLine
cells I-CellLine I-CellLine
and O O
the O O
beta O O
gene O O
in O O
fetal O O
and O O
adult O O
erythroid B-CellLine B-CellLine
cells I-CellLine I-CellLine
. O O

Several O O
of O O
the O O
cis O O
- O O
acting O O
DNA O O
sequences O O
thought O O
to O O
be O O
responsible O O
for O O
these O O
patterns O O
of O O
expression O O
are O O
located O O
5 O O
' O O
to O O
the O O
G O O
gamma O O
- O O
globin O O
gene O O
and O O
3 O O
' O O
to O O
the O O
beta O O
- O O
globin O O
gene O O
. O O

To O O
further O O
define O O
the O O
locations O O
and O O
functional O O
roles O O
of O O
these O O
elements O O
, O O
we O O
examined O O
the O O
effects O O
of O O
5 O O
' O O
truncations O O
on O O
the O O
expression O O
of O O
the O O
G O O
gamma O O
- O O
globin O O
gene O O
, O O
as O O
well O O
as O O
the O O
ability O O
of O O
G O O
gamma O O
- O O
globin O O
upstream O O
sequences O O
to O O
alter O O
the O O
developmental O O
regulation O O
of O O
a O O
beta O O
- O O
globin O O
gene O O
, O O
as O O
well O O
as O O
the O O
ability O O
of O O
G O O
gamma O O
- O O
globin O O
upstream O O
sequences O O
to O O
alter O O
the O O
developmental O O
regulation O O
of O O
a O O
beta O O
- O O
globin O O
gene O O
. O O

We O O
found O O
that O O
sequences O O
between O O
- O O
201 O O
and O O
- O O
136 O O
are O O
essential O O
for O O
expression O O
of O O
the O O
G O O
gamma O O
- O O
globin O O
gene O O
, O O
whereas O O
those O O
upstream O O
of O O
- O O
201 O O
have O O
little O O
effect O O
on O O
the O O
level O O
or O O
tissue O O
or O O
stage O O
specificity O O
of O O
G O O
gamma O O
- O O
globin O O
expression O O
. O O

The O O
G O O
gamma O O
- O O
globin O O
upstream O O
sequences O O
from O O
- O O
201 O O
to O O
- O O
136 O O
were O O
, O O
furthermore O O
, O O
capable O O
of O O
activating O O
a O O
linked O O
beta O O
- O O
globin O O
gene O O
in O O
embryonic B-CellLine O
blood I-CellLine B-CellLine
cells I-CellLine O
; O O
however O O
, O O
a O O
G O O
gamma O O
- O O
globin O O
fragment O O
from O O
- O O
383 O O
to O O
- O O
206 O O
was O O
similarly O O
active O O
in O O
this O O
assay O O
, O O
and O O
the O O
complete O O
fragment O O
from O O
- O O
383 O O
to O O
- O O
136 O O
was O O
considerably O O
more O O
active O O
than O O
either O O
of O O
the O O
smaller O O
fragments O O
, O O
suggesting O O
the O O
presence O O
of O O
multiple O O
cis O O
- O O
acting O O
elements O O
for O O
embryonic B-CellLine B-CellLine
blood I-CellLine I-CellLine
cells I-CellLine I-CellLine
. O O

Our O O
data O O
also O O
suggested O O
the O O
possibility O O
of O O
a O O
negative O O
regulatory O O
element O O
between O O
- O O
201 O O
and O O
- O O
136 O O
. O O

These O O
results O O
are O O
discussed O O
in O O
relation O O
to O O
several O O
DNA O O
elements O O
in O O
the O O
G O O
gamma O O
- O O
globin O O
upstream O O
region O O
, O O
which O O
have O O
been O O
shown O O
to O O
bind O O
nuclear O O
factors O O
in O O
erythroid B-CellLine B-CellLine
cells I-CellLine I-CellLine
. O O

Finally O O
, O O
we O O
observed O O
that O O
removal O O
of O O
the O O
beta O O
- O O
globin O O
3 O O
' O O
- O O
flanking O O
sequences O O
, O O
including O O
the O O
3 O O
' O O
enhancer O O
, O O
from O O
the O O
G O O
gamma O O
- O O
globin O O
upstream O O
- O O
beta O O
- O O
globin O O
hybrid O O
gene O O
resulted O O
in O O
a O O
25 O O
- O O
fold O O
reduction O O
in O O
expression O O
in O O
embryonic B-CellLine O
blood I-CellLine B-CellLine
cells I-CellLine O
. O O

This O O
suggests O O
that O O
the O O
beta O O
- O O
globin O O
3 O O
' O O
enhancer O O
is O O
potentially O O
active O O
at O O
the O O
embryonic O O
stage O O
and O O
thus O O
cannot O O
be O O
solely O O
responsible O O
for O O
the O O
fetal O O
or O O
adult O O
specificity O O
of O O
the O O
beta O O
- O O
globin O O
gene O O
. O O
This O O
suggests O O
that O O
the O O
beta O O
- O O
globin O O
3 O O
' O O
enhancer O O
is O O
potentially O O
active O O
at O O
the O O
embryonic O O
stage O O
and O O
thus O O
cannot O O
be O O
solely O O
responsible O O
for O O
the O O
fetal O O
or O O
adult O O
specificity O O
of O O
the O O
beta O O
- O O
globin O O
gene O O
. O O

A O O
complex O O
chromatin O O
landscape O O
revealed O O
by O O
patterns O O
of O O
nuclease O O
sensitivity O O
and O O
histone O O
modification O O
within O O
the O O
mouse O O
beta O O
- O O
globin O O
locus O O
. O O

In O O
order O O
to O O
create O O
an O O
extended O O
map O O
of O O
chromatin O O
features O O
within O O
a O O
mammalian O O
multigene O O
locus O O
, O O
we O O
have O O
determined O O
the O O
extent O O
of O O
nuclease O O
sensitivity O O
and O O
the O O
pattern O O
of O O
histone O O
modifications O O
associated O O
with O O
the O O
mouse O O
beta O O
- O O
globin O O
genes O O
in O O
adult O O
erythroid B-CellLine B-CellLine
tissue O I-CellLine
. O O

We O O
show O O
that O O
the O O
nuclease O O
- O O
sensitive O O
domain O O
encompasses O O
the O O
beta O O
- O O
globin O O
genes O O
along O O
with O O
several O O
flanking O O
olfactory O O
receptor O O
genes O O
that O O
are O O
inactive O O
in O O
erythroid B-CellLine B-CellLine
cells I-CellLine I-CellLine
. O O

We O O
describe O O
enhancer O O
- O O
blocking O O
or O O
boundary O O
elements O O
on O O
either O O
side O O
of O O
the O O
locus O O
that O O
are O O
bound O O
in O O
vivo O O
by O O
the O O
transcription O O
factor O O
CTCF O O
, O O
but O O
we O O
found O O
that O O
they O O
do O O
not O O
coincide O O
with O O
transitions O O
in O O
nuclease O O
sensitivity O O
flanking O O
the O O
locus O O
or O O
with O O
patterns O O
of O O
histone O O
modifications O O
within O O
it O O
. O O

In O O
addition O O
, O O
histone O O
hyperacetylation O O
and O O
dimethylation O O
of O O
histone O O
H3 O O
K4 O O
are O O
not O O
uniform O O
features O O
of O O
the O O
nuclease O O
- O O
sensitive O O
mouse O O
beta O O
- O O
globin O O
domain O O
but O O
rather O O
define O O
distinct O O
subdomains O O
within O O
it O O
. O O

Our O O
results O O
reveal O O
a O O
complex O O
chromatin O O
landscape O O
for O O
the O O
active O O
beta O O
- O O
globin O O
locus O O
and O O
illustrate O O
the O O
complexity O O
of O O
broad O O
structural O O
changes O O
that O O
accompany O O
gene O O
activation O O
. O O

Long O O
- O O
range O O
interactions O O
between O O
three O O
transcriptional O O
enhancers O O
, O O
active O O
Vkappa O O
gene O O
promoters O O
, O O
and O O
a O O
3 O O
' O O
boundary O O
sequence O O
spanning O O
46 O O
kilobases O O
. O O

The O O
mouse O O
immunoglobulin O O
kappa O O
( O O
Igkappa O O
) O O
gene O O
contains O O
an O O
intronic O O
enhancer O O
and O O
two O O
enhancers O O
downstream O O
of O O
its O O
transcription O O
unit O O
. O O

Using O O
chromosome O O
conformation O O
capture O O
technology O O
, O O
we O O
demonstrate O O
that O O
rearranged O O
and O O
actively O O
transcribed O O
Igkappa O O
alleles O O
in O O
MPC B-CellLine B-CellLine
- I-CellLine I-CellLine
11 I-CellLine I-CellLine
plasmacytoma I-CellLine I-CellLine
cells I-CellLine I-CellLine
exhibit O O
mutual O O
interactions O O
over O O
22 O O
kb O O
between O O
these O O
three O O
enhancers O O
and O O
Vkappa O O
gene O O
promoters O O
. O O

In O O
addition O O
, O O
the O O
5 O O
' O O
region O O
of O O
the O O
active O O
transcription O O
unit O O
exhibits O O
a O O
continuum O O
of O O
interactions O O
with O O
downstream O O
chromatin O O
segments O O
. O O

We O O
also O O
observe O O
interactions O O
between O O
Ei O O
and O O
E3 O O
' O O
with O O
3 O O
' O O
boundary O O
sequences O O
24 O O
kb O O
downstream O O
of O O
Ed O O
, O O
adjacent O O
to O O
a O O
neighboring O O
housekeeping O O
gene O O
. O O

Very O O
similar O O
interactions O O
between O O
the O O
enhancers O O
are O O
also O O
exhibited O O
by O O
normal O O
B B-CellLine B-CellLine
cells I-CellLine I-CellLine
isolated O O
from O O
mouse O O
splenic O O
tissue O O
but O O
not O O
by O O
germ O B-CellLine
line O I-CellLine
transcriptionally O O
inactive O O
alleles O O
of O O
T B-CellLine B-CellLine
cells I-CellLine I-CellLine
or O O
P815 B-CellLine B-CellLine
mastocytoma I-CellLine I-CellLine
cells I-CellLine I-CellLine
, O O
which O O
exhibit O O
a O O
seemingly O O
linear O O
chromatin O O
organization O O
. O O

These O O
results O O
fit O O
a O O
looping O O
mechanism O O
for O O
enhancer O O
function O O
like O O
in O O
the O O
beta O O
- O O
globin O O
locus O O
and O O
suggest O O
a O O
dynamic O O
modulation O O
of O O
the O O
spatial O O
organization O O
of O O
the O O
active O O
Igkappa O O
locus O O
. O O

Chromatin O O
immunoprecipitation O O
experiments O O
reveal O O
that O O
the O O
interacting O O
Igkappa O O
gene O O
cis O O
- O O
acting O O
sequences O O
are O O
associated O O
with O O
AP O O
- O O
4 O O
, O O
E47 O O
, O O
and O O
p65NF O O
- O O
kappaB O O
, O O
potential O O
protein O O
candidates O O
that O O
may O O
be O O
responsible O O
for O O
initiating O O
and O O
/ O O
or O O
maintaining O O
the O O
formation O O
of O O
these O O
higher O O
- O O
order O O
complexes O O
. O O

However O O
, O O
S107 B-CellLine B-CellLine
plasmacytoma I-CellLine I-CellLine
cells I-CellLine I-CellLine
that O O
lack O O
NF O O
- O O
kappaB O O
still O O
exhibit O O
mutual O O
interactions O O
between O O
the O O
Igkappa O O
gene O O
enhancers O O
. O O
However O O
, O O
S107 B-CellLine B-CellLine
plasmacytoma I-CellLine I-CellLine
cells I-CellLine I-CellLine
that O O
lack O O
NF O O
- O O
kappaB O O
still O O
exhibit O O
mutual O O
interactions O O
between O O
the O O
Igkappa O O
gene O O
enhancers O O
. O O

Beta O O
- O O
globin O O
intergenic O O
transcription O O
and O O
histone O O
acetylation O O
dependent O O
on O O
an O O
enhancer O O
. O O

Histone O O
acetyltransferases O O
are O O
associated O O
with O O
the O O
elongating O O
RNA O O
polymerase O O
II O O
( O O
Pol O O
II O O
) O O
complex O O
, O O
supporting O O
the O O
idea O O
that O O
histone O O
acetylation O O
and O O
transcription O O
are O O
intertwined O O
mechanistically O O
in O O
gene O O
coding O O
sequences O O
. O O

Here O O
, O O
we O O
studied O O
the O O
establishment O O
and O O
function O O
of O O
histone O O
acetylation O O
and O O
transcription O O
in O O
noncoding O O
sequences O O
by O O
using O O
a O O
model O O
locus O O
linking O O
the O O
beta O O
- O O
globin O O
HS2 O O
enhancer O O
and O O
the O O
embryonic O O
epsilon O O
- O O
globin O O
gene O O
in O O
chromatin O O
. O O
Here O O
, O O
we O O
studied O O
the O O
establishment O O
and O O
function O O
of O O
histone O O
acetylation O O
and O O
transcription O O
in O O
noncoding O O
sequences O O
by O O
using O O
a O O
model O O
locus O O
linking O O
the O O
beta O O
- O O
globin O O
HS2 O O
enhancer O O
and O O
the O O
embryonic O O
epsilon O O
- O O
globin O O
gene O O
in O O
chromatin O O
. O O

An O O
intact O O
HS2 O O
enhancer O O
that O O
recruits O O
RNA O O
Pol O O
II O O
is O O
required O O
for O O
intergenic O O
transcription O O
and O O
histone O O
H3 O O
acetylation O O
and O O
K4 O O
methylation O O
between O O
the O O
enhancer O O
and O O
target O O
gene O O
. O O

RNA O O
Pol O O
II O O
recruitment O O
to O O
the O O
target O O
gene O O
TATA O O
box O O
is O O
not O O
required O O
for O O
the O O
intergenic O O
transcription O O
or O O
intergenic O O
histone O O
modifications O O
, O O
strongly O O
implying O O
that O O
they O O
are O O
properties O O
conferred O O
by O O
the O O
enhancer O O
. O O

However O O
, O O
Pol O O
II O O
recruitment O O
at O O
HS2 O O
, O O
intergenic O O
transcription O O
, O O
and O O
intergenic O O
histone O O
modification O O
are O O
not O O
sufficient O O
for O O
transcription O O
or O O
modification O O
of O O
the O O
target O O
gene O O
: O O
these O O
changes O O
require O O
initiation O O
at O O
the O O
TATA O O
box O O
of O O
the O O
gene O O
. O O

The O O
results O O
suggest O O
that O O
intergenic O O
and O O
genic O O
transcription O O
complexes O O
are O O
independent O O
and O O
possibly O O
differ O O
from O O
one O O
another O O
. O O

X O O
- O O
linked O O
congenital O O
adrenal O O
hypoplasia O O
with O O
hypogonadotropic O O
hypogonadism O O
caused O O
by O O
an O O
inversion O O
disrupting O O
a O O
conserved O O
noncoding O O
element O O
upstream O O
of O O
the O O
NR0B1 O O
( O O
DAX1 O O
) O O
gene O O
. O O

CONTEXT O O
: O O
X O O
- O O
linked O O
congenital O O
adrenal O O
hypoplasia O O
with O O
hypogonadotropic O O
hypogonadism O O
( O O
AHCH O O
) O O
is O O
known O O
to O O
be O O
caused O O
by O O
coding O O
mutations O O
in O O
the O O
nuclear O O
receptor O O
subfamily O O
0 O O
, O O
group O O
B O O
, O O
member O O
1 O O
( O O
NR0B1 O O
) O O
gene O O
, O O
encoding O O
the O O
transcriptional O O
repressor O O
dosage O O
- O O
sensitive O O
sex O O
- O O
reversal O O
adrenal O O
hypoplasia O O
critical O O
region O O
on O O
the O O
X O O
chromosome O O
protein O O
1 O O
( O O
DAX1 O O
) O O
. O O

OBJECTIVE O O
/ O O
PATIENTS O O
: O O
Four O O
males O O
in O O
a O O
family O O
were O O
affected O O
by O O
AHCH O O
. O O

Our O O
aim O O
was O O
to O O
locate O O
the O O
genetic O O
cause O O
of O O
their O O
disease O O
, O O
knowing O O
that O O
they O O
had O O
no O O
mutation O O
in O O
the O O
obvious O O
candidate O O
gene O O
, O O
NR0B1 O O
. O O

DESIGN O O
: O O
Linkage O O
analysis O O
of O O
the O O
X O O
chromosome O O
and O O
mutational O O
screening O O
of O O
conserved O O
noncoding O O
regions O O
upstream O O
of O O
NR0B1 O O
were O O
performed O O
. O O

To O O
functionally O O
characterize O O
the O O
genetic O O
defect O O
, O O
studies O O
of O O
transcription O O
and O O
expression O O
of O O
DAX1 O O
and O O
steroidogenic O O
factor O O
1 O O
( O O
SF O O
- O O
1 O O
) O O
were O O
done O O
. O O

RESULTS O O
: O O
A O O
60 O O
Mb O O
inversion O O
on O O
the O O
X O O
chromosome O O
with O O
one O O
of O O
the O O
inversion O O
breakpoints O O
located O O
in O O
a O O
conserved O O
noncoding O O
region O O
4 O O
kb O O
upstream O O
of O O
NR0B1 O O
was O O
detected O O
. O O
RESULTS O O
: O O
A O O
60 O O
Mb O O
inversion O O
on O O
the O O
X O O
chromosome O O
with O O
one O O
of O O
the O O
inversion O O
breakpoints O O
located O O
in O O
a O O
conserved O O
noncoding O O
region O O
4 O O
kb O O
upstream O O
of O O
NR0B1 O O
was O O
detected O O
. O O

The O O
inversion O O
causes O O
relocation O O
of O O
a O O
putative O O
SF O O
- O O
1 O O
binding O O
site O O
implicated O O
in O O
murine O O
gonadal O O
development O O
. O O
The O O
inversion O O
causes O O
relocation O O
of O O
a O O
putative O O
SF O O
- O O
1 O O
binding O O
site O O
implicated O O
in O O
murine O O
gonadal O O
development O O
. O O

A O O
reporter O O
construct O O
lacking O O
this O O
enhancer O O
element O O
upstream O O
of O O
NR0B1 O O
was O O
unresponsive O O
to O O
SF O O
- O O
1 O O
transcriptional O O
activation O O
. O O
A O O
reporter O O
construct O O
lacking O O
this O O
enhancer O O
element O O
upstream O O
of O O
NR0B1 O O
was O O
unresponsive O O
to O O
SF O O
- O O
1 O O
transcriptional O O
activation O O
. O O

Immunohistochemistry O O
suggested O O
that O O
the O O
inversion O O
leads O O
to O O
SF O O
- O O
1 O O
silencing O O
in O O
the O O
patients O O
' O O
testes B-CellLine B-CellLine
both O O
in O O
childhood O O
and O O
in O O
adult O O
life O O
. O O

CONCLUSION O O
: O O
We O O
report O O
a O O
noncoding O O
mutation O O
causing O O
AHCH O O
, O O
an O O
inversion O O
resulting O O
in O O
a O O
phenotype O O
similar O O
to O O
what O O
is O O
caused O O
by O O
intragenic O O
NR0B1 O O
null O O
mutations O O
. O O

The O O
inversion O O
seems O O
to O O
disrupt O O
and O O
/ O O
or O O
relocate O O
regulatory O O
sites O O
crucial O O
in O O
DAX1 O O
expression O O
. O O

c O O
- O O
Maf O O
activates O O
the O O
promoter O O
and O O
enhancer O O
of O O
the O O
IL O O
- O O
21 O O
gene O O
, O O
and O O
TGF O O
- O O
beta O O
inhibits O O
c O O
- O O
Maf O O
- O O
induced O O
IL O O
- O O
21 O O
production O O
in O O
CD4 B-CellLine B-CellLine
+ I-CellLine I-CellLine
T I-CellLine I-CellLine
cells I-CellLine I-CellLine
. O O
c O O
- O O
Maf O O
activates O O
the O O
promoter O O
and O O
enhancer O O
of O O
the O O
IL O O
- O O
21 O O
gene O O
, O O
and O O
TGF O O
- O O
beta O O
inhibits O O
c O O
- O O
Maf O O
- O O
induced O O
IL O O
- O O
21 O O
production O O
in O O
CD4 B-CellLine B-CellLine
+ I-CellLine I-CellLine
T I-CellLine I-CellLine
cells I-CellLine I-CellLine
. O O

Previous O O
studies O O
have O O
shown O O
that O O
IL O O
- O O
6 O O
potently O O
induces O O
IL O O
- O O
21 O O
production O O
in O O
CD4 B-CellLine B-CellLine
( I-CellLine I-CellLine
+ I-CellLine I-CellLine
) I-CellLine I-CellLine
T I-CellLine I-CellLine
cells I-CellLine I-CellLine
, O O
whereas O O
TGF O O
- O O
beta O O
inhibits O O
IL O O
- O O
6 O O
- O O
induced O O
IL O O
- O O
21 O O
production O O
in O O
CD4 B-CellLine B-CellLine
( I-CellLine I-CellLine
+ I-CellLine I-CellLine
) I-CellLine I-CellLine
T I-CellLine I-CellLine
cells I-CellLine I-CellLine
. O O

In O O
this O O
study O O
, O O
we O O
addressed O O
the O O
mechanisms O O
underlying O O
the O O
transcriptional O O
regulation O O
of O O
IL O O
- O O
21 O O
production O O
in O O
CD4 B-CellLine B-CellLine
( I-CellLine I-CellLine
+ I-CellLine I-CellLine
) I-CellLine I-CellLine
T I-CellLine I-CellLine
cells I-CellLine I-CellLine
. O O

We O O
found O O
that O O
IL O O
- O O
6 O O
induced O O
c O O
- O O
Maf O O
expression O O
in O O
CD4 B-CellLine B-CellLine
( I-CellLine I-CellLine
+ I-CellLine I-CellLine
) I-CellLine I-CellLine
T I-CellLine I-CellLine
cells I-CellLine I-CellLine
and O O
that O O
the O O
enforced O O
expression O O
of O O
c O O
- O O
Maf O O
induced O O
IL O O
- O O
21 O O
production O O
in O O
CD4 B-CellLine B-CellLine
( I-CellLine I-CellLine
+ I-CellLine I-CellLine
) I-CellLine I-CellLine
T I-CellLine I-CellLine
cells I-CellLine I-CellLine
without O O
IL O O
- O O
6 O O
, O O
IL O O
- O O
4 O O
/ O O
STAT6 O O
signaling O O
, O O
or O O
an O O
autocrine O O
effect O O
of O O
IL O O
- O O
21 O O
. O O

Moreover O O
, O O
we O O
found O O
that O O
c O O
- O O
Maf O O
directly O O
bound O O
to O O
and O O
activated O O
IL O O
- O O
21P O O
and O O
the O O
CNS O O
- O O
2 O O
enhancer O O
through O O
MARE O O
sites O O
. O O

On O O
the O O
other O O
hand O O
, O O
we O O
also O O
found O O
that O O
although O O
TGF O O
- O O
beta O O
up O O
- O O
regulated O O
IL O O
- O O
6 O O
- O O
induced O O
c O O
- O O
Maf O O
expression O O
in O O
CD4 B-CellLine B-CellLine
( I-CellLine I-CellLine
+ I-CellLine I-CellLine
) I-CellLine I-CellLine
T I-CellLine I-CellLine
cells I-CellLine I-CellLine
, O O
TGF O O
- O O
beta O O
inhibited O O
c O O
- O O
Maf O O
- O O
induced O O
IL O O
- O O
21 O O
production O O
in O O
CD4 B-CellLine B-CellLine
( I-CellLine I-CellLine
+ I-CellLine I-CellLine
) I-CellLine I-CellLine
T I-CellLine I-CellLine
cells I-CellLine I-CellLine
. O O

Finally O O
, O O
we O O
found O O
that O O
Foxp3 O O
bound O O
to O O
IL O O
- O O
21P O O
and O O
the O O
CNS O O
- O O
2 O O
enhancer O O
and O O
inhibited O O
c O O
- O O
Maf O O
- O O
induced O O
IL O O
- O O
21 O O
production O O
modestly O O
but O O
significantly O O
in O O
CD4 B-CellLine B-CellLine
( I-CellLine I-CellLine
+ I-CellLine I-CellLine
) I-CellLine I-CellLine
T I-CellLine I-CellLine
cells I-CellLine I-CellLine
. O O

Taken O O
together O O
, O O
these O O
results O O
suggest O O
that O O
c O O
- O O
Maf O O
induces O O
IL O O
- O O
21 O O
production O O
directly O O
in O O
CD4 B-CellLine B-CellLine
( I-CellLine I-CellLine
+ I-CellLine I-CellLine
) I-CellLine I-CellLine
T I-CellLine I-CellLine
cells I-CellLine I-CellLine
by O O
activating O O
IL O O
- O O
21P O O
and O O
the O O
CNS O O
- O O
2 O O
enhancer O O
and O O
that O O
TGF O O
- O O
beta O O
suppresses O O
c O O
- O O
Maf O O
- O O
induced O O
IL O O
- O O
21 O O
production O O
in O O
CD4 B-CellLine B-CellLine
( I-CellLine I-CellLine
+ I-CellLine I-CellLine
) I-CellLine I-CellLine
T I-CellLine I-CellLine
cells I-CellLine I-CellLine
. O O

Nuclear O O
factor O O
kappaB O O
- O O
and O O
specificity O O
protein O O
1 O O
- O O
dependent O O
p53 O O
- O O
mediated O O
bi O O
- O O
directional O O
regulation O O
of O O
the O O
human O O
manganese O O
superoxide O O
dismutase O O
gene O O
. O O
Tumor O O
suppressor O O
p53 O O
is O O
known O O
to O O
activate O O
certain O O
sets O O
of O O
genes O O
while O O
suppressing O O
others O O
. O O

However O O
, O O
whether O O
p53 O O
can O O
both O O
activate O O
and O O
suppress O O
the O O
same O O
gene O O
is O O
unclear O O
. O O

To O O
address O O
this O O
question O O
, O O
concentration O O
- O O
dependent O O
p53 O O
effect O O
on O O
the O O
manganese O O
superoxide O O
dismutase O O
( O O
MnSOD O O
) O O
gene O O
was O O
investigated O O
. O O

By O O
transfecting O O
p53 O O
in O O
PC B-CellLine B-CellLine
- I-CellLine I-CellLine
3 I-CellLine I-CellLine
cells I-CellLine I-CellLine
, O O
we O O
demonstrate O O
that O O
low O O
concentrations O O
of O O
p53 O O
increase O O
while O O
high O O
concentrations O O
suppress O O
MnSOD O O
expression O O
. O O

The O O
physiological O O
relevance O O
of O O
this O O
effect O O
was O O
determined O O
in O O
vitro O O
and O O
in O O
vivo O O
using O O
combined O O
UVB O O
- O O
mediated O O
activation O O
and O O
small O O
interference O O
RNA O O
- O O
mediated O O
suppression O O
of O O
p53 O O
. O O

Results O O
were O O
consistent O O
with O O
the O O
bi O O
- O O
directional O O
effect O O
of O O
p53 O O
on O O
MnSOD O O
expression O O
. O O

MnSOD O O
- O O
promoter O O
/ O O
enhancer O O
analysis O O
demonstrates O O
that O O
p53 O O
is O O
suppressive O O
to O O
the O O
promoter O O
activity O O
regardless O O
of O O
the O O
presence O O
or O O
absence O O
of O O
putative O O
p53 O O
binding O O
sites O O
. O O
MnSOD O O
- O O
promoter O O
/ O O
enhancer O O
analysis O O
demonstrates O O
that O O
p53 O O
is O O
suppressive O O
to O O
the O O
promoter O O
activity O O
regardless O O
of O O
the O O
presence O O
or O O
absence O O
of O O
putative O O
p53 O O
binding O O
sites O O
. O O

However O O
, O O
a O O
low O O
level O O
of O O
p53 O O
increases O O
MnSOD O O
gene O O
transcription O O
in O O
the O O
presence O O
of O O
the O O
intronic O O
- O O
enhancer O O
element O O
, O O
and O O
this O O
effect O O
is O O
dependent O O
on O O
nuclear O O
- O O
factor O O
kappaB O O
( O O
NF O O
- O O
kappaB O O
) O O
binding O O
sites O O
. O O
However O O
, O O
a O O
low O O
level O O
of O O
p53 O O
increases O O
MnSOD O O
gene O O
transcription O O
in O O
the O O
presence O O
of O O
the O O
intronic O O
- O O
enhancer O O
element O O
, O O
and O O
this O O
effect O O
is O O
dependent O O
on O O
nuclear O O
- O O
factor O O
kappaB O O
( O O
NF O O
- O O
kappaB O O
) O O
binding O O
sites O O
. O O

Expression O O
of O O
p53 O O
enhances O O
nuclear O O
levels O O
of O O
p65 O O
with O O
corresponding O O
increase O O
in O O
the O O
DNA O O
- O O
binding O O
activity O O
of O O
NF O O
- O O
kappaB O O
as O O
detected O O
by O O
electrophoretic O O
mobility O O
shift O O
and O O
chromatin O O
immunoprecipitation O O
assays O O
. O O

Transfection O O
of O O
p65 O O
small O O
interference O O
RNA O O
reduces O O
the O O
positive O O
effect O O
of O O
p53 O O
on O O
MnSOD O O
gene O O
transcription O O
. O O

These O O
data O O
suggest O O
that O O
p65 O O
can O O
overcome O O
the O O
negative O O
effect O O
of O O
p53 O O
on O O
MnSOD O O
expression O O
. O O

However O O
, O O
when O O
the O O
level O O
of O O
p53 O O
was O O
further O O
increased O O
, O O
the O O
suppressive O O
effect O O
of O O
p53 O O
outweighed O O
the O O
positive O O
effect O O
of O O
p65 O O
and O O
led O O
to O O
the O O
suppression O O
of O O
MnSOD O O
gene O O
transcription O O
. O O

These O O
results O O
demonstrated O O
that O O
p53 O O
can O O
both O O
suppress O O
and O O
induce O O
MnSOD O O
expression O O
depending O O
on O O
the O O
balance O O
of O O
promoter O O
and O O
enhancer O O
binding O O
transcription O O
factors O O
. O O

Prep1 O O
controls O O
insulin O O
glucoregulatory O O
function O O
in O O
liver B-CellLine B-CellLine
by O O
transcriptional O O
targeting O O
of O O
SHP1 O O
tyrosine O O
phosphatase O O
. O O

OBJECTIVE O O
: O O
We O O
investigated O O
the O O
function O O
of O O
the O O
Prep1 O O
gene O O
in O O
insulin O O
- O O
dependent O O
glucose O O
homeostasis O O
in O O
liver B-CellLine B-CellLine
. O O

RESEARCH O O
DESIGN O O
AND O O
METHODS O O
: O O
Prep1 O O
action O O
on O O
insulin O O
glucoregulatory O O
function O O
has O O
been O O
analyzed O O
in O O
liver B-CellLine B-CellLine
of O O
Prep1 O O
- O O
hypomorphic O O
mice O O
( O O
Prep1 O O
( O O
i O O
/ O O
i O O
) O O
) O O
, O O
which O O
express O O
2 O O
- O O
3 O O
% O O
of O O
Prep1 O O
mRNA O O
. O O

RESULTS O O
: O O
Based O O
on O O
euglycemic O O
hyperinsulinemic O O
clamp O O
studies O O
and O O
measurement O O
of O O
glycogen O O
content O O
, O O
livers B-CellLine B-CellLine
from O O
Prep1 O O
( O O
i O O
/ O O
i O O
) O O
mice O O
feature O O
increased O O
sensitivity O O
to O O
insulin O O
. O O

Tyrosine O O
phosphorylation O O
of O O
both O O
insulin O O
receptor O O
( O O
IR O O
) O O
and O O
insulin O O
receptor O O
substrate O O
( O O
IRS O O
) O O
1 O O
/ O O
2 O O
was O O
significantly O O
enhanced O O
in O O
Prep1 O O
( O O
i O O
/ O O
i O O
) O O
livers B-CellLine B-CellLine
accompanied O O
by O O
a O O
specific O O
downregulation O O
of O O
the O O
SYP O O
and O O
SHP1 O O
tyrosine O O
phosphatases O O
. O O
Prep1 O O
overexpression O O
in O O
HepG2 B-CellLine B-CellLine
liver I-CellLine I-CellLine
cells I-CellLine I-CellLine
upregulated O O
SYP O O
and O O
SHP1 O O
and O O
inhibited O O
insulin O O
- O O
induced O O
IR O O
and O O
IRS1 O O
/ O O
2 O O
phosphorylation O O
and O O
was O O
accompanied O O
by O O
reduced O O
glycogen O O
content O O
. O O

Consistently O O
, O O
overexpression O O
of O O
the O O
Prep1 O O
partner O O
Pbx1 O O
, O O
but O O
not O O
of O O
p160MBP O O
, O O
mimicked O O
Prep1 O O
effects O O
on O O
tyrosine O O
phosphorylations O O
, O O
glycogen O O
content O O
, O O
and O O
on O O
SYP O O
and O O
SHP1 O O
expression O O
. O O

In O O
Prep1 O O
overexpressing O O
cells O O
, O O
antisense O O
silencing O O
of O O
SHP1 O O
, O O
but O O
not O O
that O O
of O O
SYP O O
, O O
rescued O O
insulin O O
- O O
dependent O O
IR O O
phosphorylation O O
and O O
glycogen O O
accumulation O O
. O O

Both O O
Prep1 O O
and O O
Pbx1 O O
bind O O
SHP1 O O
promoter O O
at O O
a O O
site O O
located O O
between O O
nucleotides O O
- O O
2 O O
, O O
113 O O
and O O
- O O
1 O O
, O O
778 O O
. O O
Both O O
Prep1 O O
and O O
Pbx1 O O
bind O O
SHP1 O O
promoter O O
at O O
a O O
site O O
located O O
between O O
nucleotides O O
- O O
2 O O
, O O
113 O O
and O O
- O O
1 O O
, O O
778 O O
. O O

This O O
fragment O O
features O O
enhancer O O
activity O O
and O O
induces O O
luciferase O O
function O O
by O O
7 O O
- O O
, O O
6 O O
- O O
, O O
and O O
30 O O
- O O
fold O O
, O O
respectively O O
, O O
in O O
response O O
to O O
Prep1 O O
, O O
Pbx1 O O
, O O
or O O
both O O
. O O

CONCLUSIONS O O
: O O
SHP1 O O
, O O
a O O
known O O
silencer O O
of O O
insulin O O
signal O O
, O O
is O O
a O O
transcriptional O O
target O O
of O O
Prep1 O O
. O O

In O O
liver B-CellLine B-CellLine
, O O
transcriptional O O
activation O O
of O O
SHP1 O O
gene O O
by O O
Prep1 O O
attenuates O O
insulin O O
signal O O
transduction O O
and O O
reduces O O
glucose O O
storage O O
. O O

Tbx6 O O
- O O
dependent O O
Sox2 O O
regulation O O
determines O O
neural O O
or O O
mesodermal O O
fate O O
in O O
axial B-CellLine B-CellLine
stem I-CellLine I-CellLine
cells I-CellLine I-CellLine
. O O

The O O
classical O O
view O O
of O O
neural B-CellLine B-CellLine
plate I-CellLine I-CellLine
development O O
held O O
that O O
it O O
arises O O
from O O
the O O
ectoderm B-CellLine B-CellLine
, O O
after O O
its O O
separation O O
from O O
the O O
mesodermal O B-CellLine
and O O
endodermal O B-CellLine
lineages O I-CellLine
. O O

However O O
, O O
recent O O
cell O O
- O O
lineage O O
- O O
tracing O O
experiments O O
indicate O O
that O O
the O O
caudal O B-CellLine
neural B-CellLine I-CellLine
plate I-CellLine I-CellLine
and O O
paraxial O B-CellLine
mesoderm B-CellLine I-CellLine
are O O
generated O O
from O O
common O O
bipotential O O
axial B-CellLine B-CellLine
stem I-CellLine I-CellLine
cells I-CellLine I-CellLine
originating O O
from O O
the O O
caudal O O
lateral O B-CellLine
epiblast B-CellLine I-CellLine
. O O
Tbx6 O O
null O O
mutant O O
mouse O O
embryos B-CellLine B-CellLine
which O O
produce O O
ectopic O O
neural B-CellLine B-CellLine
tubes I-CellLine I-CellLine
at O O
the O O
expense O O
of O O
paraxial O B-CellLine
mesoderm B-CellLine I-CellLine
must O O
provide O O
a O O
clue O O
to O O
the O O
regulatory O O
mechanism O O
underlying O O
this O O
neural O O
versus O O
mesodermal O O
fate O O
choice O O
. O O

Here O O
we O O
demonstrate O O
that O O
Tbx6 O O
- O O
dependent O O
regulation O O
of O O
Sox2 O O
determines O O
the O O
fate O O
of O O
axial B-CellLine B-CellLine
stem I-CellLine I-CellLine
cells I-CellLine I-CellLine
. O O

In O O
wild O O
- O O
type O O
embryos B-CellLine B-CellLine
, O O
enhancer O O
N1 O O
of O O
the O O
neural O O
primordial O O
gene O O
Sox2 O O
is O O
activated O O
in O O
the O O
caudal O O
lateral O B-CellLine
epiblast B-CellLine I-CellLine
, O O
and O O
the O O
cells O O
staying O O
in O O
the O O
superficial O B-CellLine
layer O I-CellLine
sustain O O
N1 O O
activity O O
and O O
activate O O
Sox2 O O
expression O O
in O O
the O O
neural B-CellLine B-CellLine
plate I-CellLine I-CellLine
. O O

In O O
contrast O O
, O O
the O O
cells O O
destined O O
to O O
become O O
mesoderm B-CellLine B-CellLine
activate O O
Tbx6 O O
and O O
turn O O
off O O
enhancer O O
N1 O O
before O O
migrating O O
into O O
the O O
paraxial O B-CellLine
mesoderm B-CellLine I-CellLine
compartment O O
. O O

In O O
Tbx6 O O
mutant O O
embryos B-CellLine B-CellLine
, O O
however O O
, O O
enhancer O O
N1 O O
activity O O
persists O O
in O O
the O O
paraxial O B-CellLine
mesoderm B-CellLine I-CellLine
compartment O O
, O O
eliciting O O
ectopic O O
Sox2 O O
activation O O
and O O
transforming O O
the O O
paraxial O B-CellLine
mesoderm B-CellLine I-CellLine
into O O
neural B-CellLine B-CellLine
tubes I-CellLine I-CellLine
. O O

An O O
enhancer O O
- O O
N1 O O
- O O
specific O O
deletion O O
mutation O O
introduced O O
into O O
Tbx6 O O
mutant O O
embryos B-CellLine B-CellLine
prevented O O
this O O
Sox2 O O
activation O O
in O O
the O O
mesodermal B-CellLine O
compartment I-CellLine O
and O O
subsequent O O
development O O
of O O
ectopic O O
neural B-CellLine B-CellLine
tubes I-CellLine I-CellLine
, O O
indicating O O
that O O
Tbx6 O O
regulates O O
Sox2 O O
via O O
enhancer O O
N1 O O
. O O
Tbx6 O O
- O O
dependent O O
repression O O
of O O
Wnt3a O O
in O O
the O O
paraxial O O
mesodermal B-CellLine O
compartment I-CellLine O
is O O
implicated O O
in O O
this O O
regulatory O O
process O O
. O O

Paraxial O B-CellLine
mesoderm B-CellLine I-CellLine
- O O
specific O O
misexpression O O
of O O
a O O
Sox2 O O
transgene O O
in O O
wild O O
- O O
type O O
embryos B-CellLine B-CellLine
resulted O O
in O O
ectopic O O
neural B-CellLine B-CellLine
tube I-CellLine I-CellLine
development O O
. O O

Thus O O
, O O
Tbx6 O O
represses O O
Sox2 O O
by O O
inactivating O O
enhancer O O
N1 O O
to O O
inhibit O O
neural O O
development O O
, O O
and O O
this O O
is O O
an O O
essential O O
step O O
for O O
the O O
specification O O
of O O
paraxial O B-CellLine
mesoderm B-CellLine I-CellLine
from O O
the O O
axial B-CellLine B-CellLine
stem I-CellLine I-CellLine
cells I-CellLine I-CellLine
. O O

TGF O O
- O O
beta1 O O
reduces O O
Wilms O O
' O O
tumor O O
suppressor O O
gene O O
expression O O
in O O
podocytes B-CellLine B-CellLine
. O O

BACKGROUND O O
: O O
Wilms O O
' O O
tumor O O
suppressor O O
gene O O
( O O
WT1 O O
) O O
is O O
essential O O
for O O
normal O O
podocyte B-CellLine B-CellLine
function O O
, O O
and O O
transforming O O
growth O O
factor O O
( O O
TGF O O
) O O
- O O
beta O O
contributes O O
to O O
focal O O
segmental O O
glomerulosclerosis O O
( O O
FSGS O O
) O O
. O O

We O O
aimed O O
to O O
address O O
whether O O
TGF O O
- O O
beta O O
affects O O
WT1 O O
expression O O
in O O
podocytes B-CellLine B-CellLine
. O O

METHODS O O
: O O
A O O
human O O
podocyte B-CellLine B-CellLine
cell I-CellLine I-CellLine
line I-CellLine I-CellLine
treated O O
with O O
TGF O O
- O O
beta1 O O
and O O
kidneys B-CellLine B-CellLine
in O O
Alb O O
/ O O
TGF O O
- O O
beta1 O O
- O O
transgenic O O
mice O O
were O O
analyzed O O
for O O
WT1 O O
expression O O
. O O

RESULTS O O
: O O
In O O
cultured O O
podocytes B-CellLine B-CellLine
, O O
TGF O O
- O O
beta1 O O
reduced O O
WT1 O O
protein O O
expression O O
determined O O
by O O
western O O
blotting O O
beginning O O
at O O
8 O O
h O O
and O O
decreased O O
WT1 O O
messenger O O
RNA O O
( O O
mRNA O O
) O O
expression O O
measured O O
by O O
quantitative O O
reverse O O
transcription O O
- O O
polymerase O O
chain O O
reaction O O
beginning O O
at O O
3 O O
h O O
. O O

Knockdown O O
of O O
Smad4 O O
by O O
small O O
hairpin O O
( O O
sh O O
) O O
RNA O O
partially O O
rescued O O
the O O
TGF O O
- O O
beta1 O O
- O O
induced O O
reduction O O
of O O
both O O
WT1 O O
protein O O
and O O
mRNA O O
expressions O O
in O O
the O O
cultured O O
podocytes B-CellLine B-CellLine
. O O
TGF O O
- O O
beta1 O O
did O O
not O O
alter O O
luciferase O O
activity O O
of O O
the O O
reporter O O
construct O O
for O O
a O O
human O O
WT1 O O
promoter O O
but O O
reduced O O
that O O
for O O
a O O
human O O
WT1 O O
5 O O
' O O
enhancer O O
construct O O
, O O
suggesting O O
that O O
TGF O O
- O O
beta1 O O
may O O
regulate O O
WT1 O O
expression O O
by O O
altering O O
the O O
5 O O
' O O
enhancer O O
activity O O
. O O
Knockdown O O
of O O
Smad4 O O
by O O
small O O
hairpin O O
( O O
sh O O
) O O
RNA O O
partially O O
rescued O O
the O O
TGF O O
- O O
beta1 O O
- O O
induced O O
reduction O O
of O O
both O O
WT1 O O
protein O O
and O O
mRNA O O
expressions O O
in O O
the O O
cultured O O
podocytes B-CellLine B-CellLine
. O O
TGF O O
- O O
beta1 O O
did O O
not O O
alter O O
luciferase O O
activity O O
of O O
the O O
reporter O O
construct O O
for O O
a O O
human O O
WT1 O O
promoter O O
but O O
reduced O O
that O O
for O O
a O O
human O O
WT1 O O
5 O O
' O O
enhancer O O
construct O O
, O O
suggesting O O
that O O
TGF O O
- O O
beta1 O O
may O O
regulate O O
WT1 O O
expression O O
by O O
altering O O
the O O
5 O O
' O O
enhancer O O
activity O O
. O O

In O O
the O O
transgenic O O
mice O O
, O O
WT1 O O
protein O O
expression O O
in O O
podocytes B-CellLine B-CellLine
was O O
decreased O O
at O O
1 O O
and O O
3 O O
weeks O O
of O O
age O O
, O O
while O O
glomeruloclerosis O O
developed O O
after O O
3 O O
weeks O O
. O O

CONCLUSION O O
: O O
TGF O O
- O O
beta1 O O
reduces O O
WT1 O O
expression O O
in O O
cultured O O
human O O
podocytes B-CellLine B-CellLine
and O O
podocytes B-CellLine B-CellLine
in O O
mice O O
before O O
overt O O
glomerulosclerosis O O
begins O O
. O O

The O O
effects O O
are O O
at O O
least O O
partially O O
Smad4 O O
dependent O O
. O O

Our O O
findings O O
identify O O
a O O
novel O O
pathway O O
linking O O
TGF O O
- O O
beta1 O O
to O O
podocyte O O
injury O O
and O O
FSGS O O
. O O

The O O
WT1 O O
reduction O O
may O O
be O O
a O O
useful O O
marker O O
for O O
early O O
podocyte O O
injury O O
. O O

Progesterone O O
receptor O O
directly O O
inhibits O O
beta O O
- O O
casein O O
gene O O
transcription O O
in O O
mammary B-CellLine B-CellLine
epithelial I-CellLine I-CellLine
cells I-CellLine I-CellLine
through O O
promoting O O
promoter O O
and O O
enhancer O O
repressive O O
chromatin O O
modifications O O
. O O

Differentiated O O
HC B-CellLine B-CellLine
- I-CellLine I-CellLine
11 I-CellLine I-CellLine
cells I-CellLine I-CellLine
ectopically O O
expressing O O
progesterone O O
receptor O O
( O O
PR O O
) O O
were O O
used O O
to O O
explore O O
the O O
molecular O O
mechanisms O O
by O O
which O O
progesterone O O
suppresses O O
beta O O
- O O
casein O O
gene O O
transcription O O
induced O O
by O O
prolactin O O
( O O
PRL O O
) O O
and O O
glucocorticoids O O
in O O
the O O
mammary B-CellLine B-CellLine
gland I-CellLine I-CellLine
. O O

As O O
detected O O
by O O
chromatin O O
immunoprecipitation O O
assays O O
, O O
treatment O O
of O O
cells O O
with O O
the O O
progestin O O
agonist O O
R5020 O O
induced O O
a O O
rapid O O
recruitment O O
( O O
5 O O
min O O
) O O
of O O
PR O O
to O O
the O O
proximal O O
promoter O O
( O O
- O O
235 O O
bp O O
) O O
and O O
distal O O
enhancer O O
( O O
- O O
6 O O
kb O O
upstream O O
of O O
transcription O O
start O O
site O O
) O O
of O O
beta O O
- O O
casein O O
. O O
PR O O
remained O O
bound O O
for O O
4 O O
h O O
and O O
was O O
dissociated O O
by O O
24 O O
h O O
after O O
treatment O O
. O O
As O O
detected O O
by O O
chromatin O O
immunoprecipitation O O
assays O O
, O O
treatment O O
of O O
cells O O
with O O
the O O
progestin O O
agonist O O
R5020 O O
induced O O
a O O
rapid O O
recruitment O O
( O O
5 O O
min O O
) O O
of O O
PR O O
to O O
the O O
proximal O O
promoter O O
( O O
- O O
235 O O
bp O O
) O O
and O O
distal O O
enhancer O O
( O O
- O O
6 O O
kb O O
upstream O O
of O O
transcription O O
start O O
site O O
) O O
of O O
beta O O
- O O
casein O O
. O O
PR O O
remained O O
bound O O
for O O
4 O O
h O O
and O O
was O O
dissociated O O
by O O
24 O O
h O O
after O O
treatment O O
. O O

Despite O O
efficient O O
binding O O
, O O
the O O
hormone O O
agonist O O
- O O
occupied O O
PR O O
did O O
not O O
stimulate O O
transcription O O
of O O
the O O
beta O O
- O O
casein O O
gene O O
. O O

Recruitment O O
of O O
signal O O
transducer O O
and O O
activator O O
of O O
transcription O O
5a O O
, O O
glucocorticoid O O
receptor O O
, O O
and O O
the O O
CCAAT O O
enhancer O O
binding O O
protein O O
beta O O
to O O
the O O
enhancer O O
and O O
proximal O O
promoter O O
of O O
beta O O
- O O
casein O O
induced O O
by O O
PRL O O
and O O
glucocorticoids O O
was O O
blocked O O
by O O
progestin O O
cotreatment O O
, O O
whereas O O
PR O O
binding O O
was O O
induced O O
under O O
these O O
conditions O O
. O O
PRL O O
/ O O
glucocorticoid O O
- O O
induced O O
histone O O
acetylation O O
and O O
the O O
recruitment O O
of O O
the O O
coactivator O O
p300 O O
and O O
RNA O O
polymerase O O
II O O
required O O
for O O
gene O O
activation O O
were O O
also O O
inhibited O O
by O O
progestin O O
. O O
Recruitment O O
of O O
signal O O
transducer O O
and O O
activator O O
of O O
transcription O O
5a O O
, O O
glucocorticoid O O
receptor O O
, O O
and O O
the O O
CCAAT O O
enhancer O O
binding O O
protein O O
beta O O
to O O
the O O
enhancer O O
and O O
proximal O O
promoter O O
of O O
beta O O
- O O
casein O O
induced O O
by O O
PRL O O
and O O
glucocorticoids O O
was O O
blocked O O
by O O
progestin O O
cotreatment O O
, O O
whereas O O
PR O O
binding O O
was O O
induced O O
under O O
these O O
conditions O O
. O O
PRL O O
/ O O
glucocorticoid O O
- O O
induced O O
histone O O
acetylation O O
and O O
the O O
recruitment O O
of O O
the O O
coactivator O O
p300 O O
and O O
RNA O O
polymerase O O
II O O
required O O
for O O
gene O O
activation O O
were O O
also O O
inhibited O O
by O O
progestin O O
. O O

In O O
addition O O
, O O
progestin O O
prevented O O
dissociation O O
of O O
the O O
corepressors O O
Yin O O
and O O
Yang O O
1 O O
and O O
histone O O
deacetylase O O
3 O O
from O O
the O O
promoter O O
, O O
and O O
demethylation O O
of O O
lysine O O
9 O O
of O O
histone O O
3 O O
induced O O
by O O
PRL O O
and O O
glucocorticoids O O
. O O

These O O
studies O O
are O O
consistent O O
with O O
the O O
conclusion O O
that O O
progesterone O O
interferes O O
with O O
PRL O O
/ O O
glucocorticoid O O
induction O O
of O O
beta O O
- O O
casein O O
transcription O O
by O O
a O O
physical O O
interaction O O
of O O
PR O O
with O O
the O O
promoter O O
and O O
enhancer O O
that O O
blocks O O
assembly O O
of O O
a O O
transcriptional O O
activation O O
complex O O
and O O
dissociation O O
of O O
corepressors O O
and O O
promotes O O
repressive O O
chromatin O O
modifications O O
. O O

These O O
studies O O
define O O
a O O
novel O O
mechanism O O
of O O
steroid O O
receptor O O
- O O
mediated O O
transcriptional O O
repression O O
of O O
a O O
physiologically O O
important O O
gene O O
in O O
mammary B-CellLine B-CellLine
gland I-CellLine I-CellLine
development O O
and O O
differentiation O O
. O O

Multiple O O
Wnt O O
/ O O
ss O O
- O O
catenin O O
responsive O O
enhancers O O
align O O
with O O
the O O
MYC O O
promoter O O
through O O
long O O
- O O
range O O
chromatin O O
loops O O
. O O

Inappropriate O O
activation O O
of O O
c O O
- O O
Myc O O
( O O
MYC O O
) O O
gene O O
expression O O
by O O
the O O
Wnt O O
/ O O
ss O O
- O O
catenin O O
signaling O O
pathway O O
is O O
required O O
for O O
colorectal O O
carcinogenesis O O
. O O

The O O
elevated O O
MYC O O
levels O O
in O O
colon B-CellLine B-CellLine
cancer I-CellLine I-CellLine
cells I-CellLine I-CellLine
are O O
attributed O O
in O O
part O O
to O O
ss O O
- O O
catenin O O
/ O O
TCF4 O O
transcription O O
complexes O O
that O O
are O O
assembled O O
at O O
proximal O O
Wnt O O
/ O O
ss O O
- O O
catenin O O
responsive O O
enhancers O O
( O O
WREs O O
) O O
. O O

Recent O O
studies O O
suggest O O
that O O
additional O O
WREs O O
that O O
control O O
MYC O O
expression O O
reside O O
far O O
upstream O O
of O O
the O O
MYC O O
transcription O O
start O O
site O O
. O O
Recent O O
studies O O
suggest O O
that O O
additional O O
WREs O O
that O O
control O O
MYC O O
expression O O
reside O O
far O O
upstream O O
of O O
the O O
MYC O O
transcription O O
start O O
site O O
. O O

Here O O
, O O
I O O
report O O
the O O
characterization O O
of O O
five O O
novel O O
WREs O O
that O O
localize O O
to O O
a O O
region O O
over O O
400 O O
kb O O
upstream O O
from O O
MYC O O
. O O
Here O O
, O O
I O O
report O O
the O O
characterization O O
of O O
five O O
novel O O
WREs O O
that O O
localize O O
to O O
a O O
region O O
over O O
400 O O
kb O O
upstream O O
from O O
MYC O O
. O O

These O O
WREs O O
harbor O O
nucleosomes O O
with O O
post O O
- O O
translational O O
histone O O
modifications O O
that O O
demarcate O O
enhancer O O
and O O
gene O O
promoter O O
regions O O
. O O

Using O O
quantitative O O
chromatin O O
conformation O O
capture O O
, O O
I O O
show O O
that O O
the O O
distal O O
WREs O O
are O O
aligned O O
with O O
the O O
MYC O O
promoter O O
through O O
large O O
chromatin O O
loops O O
. O O
Using O O
quantitative O O
chromatin O O
conformation O O
capture O O
, O O
I O O
show O O
that O O
the O O
distal O O
WREs O O
are O O
aligned O O
with O O
the O O
MYC O O
promoter O O
through O O
large O O
chromatin O O
loops O O
. O O

The O O
chromatin O O
loops O O
are O O
not O O
restricted O O
to O O
colon B-CellLine B-CellLine
cancer I-CellLine I-CellLine
cells I-CellLine I-CellLine
, O O
but O O
are O O
also O O
found O O
in O O
kidney B-CellLine B-CellLine
epithelial I-CellLine B-CellLine
and O O
lung B-CellLine B-CellLine
fibroblast I-CellLine I-CellLine
cell I-CellLine I-CellLine
lines I-CellLine I-CellLine
that O O
lack O O
de O O
- O O
regulated O O
Wnt O O
signaling O O
and O O
nuclear O O
ss O O
- O O
catenin O O
/ O O
TCF4 O O
complexes O O
. O O

While O O
each O O
chromatin O O
loop O O
is O O
detected O O
in O O
quiescent O O
cells O O
, O O
the O O
positioning O O
of O O
three O O
of O O
the O O
five O O
distal O O
enhancers O O
with O O
the O O
MYC O O
promoter O O
is O O
induced O O
by O O
serum O O
mitogens O O
. O O
While O O
each O O
chromatin O O
loop O O
is O O
detected O O
in O O
quiescent O O
cells O O
, O O
the O O
positioning O O
of O O
three O O
of O O
the O O
five O O
distal O O
enhancers O O
with O O
the O O
MYC O O
promoter O O
is O O
induced O O
by O O
serum O O
mitogens O O
. O O

These O O
findings O O
suggest O O
that O O
the O O
architecture O O
of O O
the O O
MYC O O
promoter O O
is O O
comprised O O
of O O
distal O O
elements O O
that O O
are O O
juxtaposed O O
through O O
large O O
chromatin O O
loops O O
and O O
that O O
ss O O
- O O
catenin O O
/ O O
TCF4 O O
complexes O O
utilize O O
this O O
conformation O O
to O O
activate O O
MYC O O
expression O O
in O O
colon B-CellLine B-CellLine
cancer I-CellLine I-CellLine
cells I-CellLine I-CellLine
. O O
These O O
findings O O
suggest O O
that O O
the O O
architecture O O
of O O
the O O
MYC O O
promoter O O
is O O
comprised O O
of O O
distal O O
elements O O
that O O
are O O
juxtaposed O O
through O O
large O O
chromatin O O
loops O O
and O O
that O O
ss O O
- O O
catenin O O
/ O O
TCF4 O O
complexes O O
utilize O O
this O O
conformation O O
to O O
activate O O
MYC O O
expression O O
in O O
colon B-CellLine B-CellLine
cancer I-CellLine I-CellLine
cells I-CellLine I-CellLine
. O O

Suppression O O
of O O
the O O
pancreatic O O
duodenal O O
homeodomain O O
transcription O O
factor O O
- O O
1 O O
( O O
Pdx O O
- O O
1 O O
) O O
promoter O O
by O O
sterol O O
regulatory O O
element O O
- O O
binding O O
protein O O
- O O
1c O O
( O O
SREBP O O
- O O
1c O O
) O O
. O O
Suppression O O
of O O
the O O
pancreatic O O
duodenal O O
homeodomain O O
transcription O O
factor O O
- O O
1 O O
( O O
Pdx O O
- O O
1 O O
) O O
promoter O O
by O O
sterol O O
regulatory O O
element O O
- O O
binding O O
protein O O
- O O
1c O O
( O O
SREBP O O
- O O
1c O O
) O O
. O O

Overexpression O O
of O O
sterol O O
regulatory O O
element O O
- O O
binding O O
protein O O
- O O
1c O O
( O O
SREBP O O
- O O
1c O O
) O O
in O O
beta B-CellLine B-CellLine
cells I-CellLine I-CellLine
causes O O
impaired O O
insulin O O
secretion O O
and O O
beta B-CellLine B-CellLine
cell I-CellLine I-CellLine
dysfunction O O
associated O O
with O O
diminished O O
pancreatic O O
duodenal O O
homeodomain O O
transcription O O
factor O O
- O O
1 O O
( O O
PDX O O
- O O
1 O O
) O O
expression O O
in O O
vitro O O
and O O
in O O
vivo O O
. O O

To O O
identify O O
the O O
molecular O O
mechanism O O
responsible O O
for O O
this O O
effect O O
, O O
the O O
mouse O O
Pdx O O
- O O
1 O O
gene O O
promoter O O
( O O
2 O O
. O O
7 O O
kb O O
) O O
was O O
analyzed O O
in O O
beta B-CellLine B-CellLine
cell I-CellLine I-CellLine
and O O
non O B-CellLine
- O I-CellLine
beta B-CellLine I-CellLine
cell I-CellLine I-CellLine
lines I-CellLine I-CellLine
. O O
To O O
identify O O
the O O
molecular O O
mechanism O O
responsible O O
for O O
this O O
effect O O
, O O
the O O
mouse O O
Pdx O O
- O O
1 O O
gene O O
promoter O O
( O O
2 O O
. O O
7 O O
kb O O
) O O
was O O
analyzed O O
in O O
beta B-CellLine B-CellLine
cell I-CellLine I-CellLine
and O O
non O B-CellLine
- O I-CellLine
beta B-CellLine I-CellLine
cell I-CellLine I-CellLine
lines I-CellLine I-CellLine
. O O

Despite O O
no O O
apparent O O
sterol O O
regulatory O O
element O O
- O O
binding O O
protein O O
- O O
binding O O
sites O O
, O O
the O O
Pdx O O
- O O
1 O O
promoter O O
was O O
suppressed O O
by O O
SREBP O O
- O O
1c O O
in O O
beta B-CellLine B-CellLine
cells I-CellLine I-CellLine
in O O
a O O
dose O O
- O O
dependent O O
manner O O
. O O
PDX O O
- O O
1 O O
activated O O
its O O
own O O
promoter O O
. O O
Despite O O
no O O
apparent O O
sterol O O
regulatory O O
element O O
- O O
binding O O
protein O O
- O O
binding O O
sites O O
, O O
the O O
Pdx O O
- O O
1 O O
promoter O O
was O O
suppressed O O
by O O
SREBP O O
- O O
1c O O
in O O
beta B-CellLine B-CellLine
cells I-CellLine I-CellLine
in O O
a O O
dose O O
- O O
dependent O O
manner O O
. O O
PDX O O
- O O
1 O O
activated O O
its O O
own O O
promoter O O
. O O

The O O
E O O
- O O
box O O
( O O
- O O
104 O O
/ O O
- O O
99 O O
bp O O
) O O
in O O
the O O
proximal O O
region O O
, O O
occupied O O
by O O
ubiquitously O O
expressed O O
upstream O O
stimulatory O O
factors O O
( O O
USFs O O
) O O
, O O
was O O
crucial O O
for O O
the O O
PDX O O
- O O
1 O O
- O O
positive O O
autoregulatory O O
loop O O
through O O
direct O O
PDX O O
- O O
1 O O
USF O O
binding O O
. O O

This O O
positive O O
feedback O O
activation O O
was O O
a O O
prerequisite O O
for O O
SREBP O O
- O O
1c O O
suppression O O
of O O
the O O
promoter O O
in O O
non O O
- O O
beta B-CellLine B-CellLine
cells I-CellLine I-CellLine
. O O
SREBP O O
- O O
1c O O
and O O
PDX O O
- O O
1 O O
directly O O
interact O O
through O O
basic O O
helix O O
- O O
loop O O
- O O
helix O O
and O O
homeobox O O
domains O O
, O O
respectively O O
. O O

This O O
robust O O
SREBP O O
- O O
1c O O
PDX O O
- O O
1 O O
complex O O
interferes O O
with O O
PDX O O
- O O
1 O O
USF O O
formation O O
and O O
inhibits O O
the O O
recruitment O O
of O O
PDX O O
- O O
1 O O
coactivators O O
. O O
SREBP O O
- O O
1c O O
also O O
inhibits O O
PDX O O
- O O
1 O O
binding O O
to O O
the O O
previously O O
described O O
PDX O O
- O O
1 O O
- O O
binding O O
site O O
( O O
- O O
2721 O O
/ O O
- O O
2646 O O
bp O O
) O O
in O O
the O O
distal O O
enhancer O O
region O O
of O O
the O O
Pdx O O
- O O
1 O O
promoter O O
. O O
This O O
robust O O
SREBP O O
- O O
1c O O
PDX O O
- O O
1 O O
complex O O
interferes O O
with O O
PDX O O
- O O
1 O O
USF O O
formation O O
and O O
inhibits O O
the O O
recruitment O O
of O O
PDX O O
- O O
1 O O
coactivators O O
. O O
SREBP O O
- O O
1c O O
also O O
inhibits O O
PDX O O
- O O
1 O O
binding O O
to O O
the O O
previously O O
described O O
PDX O O
- O O
1 O O
- O O
binding O O
site O O
( O O
- O O
2721 O O
/ O O
- O O
2646 O O
bp O O
) O O
in O O
the O O
distal O O
enhancer O O
region O O
of O O
the O O
Pdx O O
- O O
1 O O
promoter O O
. O O

Endogenous O O
up O O
- O O
regulation O O
of O O
SREBP O O
- O O
1c O O
in O O
INS B-CellLine B-CellLine
- I-CellLine I-CellLine
1 I-CellLine I-CellLine
cells I-CellLine I-CellLine
through O O
the O O
activation O O
of O O
liver B-CellLine O
X O O
receptor O O
and O O
retinoid O O
X O O
receptor O O
by O O
9 O O
- O O
cis O O
- O O
retinoic O O
acid O O
and O O
22 O O
- O O
hydroxycholesterol O O
inhibited O O
PDX O O
- O O
1 O O
mRNA O O
and O O
protein O O
expression O O
. O O

Conversely O O
, O O
SREBP O O
- O O
1c O O
RNAi O O
restored O O
Pdx O O
- O O
1 O O
mRNA O O
and O O
protein O O
levels O O
. O O

Through O O
these O O
multiple O O
mechanisms O O
, O O
SREBP O O
- O O
1c O O
, O O
when O O
induced O O
in O O
a O O
lipotoxic O O
state O O
, O O
repressed O O
PDX O O
- O O
1 O O
expression O O
contributing O O
to O O
the O O
inhibition O O
of O O
insulin O O
expression O O
and O O
beta B-CellLine B-CellLine
cell I-CellLine I-CellLine
dysfunction O O
. O O

Sox2 O O
expression O O
in O O
breast O O
tumours O O
and O O
activation O O
in O O
breast B-CellLine B-CellLine
cancer I-CellLine I-CellLine
stem I-CellLine I-CellLine
cells I-CellLine I-CellLine
. O O

The O O
cancer B-CellLine B-CellLine
stem I-CellLine I-CellLine
cell I-CellLine I-CellLine
( O O
CSC B-CellLine B-CellLine
) O O
model O O
does O O
not O O
imply O O
that O O
tumours O O
are O O
generated O O
from O O
transformed O O
tissue O B-CellLine
stem O I-CellLine
cells O I-CellLine
. O O

The O O
target O O
of O O
transformation O O
could O O
be O O
a O O
tissue O B-CellLine
stem B-CellLine I-CellLine
cell I-CellLine I-CellLine
, O O
a O O
progenitor B-CellLine O
cell I-CellLine O
, O O
or O O
a O O
differentiated O O
cell O O
that O O
acquires O O
self O O
- O O
renewal O O
ability O O
. O O

The O O
observation O O
that O O
induced O O
pluripotency O O
reprogramming O O
and O O
cancer O O
are O O
related O O
has O O
lead O O
to O O
the O O
speculation O O
that O O
CSCs B-CellLine B-CellLine
may O O
arise O O
through O O
a O O
reprogramming O O
- O O
like O O
mechanism O O
. O O

Expression O O
of O O
pluripotency O O
genes O O
( O O
Oct4 O O
, O O
Nanog O O
and O O
Sox2 O O
) O O
was O O
tested O O
in O O
breast O O
tumours O O
by O O
immunohistochemistry O O
and O O
it O O
was O O
found O O
that O O
Sox2 O O
is O O
expressed O O
in O O
early O O
stage O O
breast O O
tumours O O
. O O

However O O
, O O
expression O O
of O O
Oct4 O O
or O O
Nanog O O
was O O
not O O
found O O
. O O

Mammosphere O O
formation O O
in O O
culture O O
was O O
used O O
to O O
reveal O O
stem B-CellLine B-CellLine
cell I-CellLine I-CellLine
properties O O
, O O
where O O
expression O O
of O O
Sox2 O O
, O O
but O O
not O O
Oct4 O O
or O O
Nanog O O
, O O
was O O
induced O O
. O O

Over O O
- O O
expression O O
of O O
Sox2 O O
increased O O
mammosphere O O
formation O O
, O O
effect O O
dependent O O
on O O
continuous O O
Sox2 O O
expression O O
; O O
furthermore O O
, O O
Sox2 O O
knockdown O O
prevented O O
mammosphere O O
formation O O
and O O
delayed O O
tumour O O
formation O O
in O O
xenograft O O
tumour O O
initiation O O
models O O
. O O

Induction O O
of O O
Sox2 O O
expression O O
was O O
achieved O O
through O O
activation O O
of O O
the O O
distal O O
enhancer O O
of O O
Sox2 O O
promoter O O
upon O O
sphere O O
formation O O
, O O
the O O
same O O
element O O
that O O
controls O O
Sox2 O O
transcription O O
in O O
pluripotent B-CellLine B-CellLine
stem I-CellLine I-CellLine
cells I-CellLine I-CellLine
. O O
Induction O O
of O O
Sox2 O O
expression O O
was O O
achieved O O
through O O
activation O O
of O O
the O O
distal O O
enhancer O O
of O O
Sox2 O O
promoter O O
upon O O
sphere O O
formation O O
, O O
the O O
same O O
element O O
that O O
controls O O
Sox2 O O
transcription O O
in O O
pluripotent B-CellLine B-CellLine
stem I-CellLine I-CellLine
cells I-CellLine I-CellLine
. O O

These O O
findings O O
suggest O O
that O O
reactivation O O
of O O
Sox2 O O
represents O O
an O O
early O O
step O O
in O O
breast O O
tumour O O
initiation O O
, O O
explaining O O
tumour O O
heterogeneity O O
by O O
placing O O
the O O
tumour O O
- O O
initiating O O
event O O
in O O
any O O
cell O O
along O O
the O O
axis O O
of O O
mammary O O
differentiation O O
. O O

Comparative O O
epigenetic O O
analysis O O
of O O
Oct4 O O
regulatory O O
region O O
in O O
RA O O
- O O
induced O O
differentiated O O
NT2 B-CellLine B-CellLine
cells I-CellLine I-CellLine
under O O
adherent O O
and O O
non O O
- O O
adherent O O
culture O O
conditions O O
. O O
Oct4 O O
is O O
a O O
POU O O
domain O O
homeobox O O
gene O O
, O O
expressed O O
in O O
undifferentiated O O
embryonal O O
carcinoma O O
and O O
embryonic B-CellLine B-CellLine
stem I-CellLine I-CellLine
cells I-CellLine I-CellLine
and O O
is O O
quickly O O
down O O
- O O
regulated O O
upon O O
induction O O
of O O
differentiation O O
. O O

Transcriptional O O
repression O O
of O O
Oct4 O O
is O O
followed O O
by O O
pronounced O O
epigenetic O O
changes O O
on O O
the O O
regulatory O O
region O O
of O O
the O O
gene O O
. O O
Oct4 O O
has O O
a O O
long O O
upstream O O
regulatory O O
region O O
of O O
about O O
2 O O
, O O
600 O O
bp O O
, O O
consisting O O
of O O
proximal O O
enhancer O O
( O O
PE O O
) O O
, O O
distal O O
enhancer O O
( O O
DE O O
) O O
, O O
and O O
proximal O O
promoter O O
( O O
PP O O
) O O
. O O

In O O
this O O
study O O
, O O
we O O
induced O O
differentiation O O
of O O
a O O
human O B-CellLine
embryonic B-CellLine I-CellLine
carcinoma I-CellLine I-CellLine
cell I-CellLine I-CellLine
line I-CellLine I-CellLine
, O O
NT2 B-CellLine B-CellLine
, O O
under O O
two O O
different O O
adherent O O
and O O
non O O
- O O
adherent O O
culture O O
conditions O O
, O O
and O O
compared O O
histone O O
modifications O O
as O O
the O O
epigenetic O O
marks O O
on O O
the O O
regulatory O O
region O O
of O O
Oct4 O O
gene O O
after O O
3 O O
days O O
of O O
differentiation O O
. O O

Using O O
chromatin O O
immunoprecipitation O O
coupled O O
with O O
real O O
- O O
time O O
PCR O O
technique O O
, O O
it O O
was O O
shown O O
that O O
the O O
after O O
induction O O
of O O
differentiation O O
the O O
repressive O O
epigenetic O O
marks O O
of O O
hypoacetylation O O
and O O
methylation O O
on O O
lysine O O
- O O
9 O O
of O O
histone O O
H3 O O
occurred O O
very O O
effectively O O
on O O
the O O
upstream O O
of O O
Oct4 O O
, O O
especially O O
in O O
PP O B-CellLine
region O O
. O O

Also O O
, O O
comparing O O
the O O
two O O
culturing O O
systems O O
it O O
was O O
shown O O
that O O
methylation O O
of O O
lysine O O
- O O
9 O O
of O O
H3 O O
histone O O
was O O
more O O
drastic O O
in O O
PE O O
region O O
of O O
adherent O O
cells O O
rather O O
than O O
suspension O O
cells O O
. O O

This O O
epigenetic O O
profile O O
was O O
in O O
agreement O O
with O O
the O O
difference O O
observed O O
in O O
the O O
expression O O
level O O
of O O
Oct4 O O
in O O
these O O
two O O
culturing O O
systems O O
. O O

The O O
current O O
study O O
clearly O O
shows O O
the O O
effective O O
role O O
of O O
cell O O
culture O O
condition O O
on O O
the O O
epigenetic O O
regulation O O
of O O
gene O O
expression O O
. O O

A O O
new O O
hypersensitive O O
site O O
, O O
HS10 O O
, O O
and O O
the O O
enhancers O O
, O O
E3 O O
' O O
and O O
Ed O O
, O O
differentially O O
regulate O O
Igkappa O O
gene O O
expression O O
. O O

The O O
mouse O O
Igkappa O O
gene O O
locus O O
has O O
three O O
known O O
transcriptional O O
enhancers O O
: O O
an O O
intronic O O
enhancer O O
( O O
Ei O O
) O O
, O O
a O O
3 O O
' O O
enhancer O O
( O O
E3 O O
' O O
) O O
, O O
and O O
a O O
further O O
downstream O O
enhancer O O
( O O
Ed O O
) O O
. O O

We O O
previously O O
discovered O O
, O O
using O O
the O O
chromosome O O
conformation O O
- O O
capture O O
technique O O
, O O
that O O
Ei O O
and O O
E3 O O
' O O
interact O O
with O O
a O O
novel O O
DNA O O
sequence O O
near O O
the O O
3 O O
' O O
end O O
of O O
the O O
Igkappa O O
locus O O
, O O
specifically O O
in O O
B B-CellLine B-CellLine
cells I-CellLine I-CellLine
. O O

In O O
the O O
present O O
investigation O O
, O O
we O O
examined O O
the O O
function O O
of O O
this O O
far O O
downstream O O
element O O
. O O

The O O
sequence O O
is O O
evolutionarily O O
conserved O O
and O O
exhibits O O
a O O
plasmacytoma B-CellLine B-CellLine
cell I-CellLine I-CellLine
- O O
specific O O
DNase O O
I O O
- O O
hypersensitive O O
site O O
in O O
chromatin O O
, O O
henceforth O O
termed O O
HS10 O O
in O O
the O O
locus O O
. O O

HS10 O O
acts O O
as O O
a O O
coactivator O O
of O O
E3 O O
' O O
in O O
transient O O
transfection O O
assays O O
. O O

Although O O
HS10 O O
( O O
- O O
/ O O
- O O
) O O
mice O O
exhibited O O
normal O O
patterns O O
of O O
B B-CellLine B-CellLine
cell I-CellLine I-CellLine
development O O
, O O
they O O
were O O
tested O O
further O O
along O O
with O O
E3 O O
' O O
( O O
- O O
/ O O
- O O
) O O
and O O
Ed O O
( O O
- O O
/ O O
- O O
) O O
mice O O
for O O
their O O
Igkappa O O
expression O O
levels O O
in O O
plasma B-CellLine B-CellLine
cells I-CellLine I-CellLine
, O O
as O O
well O O
as O O
for O O
both O O
allelic O O
and O O
isotype O O
exclusion O O
in O O
splenic O B-CellLine
B B-CellLine I-CellLine
cells I-CellLine I-CellLine
. O O

HS10 O O
( O O
- O O
/ O O
- O O
) O O
and O O
Ed O O
( O O
- O O
/ O O
- O O
) O O
, O O
but O O
not O O
E3 O O
' O O
( O O
- O O
/ O O
- O O
) O O
, O O
mice O O
exhibited O O
2 O O
. O O
5 O O
- O O
fold O O
lower O O
levels O O
of O O
Igkappa O O
expression O O
in O O
antigenically O O
challenged O O
plasma B-CellLine B-CellLine
cells I-CellLine I-CellLine
. O O
E3 O O
' O O
( O O
- O O
/ O O
- O O
) O O
mice O O
, O O
but O O
not O O
HS10 O O
( O O
- O O
/ O O
- O O
) O O
mice O O
, O O
exhibited O O
impaired O O
IgL O O
isotype O O
and O O
allelic O O
exclusion O O
in O O
splenic O B-CellLine
B B-CellLine I-CellLine
cells I-CellLine I-CellLine
. O O

We O O
have O O
suggestive O O
results O O
that O O
Ed O O
may O O
also O O
weakly O O
participate O O
in O O
these O O
processes O O
. O O

In O O
addition O O
, O O
HS10 O O
( O O
- O O
/ O O
- O O
) O O
mice O O
no O O
longer O O
exhibited O O
regional O O
chromosome O O
interactions O O
with O O
E3 O O
' O O
, O O
and O O
they O O
exhibited O O
modestly O O
reduced O O
somatic O O
hypermutation O O
in O O
the O O
Jkappa O O
- O O
Ckappa O O
intronic O O
region O O
in O O
germinal O B-CellLine
center O I-CellLine
B B-CellLine I-CellLine
cells I-CellLine I-CellLine
from O O
Peyer B-CellLine B-CellLine
' I-CellLine O
s I-CellLine O
patches I-CellLine O
. O O

We O O
conclude O O
that O O
the O O
HS10 O O
, O O
E3 O O
' O O
, O O
and O O
Ed O O
differentially O O
regulate O O
Igkappa O O
gene O O
dynamics O O
. O O

The O O
nuclear O O
cofactor O O
RAC3 O O
/ O O
AIB1 O O
/ O O
SRC O O
- O O
3 O O
enhances O O
Nrf2 O O
signaling O O
by O O
interacting O O
with O O
transactivation O O
domains O O
. O O
Nuclear O O
factor O O
erythroid O O
2 O O
- O O
related O O
factor O O
2 O O
( O O
Nrf2 O O
, O O
NM O O
006164 O O
, O O
605 O O
AA O O
) O O
is O O
essential O O
for O O
the O O
antioxidant O O
responsive O O
element O O
( O O
ARE O O
) O O
- O O
mediated O O
expression O O
of O O
a O O
group O O
of O O
detoxifying O O
antioxidant O O
genes O O
that O O
detoxify O O
carcinogens O O
and O O
protect O O
against O O
oxidative O O
stress O O
. O O

Several O O
proteins O O
have O O
been O O
identified O O
as O O
Nrf2 O O
- O O
interacting O O
molecules O O
. O O

In O O
this O O
study O O
, O O
we O O
found O O
that O O
the O O
overexpression O O
of O O
receptor O O
- O O
associated O O
coactivator O O
3 O O
( O O
RAC3 O O
) O O
/ O O
AIB O O
- O O
1 O O
/ O O
steroid O O
receptor O O
coactivator O O
- O O
3 O O
, O O
a O O
nuclear O O
coregulator O O
and O O
oncogene O O
frequently O O
amplified O O
in O O
human O O
breast O O
cancers O O
, O O
induced O O
heme O O
oxygenase O O
- O O
1 O O
( O O
HO O O
- O O
1 O O
) O O
through O O
Nrf2 O O
transactivation O O
in O O
HeLa B-CellLine B-CellLine
cells I-CellLine I-CellLine
. O O

Next O O
, O O
we O O
determined O O
the O O
interaction O O
between O O
RAC3 O O
and O O
Nrf2 O O
proteins O O
using O O
a O O
co O O
- O O
immunoprecipitation O O
assay O O
and O O
fluorescence O O
resonance O O
energy O O
transfer O O
analysis O O
. O O

The O O
results O O
showed O O
that O O
RAC3 O O
bound O O
directly O O
to O O
the O O
Nrf2 O O
protein O O
in O O
the O O
nucleus O O
. O O

Subsequently O O
, O O
we O O
identified O O
the O O
interacting O O
domains O O
of O O
Nrf2 O O
and O O
RAC3 O O
using O O
a O O
glutathione O O
S O O
- O O
transferase O O
pull O O
- O O
down O O
assay O O
. O O

The O O
results O O
showed O O
that O O
both O O
the O O
N O O
- O O
terminal O O
RAC3 O O
- O O
pasB O O
and O O
C O O
- O O
terminal O O
RAC3 O O
- O O
R3B3 O O
domains O O
were O O
tightly O O
bound O O
to O O
the O O
Neh4 O O
and O O
Neh5 O O
transactivation O O
domains O O
. O O

Furthermore O O
, O O
chromatin O O
immunoprecipitation O O
showed O O
that O O
RAC3 O O
bound O O
tightly O O
to O O
the O O
ARE O O
enhancer O O
region O O
of O O
the O O
HO O O
- O O
1 O O
promoter O O
via O O
Nrf2 O O
binding O O
. O O
Furthermore O O
, O O
chromatin O O
immunoprecipitation O O
showed O O
that O O
RAC3 O O
bound O O
tightly O O
to O O
the O O
ARE O O
enhancer O O
region O O
of O O
the O O
HO O O
- O O
1 O O
promoter O O
via O O
Nrf2 O O
binding O O
. O O

These O O
data O O
suggest O O
that O O
Nrf2 O O
activation O O
is O O
modulated O O
and O O
directly O O
controlled O O
through O O
interactions O O
with O O
the O O
RAC3 O O
protein O O
in O O
HeLa B-CellLine B-CellLine
cells I-CellLine I-CellLine
. O O

TBX5 O O
drives O O
Scn5a O O
expression O O
to O O
regulate O O
cardiac B-CellLine B-CellLine
conduction I-CellLine I-CellLine
system I-CellLine I-CellLine
function O O
. O O
Cardiac O B-CellLine
conduction O I-CellLine
system O I-CellLine
( O O
CCS O O
) O O
disease O O
, O O
which O O
results O O
in O O
disrupted O O
conduction O O
and O O
impaired O O
cardiac O O
rhythm O O
, O O
is O O
common O O
with O O
significant O O
morbidity O O
and O O
mortality O O
. O O

Current O O
treatment O O
options O O
are O O
limited O O
, O O
and O O
rational O O
efforts O O
to O O
develop O O
cell O O
- O O
based O O
and O O
regenerative O O
therapies O O
require O O
knowledge O O
of O O
the O O
molecular O O
networks O O
that O O
establish O O
and O O
maintain O O
CCS B-CellLine O
function O O
. O O

Recent O O
genome O O
- O O
wide O O
association O O
studies O O
( O O
GWAS O O
) O O
have O O
identified O O
numerous O O
loci O O
associated O O
with O O
adult O O
human O O
CCS B-CellLine O
function O O
, O O
including O O
TBX5 O O
and O O
SCN5A O O
. O O

We O O
hypothesized O O
that O O
TBX5 O O
, O O
a O O
critical O O
developmental O O
transcription O O
factor O O
, O O
regulates O O
transcriptional O O
networks O O
required O O
for O O
mature O O
CCS B-CellLine B-CellLine
function O O
. O O

We O O
found O O
that O O
deletion O O
of O O
Tbx5 O O
from O O
the O O
mature O O
murine O O
ventricular B-CellLine B-CellLine
conduction I-CellLine I-CellLine
system I-CellLine I-CellLine
( O O
VCS B-CellLine B-CellLine
) O O
, O O
including O O
the O O
AV B-CellLine B-CellLine
bundle I-CellLine I-CellLine
and O O
bundle B-CellLine B-CellLine
branches I-CellLine I-CellLine
, O O
resulted O O
in O O
severe O O
VCS B-CellLine O
functional O O
consequences O O
, O O
including O O
loss O O
of O O
fast O O
conduction O O
, O O
arrhythmias O O
, O O
and O O
sudden O O
death O O
. O O

Ventricular O O
contractile O O
function O O
and O O
the O O
VCS B-CellLine B-CellLine
fate O O
map O O
remained O O
unchanged O O
in O O
VCS B-CellLine O
- O O
specific O O
Tbx5 O O
knockouts O O
. O O

However O O
, O O
key O O
mediators O O
of O O
fast O O
conduction O O
, O O
including O O
Nav1 O O
. O O
5 O O
, O O
which O O
is O O
encoded O O
by O O
Scn5a O O
, O O
and O O
connexin O O
40 O O
( O O
Cx40 O O
) O O
, O O
demonstrated O O
Tbx5 O O
- O O
dependent O O
expression O O
in O O
the O O
VCS B-CellLine B-CellLine
. O O

We O O
identified O O
a O O
TBX5 O O
- O O
responsive O O
enhancer O O
downstream O O
of O O
Scn5a O O
sufficient O O
to O O
drive O O
VCS B-CellLine O
expression O O
in O O
vivo O O
, O O
dependent O O
on O O
canonical O O
T O O
- O O
box O O
binding O O
sites O O
. O O
We O O
identified O O
a O O
TBX5 O O
- O O
responsive O O
enhancer O O
downstream O O
of O O
Scn5a O O
sufficient O O
to O O
drive O O
VCS B-CellLine O
expression O O
in O O
vivo O O
, O O
dependent O O
on O O
canonical O O
T O O
- O O
box O O
binding O O
sites O O
. O O

Our O O
results O O
establish O O
a O O
direct O O
molecular O O
link O O
between O O
Tbx5 O O
and O O
Scn5a O O
and O O
elucidate O O
a O O
hierarchy O O
between O O
human O O
GWAS O O
loci O O
that O O
affects O O
function O O
of O O
the O O
mature O O
VCS B-CellLine O
, O O
establishing O O
a O O
paradigm O O
for O O
understanding O O
the O O
molecular O O
pathology O O
of O O
CCS O O
disease O O
. O O

Direct O O
cooperation O O
between O O
androgen O O
receptor O O
and O O
E2F1 O O
reveals O O
a O O
common O O
regulation O O
mechanism O O
for O O
androgen O O
- O O
responsive O O
genes O O
in O O
prostate B-CellLine B-CellLine
cells I-CellLine I-CellLine
. O O

We O O
have O O
studied O O
the O O
regulation O O
of O O
ATAD2 O O
gene O O
expression O O
by O O
androgens O O
in O O
prostate B-CellLine B-CellLine
cells I-CellLine I-CellLine
. O O
ATAD2 O O
is O O
a O O
coactivator O O
of O O
the O O
androgen O O
receptor O O
( O O
AR O O
) O O
and O O
the O O
MYC O O
protein O O
. O O

We O O
showed O O
that O O
ATAD2 O O
expression O O
is O O
directly O O
regulated O O
by O O
AR O O
via O O
an O O
AR O O
binding O O
sequence O O
( O O
ARBS O O
) O O
located O O
in O O
the O O
distal O O
enhancer O O
of O O
its O O
regulatory O O
region O O
. O O
We O O
showed O O
that O O
ATAD2 O O
expression O O
is O O
directly O O
regulated O O
by O O
AR O O
via O O
an O O
AR O O
binding O O
sequence O O
( O O
ARBS O O
) O O
located O O
in O O
the O O
distal O O
enhancer O O
of O O
its O O
regulatory O O
region O O
. O O

The O O
gene O O
is O O
also O O
regulated O O
by O O
the O O
E2F1 O O
transcription O O
factor O O
. O O

Using O O
knockdown O O
and O O
chromatin O O
immunoprecipitation O O
technique O O
approaches O O
, O O
we O O
could O O
demonstrate O O
that O O
AR O O
and O O
E2F1 O O
functionally O O
collaborate O O
and O O
physically O O
interact O O
between O O
each O O
other O O
. O O

From O O
the O O
analysis O O
of O O
chromatin O O
conformation O O
, O O
we O O
conclude O O
that O O
this O O
cooperation O O
results O O
from O O
a O O
chromatin O O
looping O O
over O O
the O O
ATAD2 O O
promoter O O
region O O
between O O
the O O
ARBS O O
and O O
E2F1 O O
binding O O
site O O
in O O
an O O
androgen O O
- O O
dependent O O
manner O O
. O O
From O O
the O O
analysis O O
of O O
chromatin O O
conformation O O
, O O
we O O
conclude O O
that O O
this O O
cooperation O O
results O O
from O O
a O O
chromatin O O
looping O O
over O O
the O O
ATAD2 O O
promoter O O
region O O
between O O
the O O
ARBS O O
and O O
E2F1 O O
binding O O
site O O
in O O
an O O
androgen O O
- O O
dependent O O
manner O O
. O O

Furthermore O O
, O O
we O O
could O O
show O O
that O O
several O O
genes O O
overexpressed O O
in O O
prostate O O
cancer O O
and O O
potentially O O
involved O O
in O O
several O O
aspects O O
of O O
tumor O O
development O O
have O O
an O O
ARBS O O
and O O
an O O
E2F1 O O
binding O O
site O O
in O O
their O O
regulatory O O
regions O O
and O O
exhibit O O
the O O
same O O
mechanism O O
of O O
regulation O O
by O O
both O O
transcription O O
factors O O
as O O
ATAD2 O O
. O O
Furthermore O O
, O O
we O O
could O O
show O O
that O O
several O O
genes O O
overexpressed O O
in O O
prostate O O
cancer O O
and O O
potentially O O
involved O O
in O O
several O O
aspects O O
of O O
tumor O O
development O O
have O O
an O O
ARBS O O
and O O
an O O
E2F1 O O
binding O O
site O O
in O O
their O O
regulatory O O
regions O O
and O O
exhibit O O
the O O
same O O
mechanism O O
of O O
regulation O O
by O O
both O O
transcription O O
factors O O
as O O
ATAD2 O O
. O O

Mitogen O O
- O O
and O O
stress O O
- O O
activated O O
protein O O
kinases O O
1 O O
and O O
2 O O
are O O
required O O
for O O
maximal O O
trefoil O O
factor O O
1 O O
induction O O
. O O

Mitogen O O
- O O
and O O
stress O O
- O O
activated O O
protein O O
kinases O O
1 O O
and O O
2 O O
( O O
MSK1 O O
and O O
MSK2 O O
) O O
, O O
activated O O
downstream O O
of O O
the O O
ERK O O
- O O
and O O
p38 O O
- O O
mitogen O O
- O O
activated O O
protein O O
kinase O O
pathways O O
are O O
involved O O
in O O
cell O O
survival O O
, O O
proliferation O O
and O O
differentiation O O
. O O

Following O O
mitogenic O O
or O O
stress O O
stimuli O O
, O O
they O O
mediate O O
the O O
nucleosomal O O
response O O
, O O
which O O
includes O O
phosphorylation O O
of O O
histone O O
H3 O O
at O O
serine O O
10 O O
( O O
H3S10ph O O
) O O
coupled O O
with O O
transcriptional O O
activation O O
of O O
immediate O O
- O O
early O O
genes O O
. O O

While O O
MSK1 O O
and O O
MSK2 O O
are O O
closely O O
related O O
, O O
their O O
relative O O
roles O O
may O O
vary O O
with O O
cellular O O
context O O
and O O
/ O O
or O O
stimuli O O
. O O

However O O
, O O
our O O
knowledge O O
of O O
MSK2 O O
recruitment O O
to O O
immediate O O
- O O
early O O
genes O O
is O O
limited O O
, O O
as O O
research O O
has O O
primarily O O
focused O O
on O O
MSK1 O O
. O O

Here O O
, O O
we O O
demonstrate O O
that O O
both O O
MSK1 O O
and O O
MSK2 O O
, O O
regulate O O
the O O
phorbol O O
ester O O
12 O O
- O O
O O O
- O O
tetradecanoylphorbol O O
- O O
13 O O
- O O
acetate O O
induced O O
expression O O
of O O
the O O
breast O O
cancer O O
marker O O
gene O O
, O O
trefoil O O
factor O O
1 O O
( O O
TFF1 O O
) O O
, O O
by O O
phosphorylating O O
H3S10 O O
at O O
its O O
5 O O
' O O
regulatory O O
regions O O
. O O

The O O
MSK O O
- O O
mediated O O
phosphorylation O O
of O O
H3S10 O O
promotes O O
the O O
recruitment O O
of O O
14 O O
- O O
3 O O
- O O
3 O O
isoforms O O
and O O
BRG1 O O
, O O
the O O
ATPase O O
subunit O O
of O O
the O O
BAF O O
/ O O
PBAF O O
remodeling O O
complex O O
, O O
to O O
the O O
enhancer O O
and O O
upstream O O
promoter O O
elements O O
of O O
TFF1 O O
. O O
The O O
MSK O O
- O O
mediated O O
phosphorylation O O
of O O
H3S10 O O
promotes O O
the O O
recruitment O O
of O O
14 O O
- O O
3 O O
- O O
3 O O
isoforms O O
and O O
BRG1 O O
, O O
the O O
ATPase O O
subunit O O
of O O
the O O
BAF O O
/ O O
PBAF O O
remodeling O O
complex O O
, O O
to O O
the O O
enhancer O O
and O O
upstream O O
promoter O O
elements O O
of O O
TFF1 O O
. O O

The O O
recruited O O
chromatin O O
remodeling O O
activity O O
leads O O
to O O
the O O
RNA O O
polymerase O O
II O O
carboxy O O
- O O
terminal O O
domain O O
phosphorylation O O
at O O
the O O
TFF1 O O
promoter O O
, O O
initiating O O
TFF1 O O
expression O O
in O O
MCF B-CellLine B-CellLine
- I-CellLine I-CellLine
7 I-CellLine I-CellLine
breast I-CellLine I-CellLine
cancer I-CellLine I-CellLine
cells I-CellLine I-CellLine
. O O
The O O
recruited O O
chromatin O O
remodeling O O
activity O O
leads O O
to O O
the O O
RNA O O
polymerase O O
II O O
carboxy O O
- O O
terminal O O
domain O O
phosphorylation O O
at O O
the O O
TFF1 O O
promoter O O
, O O
initiating O O
TFF1 O O
expression O O
in O O
MCF B-CellLine B-CellLine
- I-CellLine I-CellLine
7 I-CellLine I-CellLine
breast I-CellLine I-CellLine
cancer I-CellLine I-CellLine
cells I-CellLine I-CellLine
. O O

Moreover O O
, O O
we O O
show O O
that O O
MSK1 O O
or O O
MSK2 O O
is O O
recruited O O
to O O
TFF1 O O
regulatory O O
regions O O
, O O
but O O
as O O
components O O
of O O
different O O
multiprotein O O
complexes O O
. O O

Estrogen O O
modulates O O
plasminogen O O
promoter O O
activity O O
. O O

Postmenopausal O O
women O O
treated O O
with O O
estrogen O O
hormone O O
replacement O O
therapy O O
and O O
female O O
patients O O
with O O
hypoplasminogenemia O O
receiving O O
oral O O
contraceptives O O
show O O
increasing O O
plasminogen O O
( O O
PLG O O
) O O
concentrations O O
. O O

The O O
elevated O O
PLG O O
levels O O
are O O
in O O
contrast O O
to O O
the O O
estrogen O O
dependent O O
decline O O
of O O
lipoptrotein O O
( O O
a O O
) O O
[ O O
Lp O O
( O O
a O O
) O O
] O O
, O O
whose O O
main O O
protein O O
component O O
apolipoprotein O O
( O O
a O O
) O O
[ O O
APO O O
( O O
a O O
) O O
] O O
is O O
highly O O
homologous O O
to O O
PLG O O
in O O
protein O O
and O O
gene O O
structure O O
and O O
is O O
also O O
located O O
in O O
its O O
immediate O O
vicinity O O
on O O
chromosome O O
6q26 O O
. O O

The O O
intergenic O O
region O O
between O O
both O O
genes O O
comprises O O
several O O
transcription O O
- O O
regulatory O O
regions O O
with O O
enhancer O O
sequences O O
that O O
increase O O
the O O
basal O O
activity O O
of O O
the O O
PLG O O
core O O
promoter O O
. O O
The O O
intergenic O O
region O O
between O O
both O O
genes O O
comprises O O
several O O
transcription O O
- O O
regulatory O O
regions O O
with O O
enhancer O O
sequences O O
that O O
increase O O
the O O
basal O O
activity O O
of O O
the O O
PLG O O
core O O
promoter O O
. O O

Using O O
luciferase O O
reporter O O
assays O O
we O O
demonstrate O O
that O O
the O O
minimal O O
PLG O O
promoter O O
is O O
insensitive O O
to O O
estrogen O O
. O O
Using O O
luciferase O O
reporter O O
assays O O
we O O
demonstrate O O
that O O
the O O
minimal O O
PLG O O
promoter O O
is O O
insensitive O O
to O O
estrogen O O
. O O

However O O
, O O
an O O
estrogen O O
response O O
element O O
located O O
11 O O
. O O
5 O O
kb O O
upstream O O
of O O
the O O
PLG O O
transcription O O
start O O
site O O
is O O
able O O
to O O
convey O O
a O O
dramatic O O
estrogen O O
- O O
dependent O O
elevation O O
of O O
PLG O O
- O O
minimal O O
promoter O O
driven O O
reporter O O
gene O O
expression O O
. O O
However O O
, O O
an O O
estrogen O O
response O O
element O O
located O O
11 O O
. O O
5 O O
kb O O
upstream O O
of O O
the O O
PLG O O
transcription O O
start O O
site O O
is O O
able O O
to O O
convey O O
a O O
dramatic O O
estrogen O O
- O O
dependent O O
elevation O O
of O O
PLG O O
- O O
minimal O O
promoter O O
driven O O
reporter O O
gene O O
expression O O
. O O

In O O
contrast O O
, O O
the O O
activating O O
effect O O
of O O
two O O
additional O O
enhancer O O
elements O O
, O O
among O O
them O O
an O O
DNase O O
I O O
hypersensitivity O O
region O O
that O O
has O O
been O O
shown O O
to O O
regulate O O
the O O
APO O O
( O O
a O O
) O O
minimal O O
promoter O O
activity O O
, O O
is O O
abrogated O O
by O O
estrogen O O
. O O
In O O
contrast O O
, O O
the O O
activating O O
effect O O
of O O
two O O
additional O O
enhancer O O
elements O O
, O O
among O O
them O O
an O O
DNase O O
I O O
hypersensitivity O O
region O O
that O O
has O O
been O O
shown O O
to O O
regulate O O
the O O
APO O O
( O O
a O O
) O O
minimal O O
promoter O O
activity O O
, O O
is O O
abrogated O O
by O O
estrogen O O
. O O

Thus O O
, O O
the O O
identified O O
estrogen O O
- O O
responsive O O
elements O O
provide O O
a O O
gene O O
and O O
tissue O O
specific O O
framework O O
by O O
which O O
PLG O O
expression O O
is O O
regulated O O
and O O
whose O O
activity O O
is O O
orchestrated O O
by O O
yet O O
unknown O O
accessory O O
factors O O
. O O

Recessive O O
mutations O O
in O O
a O O
distal O O
PTF1A O O
enhancer O O
cause O O
isolated O O
pancreatic O O
agenesis O O
. O O
Recessive O O
mutations O O
in O O
a O O
distal O O
PTF1A O O
enhancer O O
cause O O
isolated O O
pancreatic O O
agenesis O O
. O O

The O O
contribution O O
of O O
cis O O
- O O
regulatory O O
mutations O O
to O O
human O O
disease O O
remains O O
poorly O O
understood O O
. O O

Whole O O
- O O
genome O O
sequencing O O
can O O
identify O O
all O O
noncoding O O
variants O O
, O O
yet O O
the O O
discrimination O O
of O O
causal O O
regulatory O O
mutations O O
represents O O
a O O
formidable O O
challenge O O
. O O

We O O
used O O
epigenomic O O
annotation O O
in O O
human B-CellLine B-CellLine
embryonic I-CellLine I-CellLine
stem I-CellLine I-CellLine
cell I-CellLine I-CellLine
( O O
hESC B-CellLine B-CellLine
) O O
- O O
derived O O
pancreatic O B-CellLine
progenitor O I-CellLine
cells O I-CellLine
to O O
guide O O
the O O
interpretation O O
of O O
whole O O
- O O
genome O O
sequences O O
from O O
individuals O O
with O O
isolated O O
pancreatic O O
agenesis O O
. O O

This O O
analysis O O
uncovered O O
six O O
different O O
recessive O O
mutations O O
in O O
a O O
previously O O
uncharacterized O O
~ O O
400 O O
- O O
bp O O
sequence O O
located O O
25 O O
kb O O
downstream O O
of O O
PTF1A O O
( O O
encoding O O
pancreas O B-CellLine
- O O
specific O O
transcription O O
factor O O
1a O O
) O O
in O O
ten O O
families O O
with O O
pancreatic O O
agenesis O O
. O O
This O O
analysis O O
uncovered O O
six O O
different O O
recessive O O
mutations O O
in O O
a O O
previously O O
uncharacterized O O
~ O O
400 O O
- O O
bp O O
sequence O O
located O O
25 O O
kb O O
downstream O O
of O O
PTF1A O O
( O O
encoding O O
pancreas O B-CellLine
- O O
specific O O
transcription O O
factor O O
1a O O
) O O
in O O
ten O O
families O O
with O O
pancreatic O O
agenesis O O
. O O

We O O
show O O
that O O
this O O
region O O
acts O O
as O O
a O O
developmental O O
enhancer O O
of O O
PTF1A O O
and O O
that O O
the O O
mutations O O
abolish O O
enhancer O O
activity O O
. O O
We O O
show O O
that O O
this O O
region O O
acts O O
as O O
a O O
developmental O O
enhancer O O
of O O
PTF1A O O
and O O
that O O
the O O
mutations O O
abolish O O
enhancer O O
activity O O
. O O

These O O
mutations O O
are O O
the O O
most O O
common O O
cause O O
of O O
isolated O O
pancreatic O O
agenesis O O
. O O

Integrating O O
genome O O
sequencing O O
and O O
epigenomic O O
annotation O O
in O O
a O O
disease O O
- O O
relevant O O
cell O O
type O O
can O O
thus O O
uncover O O
new O O
noncoding O O
elements O O
underlying O O
human O O
development O O
and O O
disease O O
. O O

Transcriptional O O
regulation O O
of O O
human O O
ferredoxin O O
reductase O O
through O O
an O O
intronic O O
enhancer O O
in O O
steroidogenic B-CellLine O
cells I-CellLine O
. O O
Ferredoxin O O
reductase O O
( O O
FDXR O O
, O O
also O O
known O O
as O O
adrenodoxin O O
reductase O O
) O O
is O O
a O O
mitochondrial O O
flavoprotein O O
that O O
transfers O O
electrons O O
from O O
NADPH O O
to O O
mitochondrial O O
cytochrome O O
P450 O O
enzymes O O
, O O
mediating O O
the O O
function O O
of O O
an O O
iron O O
- O O
sulfur O O
cluster O O
protein O O
, O O
ferredoxin O O
. O O
FDXR O O
functions O O
in O O
various O O
metabolic O O
processes O O
including O O
steroidogenesis O O
. O O

It O O
is O O
well O O
known O O
that O O
multiple O O
steroidogenic O O
enzymes O O
are O O
regulated O O
by O O
a O O
transcription O O
factor O O
steroidogenic O O
factor O O
- O O
1 O O
( O O
SF O O
- O O
1 O O
, O O
also O O
known O O
as O O
Ad4BP O O
) O O
. O O

Previously O O
, O O
we O O
have O O
shown O O
that O O
SF O O
- O O
1 O O
transduction O O
causes O O
human O O
mesenchymal B-CellLine B-CellLine
stem I-CellLine I-CellLine
cell I-CellLine I-CellLine
differentiation O O
into O O
steroidogenic B-CellLine B-CellLine
cells I-CellLine I-CellLine
. O O

Genome O O
- O O
wide O O
analysis O O
of O O
differentiated O O
cells O O
, O O
using O O
a O O
combination O O
of O O
DNA O O
microarray O O
and O O
promoter O O
tiling O O
array O O
analyses O O
, O O
showed O O
that O O
FDXR O O
is O O
a O O
novel O O
SF O O
- O O
1 O O
target O O
gene O O
. O O

In O O
this O O
study O O
, O O
the O O
transcriptional O O
regulatory O O
mechanism O O
of O O
FDXR O O
was O O
examined O O
in O O
steroidogenic B-CellLine B-CellLine
cells I-CellLine I-CellLine
. O O

A O O
chromatin O O
immunoprecipitation O O
assay O O
revealed O O
that O O
a O O
novel O O
SF O O
- O O
1 O O
binding O O
region O O
was O O
located O O
within O O
intron O O
2 O O
of O O
the O O
human O O
FDXR O O
gene O O
. O O
A O O
chromatin O O
immunoprecipitation O O
assay O O
revealed O O
that O O
a O O
novel O O
SF O O
- O O
1 O O
binding O O
region O O
was O O
located O O
within O O
intron O O
2 O O
of O O
the O O
human O O
FDXR O O
gene O O
. O O

Luciferase O O
reporter O O
assays O O
showed O O
that O O
FDXR O O
transcription O O
was O O
activated O O
through O O
the O O
novel O O
SF O O
- O O
1 O O
binding O O
site O O
within O O
intron O O
2 O O
. O O
Luciferase O O
reporter O O
assays O O
showed O O
that O O
FDXR O O
transcription O O
was O O
activated O O
through O O
the O O
novel O O
SF O O
- O O
1 O O
binding O O
site O O
within O O
intron O O
2 O O
. O O

Endogenous O O
SF O O
- O O
1 O O
knockdown O O
in O O
human O O
adrenocortical B-CellLine O
H295R I-CellLine B-CellLine
and O O
KGN B-CellLine B-CellLine
cells I-CellLine I-CellLine
decreased O O
FDXR O O
expression O O
. O O

In O O
H295R B-CellLine B-CellLine
cells I-CellLine I-CellLine
, O O
strong O O
binding O O
of O O
two O O
histone O O
markers O O
of O O
active O O
enhancers O O
, O O
histones O O
H3K27ac O O
and O O
H3K4me2 O O
, O O
were O O
detected O O
near O O
the O O
SF O O
- O O
1 O O
binding O O
site O O
within O O
intron O O
2 O O
. O O
In O O
H295R B-CellLine B-CellLine
cells I-CellLine I-CellLine
, O O
strong O O
binding O O
of O O
two O O
histone O O
markers O O
of O O
active O O
enhancers O O
, O O
histones O O
H3K27ac O O
and O O
H3K4me2 O O
, O O
were O O
detected O O
near O O
the O O
SF O O
- O O
1 O O
binding O O
site O O
within O O
intron O O
2 O O
. O O

Furthermore O O
, O O
the O O
binding O O
of O O
these O O
histone O O
markers O O
was O O
decreased O O
concurrent O O
with O O
SF O O
- O O
1 O O
knockdown O O
in O O
H295R B-CellLine B-CellLine
cells I-CellLine I-CellLine
. O O

These O O
results O O
indicated O O
that O O
abundant O O
FDXR O O
expression O O
in O O
these O O
steroidogenic B-CellLine B-CellLine
cells I-CellLine I-CellLine
was O O
maintained O O
through O O
SF O O
- O O
1 O O
binding O O
to O O
the O O
intronic O O
enhancer O O
of O O
the O O
FDXR O O
gene O O
. O O
These O O
results O O
indicated O O
that O O
abundant O O
FDXR O O
expression O O
in O O
these O O
steroidogenic B-CellLine B-CellLine
cells I-CellLine I-CellLine
was O O
maintained O O
through O O
SF O O
- O O
1 O O
binding O O
to O O
the O O
intronic O O
enhancer O O
of O O
the O O
FDXR O O
gene O O
. O O

Pancreatic O O
islet B-CellLine B-CellLine
enhancer O O
clusters O O
enriched O O
in O O
type O O
2 O O
diabetes O O
risk O O
- O O
associated O O
variants O O
. O O
Type O O
2 O O
diabetes O O
affects O O
over O O
300 O O
million O O
people O O
, O O
causing O O
severe O O
complications O O
and O O
premature O O
death O O
, O O
yet O O
the O O
underlying O O
molecular O O
mechanisms O O
are O O
largely O O
unknown O O
. O O
Pancreatic O O
islet B-CellLine O
dysfunction O O
is O O
central O O
in O O
type O O
2 O O
diabetes O O
pathogenesis O O
, O O
and O O
understanding O O
islet O B-CellLine
genome O O
regulation O O
could O O
therefore O O
provide O O
valuable O O
mechanistic O O
insights O O
. O O

We O O
have O O
now O O
mapped O O
and O O
examined O O
the O O
function O O
of O O
human O O
islet B-CellLine B-CellLine
cis O O
- O O
regulatory O O
networks O O
. O O

We O O
identify O O
genomic O O
sequences O O
that O O
are O O
targeted O O
by O O
islet B-CellLine B-CellLine
transcription O O
factors O O
to O O
drive O O
islet B-CellLine B-CellLine
- O O
specific O O
gene O O
activity O O
and O O
show O O
that O O
most O O
such O O
sequences O O
reside O O
in O O
clusters O O
of O O
enhancers O O
that O O
form O O
physical O O
three O O
- O O
dimensional O O
chromatin O O
domains O O
. O O

We O O
find O O
that O O
sequence O O
variants O O
associated O O
with O O
type O O
2 O O
diabetes O O
and O O
fasting O O
glycemia O O
are O O
enriched O O
in O O
these O O
clustered O O
islet B-CellLine B-CellLine
enhancers O O
and O O
identify O O
trait O O
- O O
associated O O
variants O O
that O O
disrupt O O
DNA O O
binding O O
and O O
islet O B-CellLine
enhancer O O
activity O O
. O O

Our O O
studies O O
illustrate O O
how O O
islet B-CellLine O
transcription O O
factors O O
interact O O
functionally O O
with O O
the O O
epigenome O O
and O O
provide O O
systematic O O
evidence O O
that O O
the O O
dysregulation O O
of O O
islet B-CellLine O
enhancers O O
is O O
relevant O O
to O O
the O O
mechanisms O O
underlying O O
type O O
2 O O
diabetes O O
. O O

Dynamic O O
reorganization O O
of O O
the O O
AC16 B-CellLine O
cardiomyocyte I-CellLine B-CellLine
transcriptome O O
in O O
response O O
to O O
TNFalpha O O
signaling O O
revealed O O
by O O
integrated O O
genomic O O
analyses O O
. O O

BACKGROUND O O
: O O
Defining O O
cell O O
type O O
- O O
specific O O
transcriptomes O O
in O O
mammals O O
can O O
be O O
challenging O O
, O O
especially O O
for O O
unannotated O O
regions O O
of O O
the O O
genome O O
. O O

We O O
have O O
developed O O
an O O
analytical O O
pipeline O O
called O O
groHMM O O
for O O
annotating O O
primary O O
transcripts O O
using O O
global O O
nuclear O O
run O O
- O O
on O O
sequencing O O
( O O
GRO O O
- O O
seq O O
) O O
data O O
. O O

Herein O O
, O O
we O O
use O O
this O O
pipeline O O
to O O
characterize O O
the O O
transcriptome O O
of O O
an O O
immortalized O O
adult O O
human O O
ventricular B-CellLine B-CellLine
cardiomyocyte I-CellLine I-CellLine
cell I-CellLine I-CellLine
line I-CellLine I-CellLine
( O O
AC16 B-CellLine B-CellLine
) O O
in O O
response O O
to O O
signaling O O
by O O
tumor O O
necrosis O O
factor O O
alpha O O
( O O
TNFalpha O O
) O O
, O O
which O O
is O O
controlled O O
in O O
part O O
by O O
NF O O
- O O
kappaB O O
, O O
a O O
key O O
transcriptional O O
regulator O O
of O O
inflammation O O
. O O

A O O
unique O O
aspect O O
of O O
this O O
work O O
is O O
the O O
use O O
of O O
the O O
RNA O O
polymerase O O
II O O
( O O
Pol O O
II O O
) O O
inhibitor O O
alpha O O
- O O
amanitin O O
, O O
which O O
we O O
used O O
to O O
define O O
a O O
set O O
of O O
RNA O O
polymerase O O
I O O
and O O
III O O
( O O
Pol O O
I O O
and O O
Pol O O
III O O
) O O
transcripts O O
. O O

RESULTS O O
: O O
Using O O
groHMM O O
, O O
we O O
identified O O
~ O O
30 O O
, O O
000 O O
coding O O
and O O
non O O
- O O
coding O O
transcribed O O
regions O O
in O O
AC16 B-CellLine B-CellLine
cells I-CellLine I-CellLine
, O O
which O O
includes O O
a O O
set O O
of O O
unique O O
Pol O O
I O O
and O O
Pol O O
III O O
primary O O
transcripts O O
. O O

Many O O
of O O
these O O
transcripts O O
have O O
not O O
been O O
annotated O O
previously O O
, O O
including O O
enhancer O O
RNAs O O
originating O O
from O O
NF O O
- O O
kappaB O O
binding O O
sites O O
. O O
Many O O
of O O
these O O
transcripts O O
have O O
not O O
been O O
annotated O O
previously O O
, O O
including O O
enhancer O O
RNAs O O
originating O O
from O O
NF O O
- O O
kappaB O O
binding O O
sites O O
. O O

In O O
addition O O
, O O
we O O
observed O O
that O O
AC16 B-CellLine B-CellLine
cells I-CellLine I-CellLine
rapidly O O
and O O
dynamically O O
reorganize O O
their O O
transcriptomes O O
in O O
response O O
to O O
TNFalpha O O
stimulation O O
in O O
an O O
NF O O
- O O
kappaB O O
- O O
dependent O O
manner O O
, O O
switching O O
from O O
a O O
basal O O
state O O
to O O
a O O
proinflammatory O O
state O O
affecting O O
a O O
spectrum O O
of O O
cardiac O O
- O O
associated O O
protein O O
- O O
coding O O
and O O
non O O
- O O
coding O O
genes O O
. O O

Moreover O O
, O O
we O O
observed O O
distinct O O
Pol O O
II O O
dynamics O O
for O O
up O O
- O O
and O O
downregulated O O
genes O O
, O O
with O O
a O O
rapid O O
release O O
of O O
Pol O O
II O O
into O O
productive O O
elongation O O
for O O
TNFalpha O O
- O O
stimulated O O
genes O O
. O O

As O O
expected O O
, O O
the O O
TNFalpha O O
- O O
induced O O
changes O O
in O O
the O O
AC16 B-CellLine O
transcriptome O O
resulted O O
in O O
corresponding O O
changes O O
in O O
cognate O O
mRNA O O
and O O
protein O O
levels O O
in O O
a O O
similar O O
manner O O
, O O
but O O
with O O
delayed O O
kinetics O O
. O O

CONCLUSIONS O O
: O O
Our O O
studies O O
illustrate O O
how O O
computational O O
genomics O O
can O O
be O O
used O O
to O O
characterize O O
the O O
signal O O
- O O
regulated O O
transcriptome O O
in O O
biologically O O
relevant O O
cell O O
types O O
, O O
providing O O
new O O
information O O
about O O
how O O
the O O
human O O
genome O O
is O O
organized O O
, O O
transcribed O O
and O O
regulated O O
. O O

In O O
addition O O
, O O
they O O
show O O
how O O
alpha O O
- O O
amanitin O O
can O O
be O O
used O O
to O O
reveal O O
the O O
Pol O O
I O O
and O O
Pol O O
III O O
transcriptome O O
. O O

Furthermore O O
, O O
they O O
shed O O
new O O
light O O
on O O
the O O
regulation O O
of O O
the O O
cardiomyocyte B-CellLine B-CellLine
transcriptome O O
in O O
response O O
to O O
a O O
proinflammatory O O
signal O O
and O O
help O O
to O O
clarify O O
the O O
link O O
between O O
inflammation O O
and O O
cardiomyocyte B-CellLine B-CellLine
function O O
at O O
the O O
transcriptional O O
level O O
. O O

A O O
mouse O O
renin O O
distal O O
enhancer O O
is O O
essential O O
for O O
blood B-CellLine B-CellLine
pressure O O
homeostasis O O
in O O
BAC O O
- O O
rescued O O
renin O O
- O O
null O O
mutant O O
mice O O
. O O
Renin O O
is O O
predominantly O O
expressed O O
in O O
juxtaglomerular B-CellLine B-CellLine
cells I-CellLine I-CellLine
in O O
the O O
kidney B-CellLine B-CellLine
and O O
regulates O O
blood B-CellLine B-CellLine
pressure O O
homeostasis O O
. O O
A O O
mouse O O
renin O O
distal O O
enhancer O O
is O O
essential O O
for O O
blood B-CellLine B-CellLine
pressure O O
homeostasis O O
in O O
BAC O O
- O O
rescued O O
renin O O
- O O
null O O
mutant O O
mice O O
. O O
Renin O O
is O O
predominantly O O
expressed O O
in O O
juxtaglomerular B-CellLine B-CellLine
cells I-CellLine I-CellLine
in O O
the O O
kidney B-CellLine B-CellLine
and O O
regulates O O
blood B-CellLine B-CellLine
pressure O O
homeostasis O O
. O O

To O O
examine O O
possible O O
in O O
vivo O O
functions O O
of O O
a O O
mouse O O
distal O O
enhancer O O
( O O
mdE O O
) O O
, O O
we O O
generated O O
transgenic O O
mice O O
( O O
TgM O O
) O O
carrying O O
either O O
wild O O
- O O
type O O
or O O
mdE O O
- O O
deficient O O
renin O O
BACs O O
( O O
bacterial O O
artificial O O
chromosome O O
) O O
, O O
integrated O O
at O O
the O O
identical O O
chromosomal O O
site O O
. O O
To O O
examine O O
possible O O
in O O
vivo O O
functions O O
of O O
a O O
mouse O O
distal O O
enhancer O O
( O O
mdE O O
) O O
, O O
we O O
generated O O
transgenic O O
mice O O
( O O
TgM O O
) O O
carrying O O
either O O
wild O O
- O O
type O O
or O O
mdE O O
- O O
deficient O O
renin O O
BACs O O
( O O
bacterial O O
artificial O O
chromosome O O
) O O
, O O
integrated O O
at O O
the O O
identical O O
chromosomal O O
site O O
. O O

In O O
the O O
kidneys B-CellLine B-CellLine
of O O
the O O
TgM O O
, O O
the O O
mdE O O
contributed O O
80 O O
% O O
to O O
basal O O
renin O O
promoter O O
activity O O
. O O
In O O
the O O
kidneys B-CellLine B-CellLine
of O O
the O O
TgM O O
, O O
the O O
mdE O O
contributed O O
80 O O
% O O
to O O
basal O O
renin O O
promoter O O
activity O O
. O O

To O O
test O O
for O O
possible O O
physiological O O
roles O O
for O O
the O O
mdE O O
, O O
renin O O
BAC O O
transgenes O O
were O O
used O O
to O O
rescue O O
the O O
hypotensive O O
renin O O
- O O
null O O
mice O O
. O O

Interestingly O O
, O O
renal O O
renin O O
expression O O
in O O
the O O
Tg O O
( O O
BAC O O
) O O
: O O
renin O O
- O O
null O O
compound O O
mice O O
was O O
indistinguishable O O
between O O
the O O
wild O O
- O O
type O O
and O O
mutant O O
BAC O O
carriers O O
. O O

Surprisingly O O
, O O
however O O
, O O
the O O
plasma O O
renin O O
activity O O
and O O
angiotensin O O
I O O
concentration O O
in O O
the O O
mdE O O
compound O O
mutant O O
mice O O
were O O
significantly O O
lower O O
than O O
the O O
same O O
parameters O O
in O O
the O O
control O O
mice O O
, O O
and O O
the O O
mutants O O
were O O
consistently O O
hypotensive O O
, O O
demonstrating O O
that O O
blood B-CellLine B-CellLine
pressure O O
homeostasis O O
is O O
regulated O O
through O O
transcriptional O O
cis O O
elements O O
controlling O O
renin O O
activity O O
. O O

The O O
identification O O
of O O
an O O
ESCC O O
susceptibility O O
SNP O O
rs920778 O O
that O O
regulates O O
the O O
expression O O
of O O
lncRNA O O
HOTAIR O O
via O O
a O O
novel O O
intronic O O
enhancer O O
. O O

Long O O
noncoding O O
RNA O O
( O O
lncRNA O O
) O O
HOX O O
transcript O O
antisense O O
RNA O O
( O O
HOTAIR O O
) O O
, O O
which O O
could O O
induce O O
genome O O
- O O
wide O O
retargeting O O
of O O
polycomb O O
- O O
repressive O O
complex O O
2 O O
, O O
trimethylates O O
histone O O
H3 O O
lysine O O
- O O
27 O O
( O O
H3K27me3 O O
) O O
and O O
deregulation O O
of O O
multiple O O
downstream O O
genes O O
, O O
is O O
involved O O
in O O
development O O
and O O
progression O O
of O O
esophageal O O
squamous O O
cell O O
carcinoma O O
( O O
ESCC O O
) O O
. O O

We O O
hypothesized O O
that O O
the O O
functional O O
single O O
nucleotide O O
polymorphisms O O
( O O
SNP O O
) O O
in O O
HOTAIR O O
may O O
affect O O
HOTAIR O O
expression O O
and O O
/ O O
or O O
its O O
function O O
and O O
, O O
thus O O
, O O
ESCC O O
risk O O
. O O

Therefore O O
, O O
we O O
examined O O
the O O
association O O
between O O
three O O
haplotype O O
- O O
tagging O O
SNPs O O
( O O
htSNP O O
) O O
across O O
the O O
whole O O
HOTAIR O O
locus O O
and O O
ESCC O O
risk O O
as O O
well O O
as O O
the O O
functional O O
relevance O O
of O O
an O O
ESCC O O
susceptibility O O
SNP O O
rs920778 O O
. O O

Genotypes O O
were O O
determined O O
in O O
three O O
independent O O
case O O
- O O
control O O
sets O O
consisted O O
of O O
2098 O O
ESCC O O
patients O O
and O O
2150 O O
controls O O
. O O

The O O
allele O O
- O O
specific O O
regulation O O
on O O
HOTAIR O O
expression O O
by O O
the O O
rs920778 O O
SNP O O
was O O
investigated O O
in O O
vitro O O
and O O
in O O
vivo O O
. O O

We O O
found O O
that O O
the O O
HOTAIR O O
rs920778 O O
TT O O
carriers O O
had O O
a O O
1 O O
. O O
37 O O
- O O
fold O O
, O O
1 O O
. O O
78 O O
- O O
fold O O
and O O
2 O O
. O O
08 O O
- O O
fold O O
increased O O
ESCC O O
risk O O
in O O
Jinan O O
, O O
Shijiazhuang O O
and O O
Huaian O O
populations O O
, O O
respectively O O
, O O
compared O O
with O O
the O O
CC O O
carriers O O
( O O
P O O
= O O
0 O O
. O O
003 O O
, O O
7 O O
. O O
7 O O
x O O
10 O O
( O O
- O O
4 O O
) O O
and O O
5 O O
. O O
9 O O
x O O
10 O O
( O O
- O O
4 O O
) O O
) O O
. O O

During O O
inspecting O O
functional O O
relevance O O
of O O
the O O
rs920778 O O
SNP O O
, O O
we O O
identified O O
a O O
novel O O
intronic O O
HOTAIR O O
enhancer O O
locating O O
between O O
+ O O
1719bp O O
and O O
+ O O
2353bp O O
from O O
the O O
transcriptional O O
start O O
site O O
through O O
reporter O O
assays O O
. O O
During O O
inspecting O O
functional O O
relevance O O
of O O
the O O
rs920778 O O
SNP O O
, O O
we O O
identified O O
a O O
novel O O
intronic O O
HOTAIR O O
enhancer O O
locating O O
between O O
+ O O
1719bp O O
and O O
+ O O
2353bp O O
from O O
the O O
transcriptional O O
start O O
site O O
through O O
reporter O O
assays O O
. O O

Moreover O O
, O O
there O O
is O O
an O O
allelic O O
regulation O O
of O O
rs920778 O O
on O O
HOTAIR O O
expression O O
via O O
this O O
enhancer O O
in O O
both O O
ESCC B-CellLine B-CellLine
cell I-CellLine I-CellLine
lines I-CellLine I-CellLine
and O O
normal O O
esophageal O O
tissue O O
specimens O O
, O O
with O O
higher O O
HOTAIR O O
expression O O
among O O
T O O
allele O O
carriers O O
. O O

These O O
results O O
demonstrate O O
that O O
functional O O
genetic O O
variants O O
influencing O O
lncRNA O O
regulation O O
may O O
explain O O
a O O
fraction O O
of O O
ESCC O O
genetic O O
basis O O
. O O

Evidence O O
that O O
breast O O
cancer O O
risk O O
at O O
the O O
2q35 O O
locus O O
is O O
mediated O O
through O O
IGFBP5 O O
regulation O O
. O O

GWAS O O
have O O
identified O O
a O O
breast O O
cancer O O
susceptibility O O
locus O O
on O O
2q35 O O
. O O

Here O O
we O O
report O O
the O O
fine O O
mapping O O
of O O
this O O
locus O O
using O O
data O O
from O O
101 O O
, O O
943 O O
subjects O O
from O O
50 O O
case O O
- O O
control O O
studies O O
. O O

We O O
genotype O O
276 O O
SNPs O O
using O O
the O O
' O O
iCOGS O O
' O O
genotyping O O
array O O
and O O
impute O O
genotypes O O
for O O
a O O
further O O
1 O O
, O O
284 O O
using O O
1000 O O
Genomes O O
Project O O
data O O
. O O

All O O
but O O
two O O
, O O
strongly O O
correlated O O
SNPs O O
( O O
rs4442975 O O
G O O
/ O O
T O O
and O O
rs6721996 O O
G O O
/ O O
A O O
) O O
are O O
excluded O O
as O O
candidate O O
causal O O
variants O O
at O O
odds O O
against O O
> O O
100 O O
: O O
1 O O
. O O

The O O
best O O
functional O O
candidate O O
, O O
rs4442975 O O
, O O
is O O
associated O O
with O O
oestrogen O O
receptor O O
positive O O
( O O
ER O O
+ O O
) O O
disease O O
with O O
an O O
odds O O
ratio O O
( O O
OR O O
) O O
in O O
Europeans O O
of O O
0 O O
. O O
85 O O
( O O
95 O O
% O O
confidence O O
interval O O
= O O
0 O O
. O O
84 O O
- O O
0 O O
. O O
87 O O
; O O
P O O
= O O
1 O O
. O O
7 O O
x O O
10 O O
( O O
- O O
43 O O
) O O
) O O
per O O
t O O
- O O
allele O O
. O O

This O O
SNP O O
flanks O O
a O O
transcriptional O O
enhancer O O
that O O
physically O O
interacts O O
with O O
the O O
promoter O O
of O O
IGFBP5 O O
( O O
encoding O O
insulin O O
- O O
like O O
growth O O
factor O O
- O O
binding O O
protein O O
5 O O
) O O
and O O
displays O O
allele O O
- O O
specific O O
gene O O
expression O O
, O O
FOXA1 O O
binding O O
and O O
chromatin O O
looping O O
. O O
This O O
SNP O O
flanks O O
a O O
transcriptional O O
enhancer O O
that O O
physically O O
interacts O O
with O O
the O O
promoter O O
of O O
IGFBP5 O O
( O O
encoding O O
insulin O O
- O O
like O O
growth O O
factor O O
- O O
binding O O
protein O O
5 O O
) O O
and O O
displays O O
allele O O
- O O
specific O O
gene O O
expression O O
, O O
FOXA1 O O
binding O O
and O O
chromatin O O
looping O O
. O O

Evidence O O
suggests O O
that O O
the O O
g O O
- O O
allele O O
confers O O
increased O O
breast O O
cancer O O
susceptibility O O
through O O
relative O O
downregulation O O
of O O
IGFBP5 O O
, O O
a O O
gene O O
with O O
known O O
roles O O
in O O
breast B-CellLine B-CellLine
cell I-CellLine I-CellLine
biology O O
. O O

A O O
role O O
for O O
noncoding O O
variation O O
in O O
schizophrenia O O
. O O

A O O
large O O
portion O O
of O O
common O O
variant O O
loci O O
associated O O
with O O
genetic O O
risk O O
for O O
schizophrenia O O
reside O O
within O O
noncoding O O
sequence O O
of O O
unknown O O
function O O
. O O

Here O O
, O O
we O O
demonstrate O O
promoter O O
and O O
enhancer O O
enrichment O O
in O O
schizophrenia O O
variants O O
associated O O
with O O
expression O O
quantitative O O
trait O O
loci O O
( O O
eQTL O O
) O O
. O O

The O O
enrichment O O
is O O
greater O O
when O O
functional O O
annotations O O
derived O O
from O O
the O O
human O O
brain B-CellLine B-CellLine
are O O
used O O
relative O O
to O O
peripheral O O
tissues O O
. O O

Regulatory O O
trait O O
concordance O O
analysis O O
ranked O O
genes O O
within O O
schizophrenia O O
genome O O
- O O
wide O O
significant O O
loci O O
for O O
a O O
potential O O
functional O O
role O O
, O O
based O O
on O O
colocalization O O
of O O
a O O
risk O O
SNP O O
, O O
eQTL O O
, O O
and O O
regulatory O O
element O O
sequence O O
. O O

We O O
identified O O
potential O O
physical O O
interactions O O
of O O
noncontiguous O O
proximal O O
and O O
distal O O
regulatory O O
elements O O
. O O

This O O
was O O
verified O O
in O O
prefrontal B-CellLine B-CellLine
cortex I-CellLine I-CellLine
and O O
- O O
induced O B-CellLine
pluripotent B-CellLine I-CellLine
stem I-CellLine I-CellLine
cell I-CellLine I-CellLine
- O O
derived O O
neurons B-CellLine B-CellLine
for O O
the O O
L O O
- O O
type O O
calcium O O
channel O O
( O O
CACNA1C O O
) O O
risk O O
locus O O
. O O

Our O O
findings O O
point O O
to O O
a O O
functional O O
link O O
between O O
schizophrenia O O
- O O
associated O O
noncoding O O
SNPs O O
and O O
3D O O
genome O O
architecture O O
associated O O
with O O
chromosomal O O
loopings O O
and O O
transcriptional O O
regulation O O
in O O
the O O
brain B-CellLine B-CellLine
. O O

Copy O O
number O O
variation O O
of O O
two O O
separate O O
regulatory O O
regions O O
upstream O O
of O O
SOX9 O O
causes O O
isolated O O
46 O O
, O O
XY O O
or O O
46 O O
, O O
XX O O
disorder O O
of O O
sex O O
development O O
. O O

BACKGROUND O O
: O O
SOX9 O O
mutations O O
cause O O
the O O
skeletal O O
malformation O O
syndrome O O
campomelic O O
dysplasia O O
in O O
combination O O
with O O
XY O O
sex O O
reversal O O
. O O

Studies O O
in O O
mice O O
indicate O O
that O O
SOX9 O O
acts O O
as O O
a O O
testis B-CellLine B-CellLine
- O O
inducing O O
transcription O O
factor O O
downstream O O
of O O
SRY O O
, O O
triggering O O
Sertoli B-CellLine B-CellLine
cell I-CellLine I-CellLine
and O O
testis B-CellLine B-CellLine
differentiation O O
. O O

An O O
SRY O O
- O O
dependent O O
testis B-CellLine B-CellLine
- O O
specific O O
enhancer O O
for O O
Sox9 O O
has O O
been O O
identified O O
only O O
in O O
mice O O
. O O
An O O
SRY O O
- O O
dependent O O
testis B-CellLine B-CellLine
- O O
specific O O
enhancer O O
for O O
Sox9 O O
has O O
been O O
identified O O
only O O
in O O
mice O O
. O O

A O O
previous O O
study O O
has O O
implicated O O
copy O O
number O O
variations O O
( O O
CNVs O O
) O O
of O O
a O O
78 O O
kb O O
region O O
517 O O
- O O
595 O O
kb O O
upstream O O
of O O
SOX9 O O
in O O
the O O
aetiology O O
of O O
both O O
46 O O
, O O
XY O O
and O O
46 O O
, O O
XX O O
disorders O O
of O O
sex O O
development O O
( O O
DSD O O
) O O
. O O

We O O
wanted O O
to O O
better O O
define O O
this O O
region O O
for O O
both O O
disorders O O
. O O

RESULTS O O
: O O
By O O
CNV O O
analysis O O
, O O
we O O
identified O O
SOX9 O O
upstream O O
duplications O O
in O O
three O O
cases O O
of O O
SRY O O
- O O
negative O O
46 O O
, O O
XX O O
DSD O O
, O O
which O O
together O O
with O O
previously O O
reported O O
duplications O O
define O O
a O O
68 O O
kb O O
region O O
, O O
516 O O
- O O
584 O O
kb O O
upstream O O
of O O
SOX9 O O
, O O
designated O O
XXSR O O
( O O
XX O O
sex O O
reversal O O
region O O
) O O
. O O

More O O
importantly O O
, O O
we O O
identified O O
heterozygous O O
deletions O O
in O O
four O O
families O O
with O O
SRY O O
- O O
positive O O
46 O O
, O O
XY O O
DSD O O
without O O
skeletal O O
phenotype O O
, O O
which O O
define O O
a O O
32 O O
. O O
5 O O
kb O O
interval O O
607 O O
. O O
1 O O
- O O
639 O O
. O O
6 O O
kb O O
upstream O O
of O O
SOX9 O O
, O O
designated O O
XY O O
sex O O
reversal O O
region O O
( O O
XYSR O O
) O O
. O O

To O O
localise O O
the O O
suspected O O
testis B-CellLine B-CellLine
- O O
specific O O
enhancer O O
, O O
XYSR O O
subfragments O O
were O O
tested O O
in O O
cell O O
transfection O O
and O O
transgenic O O
experiments O O
. O O
To O O
localise O O
the O O
suspected O O
testis B-CellLine B-CellLine
- O O
specific O O
enhancer O O
, O O
XYSR O O
subfragments O O
were O O
tested O O
in O O
cell O O
transfection O O
and O O
transgenic O O
experiments O O
. O O

While O O
transgenic O O
experiments O O
remained O O
inconclusive O O
, O O
a O O
1 O O
. O O
9 O O
kb O O
SRY O O
- O O
responsive O O
subfragment O O
drove O O
expression O O
specifically O O
in O O
Sertoli B-CellLine B-CellLine
- I-CellLine I-CellLine
like I-CellLine I-CellLine
cells I-CellLine I-CellLine
. O O

CONCLUSIONS O O
: O O
Our O O
results O O
indicate O O
that O O
isolated O O
46 O O
, O O
XY O O
and O O
46 O O
, O O
XX O O
DSD O O
can O O
be O O
assigned O O
to O O
two O O
separate O O
regulatory O O
regions O O
, O O
XYSR O O
and O O
XXSR O O
, O O
far O O
upstream O O
of O O
SOX9 O O
. O O

The O O
1 O O
. O O
9 O O
kb O O
SRY O O
- O O
responsive O O
subfragment O O
from O O
the O O
XYSR O O
might O O
constitute O O
the O O
core O O
of O O
the O O
Sertoli B-CellLine B-CellLine
- I-CellLine I-CellLine
cell I-CellLine I-CellLine
enhancer O O
of O O
human O O
SOX9 O O
, O O
representing O O
the O O
so O O
far O O
missing O O
link O O
in O O
the O O
genetic O O
cascade O O
of O O
male O O
sex O O
determination O O
. O O
The O O
1 O O
. O O
9 O O
kb O O
SRY O O
- O O
responsive O O
subfragment O O
from O O
the O O
XYSR O O
might O O
constitute O O
the O O
core O O
of O O
the O O
Sertoli B-CellLine B-CellLine
- I-CellLine I-CellLine
cell I-CellLine I-CellLine
enhancer O O
of O O
human O O
SOX9 O O
, O O
representing O O
the O O
so O O
far O O
missing O O
link O O
in O O
the O O
genetic O O
cascade O O
of O O
male O O
sex O O
determination O O
. O O

Enhancer O O
- O O
bound O O
LDB1 O O
regulates O O
a O O
corticotrope O O
promoter O O
- O O
pausing O O
repression O O
program O O
. O O

Substantial O O
evidence O O
supports O O
the O O
hypothesis O O
that O O
enhancers O O
are O O
critical O O
regulators O O
of O O
cell O O
- O O
type O O
determination O O
, O O
orchestrating O O
both O O
positive O O
and O O
negative O O
transcriptional O O
programs O O
; O O
however O O
, O O
the O O
basic O O
mechanisms O O
by O O
which O O
enhancers O O
orchestrate O O
interactions O O
with O O
cognate O O
promoters O O
during O O
activation O O
and O O
repression O O
events O O
remain O O
incompletely O O
understood O O
. O O

Here O O
we O O
report O O
the O O
required O O
actions O O
of O O
LIM O O
domain O O
- O O
binding O O
protein O O
1 O O
( O O
LDB1 O O
) O O
/ O O
cofactor O O
of O O
LIM O O
homeodomain O O
protein O O
2 O O
/ O O
nuclear O O
LIM O O
interactor O O
, O O
interacting O O
with O O
the O O
enhancer O O
- O O
binding O O
protein O O
achaete O O
- O O
scute O O
complex O O
homolog O O
1 O O
, O O
to O O
mediate O O
looping O O
to O O
target O O
gene O O
promoters O O
and O O
target O O
gene O O
regulation O O
in O O
corticotrope O B-CellLine
cells O I-CellLine
. O O
LDB1 O O
- O O
mediated O O
enhancer O O
: O O
promoter O O
looping O O
appears O O
to O O
be O O
required O O
for O O
both O O
activation O O
and O O
repression O O
of O O
these O O
target O O
genes O O
. O O

Although O O
LDB1 O O
- O O
dependent O O
activated O O
genes O O
are O O
regulated O O
at O O
the O O
level O O
of O O
transcriptional O O
initiation O O
, O O
the O O
LDB1 O O
- O O
dependent O O
repressed O O
transcription O O
units O O
appear O O
to O O
be O O
regulated O O
primarily O O
at O O
the O O
level O O
of O O
promoter O O
pausing O O
, O O
with O O
LDB1 O O
regulating O O
recruitment O O
of O O
metastasis O O
- O O
associated O O
1 O O
family O O
, O O
member O O
2 O O
, O O
a O O
component O O
of O O
the O O
nucleosome O O
remodeling O O
deacetylase O O
complex O O
, O O
on O O
these O O
negative O O
enhancers O O
, O O
required O O
for O O
the O O
repressive O O
enhancer O O
function O O
. O O

These O O
results O O
indicate O O
that O O
LDB1 O O
- O O
dependent O O
looping O O
events O O
can O O
deliver O O
repressive O O
cargo O O
to O O
cognate O O
promoters O O
to O O
mediate O O
promoter O O
pausing O O
events O O
in O O
a O O
pituitary B-CellLine B-CellLine
cell I-CellLine I-CellLine
type O O
. O O

SLC13A5 O O
is O O
a O O
novel O O
transcriptional O O
target O O
of O O
the O O
pregnane O O
X O O
receptor O O
and O O
sensitizes O O
drug O O
- O O
induced O O
steatosis O O
in O O
human O O
liver B-CellLine B-CellLine
. O O

The O O
solute O O
carrier O O
family O O
13 O O
member O O
5 O O
( O O
SLC13A5 O O
) O O
is O O
a O O
sodium O O
- O O
coupled O O
transporter O O
that O O
mediates O O
cellular O O
uptake O O
of O O
citrate O O
, O O
which O O
plays O O
important O O
roles O O
in O O
the O O
synthesis O O
of O O
fatty O O
acids O O
and O O
cholesterol O O
. O O

Recently O O
, O O
the O O
pregnane O O
X O O
receptor O O
( O O
PXR O O
, O O
NR1I2 O O
) O O
, O O
initially O O
characterized O O
as O O
a O O
xenobiotic O O
sensor O O
, O O
has O O
been O O
functionally O O
linked O O
to O O
the O O
regulation O O
of O O
various O O
physiologic O O
processes O O
that O O
are O O
associated O O
with O O
lipid O O
metabolism O O
and O O
energy O O
homeostasis O O
. O O

Here O O
, O O
we O O
show O O
that O O
the O O
SLC13A5 O O
gene O O
is O O
a O O
novel O O
transcriptional O O
target O O
of O O
PXR O O
, O O
and O O
altered O O
expression O O
of O O
SLC13A5 O O
affects O O
lipid O O
accumulation O O
in O O
human O O
liver B-CellLine B-CellLine
cells I-CellLine I-CellLine
. O O

The O O
prototypical O O
PXR O O
activator O O
rifampicin O O
markedly O O
induced O O
the O O
mRNA O O
and O O
protein O O
expression O O
of O O
SLC13A5 O O
in O O
human O O
primary O O
hepatocytes B-CellLine B-CellLine
. O O

Utilizing O O
cell O O
- O O
based O O
luciferase O O
reporter O O
assays O O
, O O
electrophoretic O O
mobility O O
shift O O
assays O O
, O O
and O O
chromatin O O
immunoprecipitation O O
assays O O
, O O
we O O
identified O O
and O O
functionally O O
characterized O O
two O O
enhancer O O
modules O O
located O O
upstream O O
of O O
the O O
SLC13A5 O O
gene O O
transcription O O
start O O
site O O
that O O
are O O
associated O O
with O O
regulation O O
of O O
PXR O O
- O O
mediated O O
SLC13A5 O O
induction O O
. O O
Utilizing O O
cell O O
- O O
based O O
luciferase O O
reporter O O
assays O O
, O O
electrophoretic O O
mobility O O
shift O O
assays O O
, O O
and O O
chromatin O O
immunoprecipitation O O
assays O O
, O O
we O O
identified O O
and O O
functionally O O
characterized O O
two O O
enhancer O O
modules O O
located O O
upstream O O
of O O
the O O
SLC13A5 O O
gene O O
transcription O O
start O O
site O O
that O O
are O O
associated O O
with O O
regulation O O
of O O
PXR O O
- O O
mediated O O
SLC13A5 O O
induction O O
. O O

Functional O O
analysis O O
further O O
revealed O O
that O O
rifampicin O O
can O O
enhance O O
lipid O O
accumulation O O
in O O
human O O
primary O O
hepatocytes B-CellLine B-CellLine
, O O
and O O
knockdown O O
of O O
SLC13A5 O O
expression O O
alone O O
leads O O
to O O
a O O
significant O O
decrease O O
of O O
the O O
lipid O O
content O O
in O O
HepG2 B-CellLine B-CellLine
cells I-CellLine I-CellLine
. O O

Overall O O
, O O
our O O
results O O
uncover O O
SLC13A5 O O
as O O
a O O
novel O O
target O O
gene O O
of O O
PXR O O
and O O
may O O
contribute O O
to O O
drug O O
- O O
induced O O
steatosis O O
and O O
metabolic O O
disorders O O
in O O
humans O O
. O O

Functional O O
annotation O O
of O O
native O O
enhancers O O
with O O
a O O
Cas9 O O
- O O
histone O O
demethylase O O
fusion O O
. O O

Understanding O O
of O O
mammalian O O
enhancers O O
is O O
limited O O
by O O
the O O
lack O O
of O O
a O O
technology O O
to O O
rapidly O O
and O O
thoroughly O O
test O O
the O O
cell O O
type O O
- O O
specific O O
function O O
. O O

Here O O
, O O
we O O
use O O
a O O
nuclease O O
- O O
deficient O O
Cas9 O O
( O O
dCas9 O O
) O O
- O O
histone O O
demethylase O O
fusion O O
to O O
functionally O O
characterize O O
previously O O
described O O
and O O
new O O
enhancer O O
elements O O
for O O
their O O
roles O O
in O O
the O O
embryonic B-CellLine B-CellLine
stem I-CellLine I-CellLine
cell I-CellLine I-CellLine
state O O
. O O

Further O O
, O O
we O O
distinguish O O
the O O
mechanism O O
of O O
action O O
of O O
dCas9 O O
- O O
LSD1 O O
at O O
enhancers O O
from O O
previous O O
dCas9 O O
- O O
effectors O O
. O O

Pregnane O O
X O O
Receptor O O
Represses O O
HNF4alpha O O
Gene O O
to O O
Induce O O
Insulin O O
- O O
Like O O
Growth O O
Factor O O
- O O
Binding O O
Protein O O
IGFBP1 O O
that O O
Alters O O
Morphology O O
of O O
and O O
Migrates O O
HepG2 B-CellLine B-CellLine
Cells I-CellLine I-CellLine
. O O

Upon O O
treatment O O
with O O
the O O
pregnane O O
X O O
receptor O O
( O O
PXR O O
) O O
activator O O
rifampicin O O
( O O
RIF O O
) O O
, O O
human O B-CellLine
hepatocellular O I-CellLine
carcinoma O I-CellLine
HepG2 B-CellLine I-CellLine
- O I-CellLine
derived O I-CellLine
ShP51 B-CellLine I-CellLine
cells I-CellLine I-CellLine
that O O
stably O O
express O O
PXR O O
showed O O
epithelial O O
- O O
mesenchymal O O
transition O O
( O O
EMT O O
) O O
- O O
like O O
morphological O O
changes O O
and O O
migration O O
. O O

Our O O
recent O O
DNA O O
microarrays O O
have O O
identified O O
hepatocyte O O
nuclear O O
factor O O
( O O
HNF O O
) O O
4alpha O O
and O O
insulin O O
- O O
like O O
growth O O
factor O O
- O O
binding O O
protein O O
( O O
IGFBP O O
) O O
1 O O
mRNAs O O
to O O
be O O
downregulated O O
and O O
upregulated O O
, O O
respectively O O
, O O
in O O
RIF O O
- O O
treated O O
ShP51 B-CellLine B-CellLine
cells I-CellLine I-CellLine
, O O
and O O
these O O
regulations O O
were O O
confirmed O O
by O O
the O O
subsequent O O
real O O
- O O
time O O
polymerase O O
chain O O
reaction O O
and O O
Western O O
blot O O
analyses O O
. O O

Using O O
this O O
cell O O
system O O
, O O
we O O
demonstrated O O
here O O
that O O
the O O
PXR O O
- O O
HNF4alpha O O
- O O
IGFBP1 O O
pathway O O
is O O
an O O
essential O O
signal O O
for O O
PXR O O
- O O
induced O O
morphological O O
changes O O
and O O
migration O O
. O O

First O O
, O O
we O O
characterized O O
the O O
molecular O O
mechanism O O
underlying O O
the O O
PXR O O
- O O
mediated O O
repression O O
of O O
the O O
HNF4alpha O O
gene O O
. O O

Chromatin O O
conformation O O
capture O O
and O O
chromatin O O
immunoprecipitation O O
( O O
ChIP O O
) O O
assays O O
revealed O O
that O O
PXR O O
activation O O
by O O
RIF O O
disrupted O O
enhancer O O
- O O
promoter O O
communication O O
and O O
prompted O O
deacetylation O O
of O O
histone O O
H3 O O
in O O
the O O
HNF4alpha O O
P1 O O
promoter O O
. O O
Chromatin O O
conformation O O
capture O O
and O O
chromatin O O
immunoprecipitation O O
( O O
ChIP O O
) O O
assays O O
revealed O O
that O O
PXR O O
activation O O
by O O
RIF O O
disrupted O O
enhancer O O
- O O
promoter O O
communication O O
and O O
prompted O O
deacetylation O O
of O O
histone O O
H3 O O
in O O
the O O
HNF4alpha O O
P1 O O
promoter O O
. O O

Cell O O
- O O
based O O
reporter O O
and O O
ChIP O O
assays O O
showed O O
that O O
PXR O O
targeted O O
the O O
distal O O
enhancer O O
of O O
the O O
HNF4alpha O O
P1 O O
promoter O O
and O O
stimulated O O
dissociation O O
of O O
HNF3beta O O
from O O
the O O
distal O O
enhancer O O
. O O
Cell O O
- O O
based O O
reporter O O
and O O
ChIP O O
assays O O
showed O O
that O O
PXR O O
targeted O O
the O O
distal O O
enhancer O O
of O O
the O O
HNF4alpha O O
P1 O O
promoter O O
and O O
stimulated O O
dissociation O O
of O O
HNF3beta O O
from O O
the O O
distal O O
enhancer O O
. O O

Subsequently O O
, O O
small O O
interfering O O
RNA O O
knockdown O O
of O O
HNF4alpha O O
connected O O
PXR O O
- O O
mediated O O
gene O O
regulation O O
with O O
the O O
PXR O O
- O O
induced O O
cellular O O
responses O O
, O O
showing O O
that O O
the O O
knockdown O O
resulted O O
in O O
the O O
upregulation O O
of O O
IGFBP1 O O
and O O
EMT O O
- O O
like O O
morphological O O
changes O O
without O O
RIF O O
treatment O O
. O O

Moreover O O
, O O
recombinant O O
IGFBP1 O O
augmented O O
migration O O
, O O
whereas O O
an O O
anti O O
- O O
IGFBP1 O O
antibody O O
attenuated O O
both O O
PXR O O
- O O
induced O O
morphological O O
changes O O
and O O
migration O O
in O O
ShP51 B-CellLine B-CellLine
cells I-CellLine I-CellLine
. O O
PXR O O
indirectly O O
activated O O
the O O
IGFBP1 O O
gene O O
by O O
repressing O O
the O O
HNF4alpha O O
gene O O
, O O
thus O O
enabling O O
upregulation O O
of O O
IGFBP1 O O
to O O
change O O
the O O
morphology O O
of O O
ShP51 B-CellLine B-CellLine
cells I-CellLine I-CellLine
and O O
cause O O
migration O O
. O O

These O O
results O O
provide O O
new O O
insights O O
into O O
PXR O O
- O O
mediated O O
cellular O O
responses O O
toward O O
xenobiotics O O
including O O
therapeutics O O
. O O

ROBO1 O O
deletion O O
as O O
a O O
novel O O
germline O O
alteration O O
in O O
breast O O
and O O
colorectal O O
cancer O O
patients O O
. O O

Despite O O
one O O
third O O
of O O
breast O O
( O O
BC O O
) O O
and O O
colorectal O O
cancer O O
( O O
CRC O O
) O O
cases O O
having O O
a O O
hereditary O O
component O O
, O O
only O O
a O O
small O O
proportion O O
can O O
be O O
explained O O
by O O
germline O O
mutations O O
. O O

The O O
aim O O
of O O
this O O
study O O
was O O
to O O
identify O O
potential O O
genomic O O
alterations O O
related O O
to O O
cancer O O
predisposition O O
. O O

Copy O O
number O O
variations O O
( O O
CNVs O O
) O O
were O O
interrogated O O
in O O
113 O O
unrelated O O
cases O O
fulfilling O O
the O O
criteria O O
for O O
hereditary O O
BC O O
/ O O
CRC O O
and O O
presenting O O
non O O
- O O
pathogenic O O
mutations O O
in O O
BRCA1 O O
, O O
BRCA2 O O
, O O
MLH1 O O
, O O
MSH2 O O
, O O
TP53 O O
, O O
and O O
CHEK2 O O
genes O O
. O O

An O O
identical O O
germline O O
deep O O
intronic O O
deletion O O
of O O
ROBO1 O O
was O O
identified O O
in O O
three O O
index O O
patients O O
using O O
two O O
microarray O O
platforms O O
( O O
Agilent O O
4x180K O O
and O O
Affymetrix O O
CytoScan O O
HD O O
) O O
. O O

The O O
ROBO1 O O
deletion O O
was O O
confirmed O O
by O O
quantitative O O
PCR O O
( O O
qPCR O O
) O O
. O O

Six O O
relatives O O
were O O
also O O
evaluated O O
by O O
CytoScan O O
HD O O
Array O O
. O O

Genomic O O
analysis O O
confirmed O O
a O O
co O O
- O O
segregation O O
of O O
the O O
ROBO1 O O
deletion O O
with O O
the O O
occurrence O O
of O O
cancer O O
in O O
two O O
families O O
. O O

Direct O O
sequencing O O
revealed O O
no O O
pathogenic O O
ROBO1 O O
point O O
mutations O O
. O O

Transcriptomic O O
analysis O O
( O O
HTA O O
2 O O
. O O
0 O O
, O O
Affymetrix O O
) O O
in O O
two O O
breast O O
carcinomas O O
from O O
a O O
single O O
patient O O
revealed O O
ROBO1 O O
down O O
- O O
expression O O
with O O
no O O
splicing O O
events O O
near O O
the O O
intronic O O
deletion O O
. O O

Deeper O O
in O O
silico O O
analysis O O
showed O O
several O O
enhancer O O
regions O O
and O O
a O O
histone O O
methylation O O
mark O O
in O O
the O O
deleted O O
region O O
. O O

The O O
ROBO1 O O
deletion O O
in O O
a O O
putative O O
transcriptional O O
regulatory O O
region O O
, O O
its O O
down O O
- O O
expression O O
in O O
tumor O O
samples O O
, O O
and O O
the O O
results O O
of O O
the O O
co O O
- O O
segregation O O
analysis O O
revealing O O
the O O
presence O O
of O O
the O O
alteration O O
in O O
affected O O
individuals O O
suggest O O
a O O
pathogenic O O
effect O O
of O O
the O O
ROBO1 O O
in O O
cancer O O
predisposition O O
. O O

Comparison O O
of O O
DNA O O
Methylation O O
and O O
Expression O O
Pattern O O
of O O
S100 O O
and O O
Other O O
Epidermal O O
Differentiation O O
Complex O O
Genes O O
in O O
Differentiating O O
Keratinocytes B-CellLine B-CellLine
. O O

Epidermal O O
Differentiation O O
Complex O O
( O O
EDC O O
) O O
is O O
a O O
gene O O
cluster O O
on O O
human O O
chromosome O O
1 O O
q21 O O
, O O
which O O
comprises O O
genes O O
encoding O O
four O O
protein O O
families O O
: O O
S100 O O
, O O
S100 O O
fused O O
( O O
SFTP O O
) O O
, O O
small O O
proline O O
- O O
rich O O
region O O
( O O
SPRR O O
) O O
and O O
late O O
cornified O O
envelope O O
( O O
LCE O O
) O O
proteins O O
. O O

Contrary O O
to O O
the O O
latter O O
three O O
families O O
, O O
which O O
group O O
proteins O O
important O O
for O O
skin B-CellLine B-CellLine
barrier O O
formation O O
, O O
the O O
role O O
of O O
S100 O O
proteins O O
has O O
not O O
been O O
well O O
defined O O
and O O
there O O
are O O
no O O
systematic O O
comparative O O
data O O
concerning O O
their O O
expression O O
in O O
the O O
epidermis B-CellLine B-CellLine
. O O

Furthermore O O
, O O
little O O
is O O
known O O
about O O
epigenetic O O
mechanisms O O
controlling O O
changes O O
in O O
S100 O O
and O O
other O O
EDC O O
genes O O
expression O O
in O O
differentiating O O
epidermis B-CellLine B-CellLine
. O O

In O O
our O O
study O O
, O O
using O O
real O O
- O O
time O O
PCR O O
, O O
we O O
followed O O
the O O
expression O O
of O O
nine O O
S100 O O
genes O O
at O O
subsequent O O
stages O O
of O O
differentiation O O
of O O
primary O O
human O O
keratinocytes B-CellLine B-CellLine
and O O
found O O
that O O
they O O
exhibited O O
different O O
expression O O
patterns O O
. O O

Then O O
, O O
we O O
confronted O O
the O O
expression O O
level O O
in O O
undifferentiated O O
and O O
differentiated O O
keratinocytes B-CellLine B-CellLine
with O O
the O O
extent O O
of O O
DNA O O
methylation O O
within O O
their O O
promoter O O
or O O
intragenic O O
regions O O
assessed O O
by O O
bisulfite O O
sequencing O O
. O O

Methylation O O
analysis O O
was O O
also O O
performed O O
for O O
three O O
other O O
EDC O O
genes O O
of O O
known O O
expression O O
pattern O O
( O O
involucrin O O
, O O
loricrin O O
, O O
and O O
NICE O O
- O O
1 O O
) O O
and O O
a O O
recently O O
identified O O
evolutionary O O
conserved O O
region O O
with O O
defined O O
enhancer O O
properties O O
. O O

The O O
results O O
indicate O O
that O O
altered O O
EDC O O
genes O O
expression O O
is O O
not O O
accompanied O O
by O O
major O O
changes O O
in O O
DNA O O
methylation O O
. O O

Gold O O
nanoparticles O O
induce O O
heme O O
oxygenase O O
- O O
1 O O
expression O O
through O O
Nrf2 O O
activation O O
and O O
Bach1 O O
export O O
in O O
human O O
vascular B-CellLine B-CellLine
endothelial I-CellLine I-CellLine
cells I-CellLine I-CellLine
. O O

It O O
has O O
been O O
reported O O
that O O
increased O O
levels O O
and O O
activity O O
of O O
the O O
heme O O
oxygenase O O
- O O
1 O O
( O O
HO O O
- O O
1 O O
) O O
protein O O
ameliorate O O
tissue O O
injuries O O
. O O

In O O
the O O
present O O
study O O
, O O
we O O
investigated O O
the O O
effects O O
and O O
mechanisms O O
of O O
action O O
of O O
gold O O
nanoparticles O O
( O O
AuNPs O O
) O O
on O O
HO O O
- O O
1 O O
protein O O
expression O O
in O O
human O O
vascular B-CellLine B-CellLine
endothelial I-CellLine I-CellLine
cells I-CellLine I-CellLine
( O O
ECs B-CellLine B-CellLine
) O O
. O O

The O O
AuNPs O O
induced O O
HO O O
- O O
1 O O
protein O O
and O O
mRNA O O
expression O O
in O O
a O O
concentration O O
- O O
and O O
time O O
- O O
dependent O O
manner O O
. O O

The O O
induction O O
was O O
reduced O O
by O O
the O O
thiol O O
- O O
containing O O
antioxidants O O
, O O
including O O
N O O
- O O
acetylcysteine O O
and O O
glutathione O O
, O O
but O O
not O O
by O O
the O O
non O O
- O O
thiol O O
- O O
containing O O
antioxidants O O
and O O
inhibitors O O
that O O
block O O
the O O
enzymes O O
for O O
intracellular O O
reactive O O
oxygen O O
species O O
generation O O
. O O

The O O
AuNPs O O
enhanced O O
Nrf2 O O
protein O O
levels O O
but O O
did O O
not O O
affect O O
Nrf2 O O
mRNA O O
expression O O
. O O

In O O
response O O
to O O
the O O
AuNP O O
treatment O O
, O O
the O O
cytosolic O O
Nrf2 O O
translocated O O
to O O
the O O
nucleus O O
, O O
and O O
, O O
concomitantly O O
, O O
Bach1 O O
exited O O
the O O
nucleus O O
and O O
its O O
tyrosine O O
phosphorylation O O
increased O O
. O O

The O O
chromatin O O
immunoprecipitation O O
assay O O
revealed O O
that O O
the O O
translocated O O
Nrf2 O O
bound O O
to O O
the O O
antioxidant O O
- O O
response O O
element O O
located O O
in O O
the O O
E2 O O
enhancer O O
region O O
of O O
the O O
HO O O
- O O
1 O O
gene O O
promoter O O
and O O
acted O O
as O O
a O O
transcription O O
factor O O
. O O
The O O
chromatin O O
immunoprecipitation O O
assay O O
revealed O O
that O O
the O O
translocated O O
Nrf2 O O
bound O O
to O O
the O O
antioxidant O O
- O O
response O O
element O O
located O O
in O O
the O O
E2 O O
enhancer O O
region O O
of O O
the O O
HO O O
- O O
1 O O
gene O O
promoter O O
and O O
acted O O
as O O
a O O
transcription O O
factor O O
. O O

Although O O
N O O
- O O
acetylcysteine O O
inhibited O O
the O O
AuNP O O
- O O
induced O O
Nrf2 O O
nuclear O O
translocation O O
, O O
the O O
AuNPs O O
did O O
not O O
promote O O
intracellular O O
reactive O O
oxygen O O
species O O
production O O
or O O
endoplasmic O O
reticulum O O
stress O O
in O O
the O O
ECs B-CellLine B-CellLine
. O O

Knockdown O O
of O O
Nrf2 O O
expression O O
by O O
RNA O O
interference O O
significantly O O
inhibited O O
AuNP O O
- O O
induced O O
HO O O
- O O
1 O O
expression O O
at O O
the O O
protein O O
and O O
mRNA O O
levels O O
. O O

In O O
summary O O
, O O
AuNPs O O
enhance O O
the O O
levels O O
and O O
nuclear O O
translocation O O
of O O
the O O
Nrf2 O O
protein O O
and O O
Bach1 O O
export O O
/ O O
tyrosine O O
phosphorylation O O
, O O
leading O O
to O O
Nrf2 O O
binding O O
to O O
the O O
HO O O
- O O
1 O O
E2 O O
enhancer O O
promoter O O
region O O
to O O
drive O O
HO O O
- O O
1 O O
expression O O
in O O
ECs B-CellLine B-CellLine
. O O
In O O
summary O O
, O O
AuNPs O O
enhance O O
the O O
levels O O
and O O
nuclear O O
translocation O O
of O O
the O O
Nrf2 O O
protein O O
and O O
Bach1 O O
export O O
/ O O
tyrosine O O
phosphorylation O O
, O O
leading O O
to O O
Nrf2 O O
binding O O
to O O
the O O
HO O O
- O O
1 O O
E2 O O
enhancer O O
promoter O O
region O O
to O O
drive O O
HO O O
- O O
1 O O
expression O O
in O O
ECs B-CellLine B-CellLine
. O O

This O O
study O O
, O O
together O O
with O O
our O O
parallel O O
findings O O
, O O
demonstrates O O
that O O
AuNPs O O
can O O
act O O
as O O
an O O
HO O O
- O O
1 O O
inducer O O
, O O
which O O
may O O
partially O O
contribute O O
to O O
their O O
anti O O
- O O
inflammatory O O
bioactivity O O
in O O
human O O
vascular O B-CellLine
ECs B-CellLine I-CellLine
. O O

Highly O O
specific O O
epigenome O O
editing O O
by O O
CRISPR O O
- O O
Cas9 O O
repressors O O
for O O
silencing O O
of O O
distal O O
regulatory O O
elements O O
. O O

Epigenome O O
editing O O
with O O
the O O
CRISPR O O
( O O
clustered O O
, O O
regularly O O
interspaced O O
, O O
short O O
palindromic O O
repeats O O
) O O
- O O
Cas9 O O
platform O O
is O O
a O O
promising O O
technology O O
for O O
modulating O O
gene O O
expression O O
to O O
direct O O
cell O O
phenotype O O
and O O
to O O
dissect O O
the O O
causal O O
epigenetic O O
mechanisms O O
of O O
gene O O
regulation O O
. O O

Fusions O O
of O O
nuclease O O
- O O
inactive O O
dCas9 O O
to O O
the O O
Kruppel O O
- O O
associated O O
box O O
( O O
KRAB O O
) O O
repressor O O
( O O
dCas9 O O
- O O
KRAB O O
) O O
can O O
silence O O
target O O
gene O O
expression O O
, O O
but O O
the O O
genome O O
- O O
wide O O
specificity O O
and O O
the O O
extent O O
of O O
heterochromatin O O
formation O O
catalyzed O O
by O O
dCas9 O O
- O O
KRAB O O
are O O
not O O
known O O
. O O

We O O
targeted O O
dCas9 O O
- O O
KRAB O O
to O O
the O O
HS2 O O
enhancer O O
, O O
a O O
distal O O
regulatory O O
element O O
that O O
orchestrates O O
the O O
expression O O
of O O
multiple O O
globin O O
genes O O
, O O
and O O
observed O O
highly O O
specific O O
induction O O
of O O
H3K9 O O
trimethylation O O
( O O
H3K9me3 O O
) O O
at O O
the O O
enhancer O O
and O O
decreased O O
chromatin O O
accessibility O O
of O O
both O O
the O O
enhancer O O
and O O
its O O
promoter O O
targets O O
. O O

Targeted O O
epigenetic O O
modification O O
of O O
HS2 O O
silenced O O
the O O
expression O O
of O O
multiple O O
globin O O
genes O O
, O O
with O O
minimal O O
off O O
- O O
target O O
changes O O
in O O
global O O
gene O O
expression O O
. O O

These O O
results O O
demonstrate O O
that O O
repression O O
mediated O O
by O O
dCas9 O O
- O O
KRAB O O
is O O
sufficiently O O
specific O O
to O O
disrupt O O
the O O
activity O O
of O O
individual O O
enhancers O O
via O O
local O O
modification O O
of O O
the O O
epigenome O O
. O O

Genetic O O
predisposition O O
to O O
neuroblastoma O O
mediated O O
by O O
a O O
LMO1 O O
super O O
- O O
enhancer O O
polymorphism O O
. O O
Neuroblastoma O O
is O O
a O O
paediatric O O
malignancy O O
that O O
typically O O
arises O O
in O O
early O O
childhood O O
, O O
and O O
is O O
derived O O
from O O
the O O
developing O O
sympathetic B-CellLine B-CellLine
nervous I-CellLine I-CellLine
system I-CellLine I-CellLine
. O O
Genetic O O
predisposition O O
to O O
neuroblastoma O O
mediated O O
by O O
a O O
LMO1 O O
super O O
- O O
enhancer O O
polymorphism O O
. O O
Neuroblastoma O O
is O O
a O O
paediatric O O
malignancy O O
that O O
typically O O
arises O O
in O O
early O O
childhood O O
, O O
and O O
is O O
derived O O
from O O
the O O
developing O O
sympathetic B-CellLine B-CellLine
nervous I-CellLine I-CellLine
system I-CellLine I-CellLine
. O O

Clinical O O
phenotypes O O
range O O
from O O
localized O O
tumours O O
with O O
excellent O O
outcomes O O
to O O
widely O O
metastatic O O
disease O O
in O O
which O O
long O O
- O O
term O O
survival O O
is O O
approximately O O
40 O O
% O O
despite O O
intensive O O
therapy O O
. O O

A O O
previous O O
genome O O
- O O
wide O O
association O O
study O O
identified O O
common O O
polymorphisms O O
at O O
the O O
LMO1 O O
gene O O
locus O O
that O O
are O O
highly O O
associated O O
with O O
neuroblastoma O O
susceptibility O O
and O O
oncogenic O O
addiction O O
to O O
LMO1 O O
in O O
the O O
tumour B-CellLine B-CellLine
cells I-CellLine I-CellLine
. O O

Here O O
we O O
investigate O O
the O O
causal O O
DNA O O
variant O O
at O O
this O O
locus O O
and O O
the O O
mechanism O O
by O O
which O O
it O O
leads O O
to O O
neuroblastoma O O
tumorigenesis O O
. O O

We O O
first O O
imputed O O
all O O
possible O O
genotypes O O
across O O
the O O
LMO1 O O
locus O O
and O O
then O O
mapped O O
highly O O
associated O O
single O O
nucleotide O O
polymorphism O O
( O O
SNPs O O
) O O
to O O
areas O O
of O O
chromatin O O
accessibility O O
, O O
evolutionary O O
conservation O O
and O O
transcription O O
factor O O
binding O O
sites O O
. O O

We O O
show O O
that O O
SNP O O
rs2168101 O O
G O O
> O O
T O O
is O O
the O O
most O O
highly O O
associated O O
variant O O
( O O
combined O O
P O O
= O O
7 O O
. O O
47 O O
x O O
10 O O
( O O
- O O
29 O O
) O O
, O O
odds O O
ratio O O
0 O O
. O O
65 O O
, O O
95 O O
% O O
confidence O O
interval O O
0 O O
. O O
60 O O
- O O
0 O O
. O O
70 O O
) O O
, O O
and O O
resides O O
in O O
a O O
super O O
- O O
enhancer O O
defined O O
by O O
extensive O O
acetylation O O
of O O
histone O O
H3 O O
lysine O O
27 O O
within O O
the O O
first O O
intron O O
of O O
LMO1 O O
. O O
We O O
show O O
that O O
SNP O O
rs2168101 O O
G O O
> O O
T O O
is O O
the O O
most O O
highly O O
associated O O
variant O O
( O O
combined O O
P O O
= O O
7 O O
. O O
47 O O
x O O
10 O O
( O O
- O O
29 O O
) O O
, O O
odds O O
ratio O O
0 O O
. O O
65 O O
, O O
95 O O
% O O
confidence O O
interval O O
0 O O
. O O
60 O O
- O O
0 O O
. O O
70 O O
) O O
, O O
and O O
resides O O
in O O
a O O
super O O
- O O
enhancer O O
defined O O
by O O
extensive O O
acetylation O O
of O O
histone O O
H3 O O
lysine O O
27 O O
within O O
the O O
first O O
intron O O
of O O
LMO1 O O
. O O

The O O
ancestral O O
G O O
allele O O
that O O
is O O
associated O O
with O O
tumour O O
formation O O
resides O O
in O O
a O O
conserved O O
GATA O O
transcription O O
factor O O
binding O O
motif O O
. O O

We O O
show O O
that O O
the O O
newly O O
evolved O O
protective O O
TATA O O
allele O O
is O O
associated O O
with O O
decreased O O
total O O
LMO1 O O
expression O O
( O O
P O O
= O O
0 O O
. O O
028 O O
) O O
in O O
neuroblastoma O O
primary O O
tumours O O
, O O
and O O
ablates O O
GATA3 O O
binding O O
( O O
P O O
< O O
0 O O
. O O
0001 O O
) O O
. O O

We O O
demonstrate O O
allelic O O
imbalance O O
favouring O O
the O O
G O O
- O O
containing O O
strand O O
in O O
tumours O O
heterozygous O O
for O O
this O O
SNP O O
, O O
as O O
demonstrated O O
both O O
by O O
RNA O O
sequencing O O
( O O
P O O
< O O
0 O O
. O O
0001 O O
) O O
and O O
reporter O O
assays O O
( O O
P O O
= O O
0 O O
. O O
002 O O
) O O
. O O

These O O
findings O O
indicate O O
that O O
a O O
recently O O
evolved O O
polymorphism O O
within O O
a O O
super O O
- O O
enhancer O O
element O O
in O O
the O O
first O O
intron O O
of O O
LMO1 O O
influences O O
neuroblastoma O O
susceptibility O O
through O O
differential O O
GATA O O
transcription O O
factor O O
binding O O
and O O
direct O O
modulation O O
of O O
LMO1 O O
expression O O
in O O
cis O O
, O O
and O O
this O O
leads O O
to O O
an O O
oncogenic O O
dependency O O
in O O
tumour B-CellLine B-CellLine
cells I-CellLine I-CellLine
. O O
These O O
findings O O
indicate O O
that O O
a O O
recently O O
evolved O O
polymorphism O O
within O O
a O O
super O O
- O O
enhancer O O
element O O
in O O
the O O
first O O
intron O O
of O O
LMO1 O O
influences O O
neuroblastoma O O
susceptibility O O
through O O
differential O O
GATA O O
transcription O O
factor O O
binding O O
and O O
direct O O
modulation O O
of O O
LMO1 O O
expression O O
in O O
cis O O
, O O
and O O
this O O
leads O O
to O O
an O O
oncogenic O O
dependency O O
in O O
tumour B-CellLine B-CellLine
cells I-CellLine I-CellLine
. O O

Identification O O
of O O
focally O O
amplified O O
lineage O O
- O O
specific O O
super O O
- O O
enhancers O O
in O O
human O O
epithelial O O
cancers O O
. O O

Whole O O
- O O
genome O O
analysis O O
approaches O O
are O O
identifying O O
recurrent O O
cancer O O
- O O
associated O O
somatic O O
alterations O O
in O O
noncoding O O
DNA O O
regions O O
. O O

We O O
combined O O
somatic O O
copy O O
number O O
analysis O O
of O O
12 O O
tumor O O
types O O
with O O
tissue O O
- O O
specific O O
epigenetic O O
profiling O O
to O O
identify O O
significant O O
regions O O
of O O
focal O O
amplification O O
harboring O O
super O O
- O O
enhancers O O
. O O

Copy O O
number O O
gains O O
of O O
noncoding O O
regions O O
harboring O O
super O O
- O O
enhancers O O
near O O
KLF5 O O
, O O
USP12 O O
, O O
PARD6B O O
and O O
MYC O O
are O O
associated O O
with O O
overexpression O O
of O O
these O O
cancer O O
- O O
related O O
genes O O
. O O

We O O
show O O
that O O
two O O
distinct O O
focal O O
amplifications O O
of O O
super O O
- O O
enhancers O O
3 O O
' O O
to O O
MYC O O
in O O
lung O O
adenocarcinoma O O
( O O
MYC O O
- O O
LASE O O
) O O
and O O
endometrial O O
carcinoma O O
( O O
MYC O O
- O O
ECSE O O
) O O
are O O
physically O O
associated O O
with O O
the O O
MYC O O
promoter O O
and O O
correlate O O
with O O
MYC O O
overexpression O O
. O O
We O O
show O O
that O O
two O O
distinct O O
focal O O
amplifications O O
of O O
super O O
- O O
enhancers O O
3 O O
' O O
to O O
MYC O O
in O O
lung O O
adenocarcinoma O O
( O O
MYC O O
- O O
LASE O O
) O O
and O O
endometrial O O
carcinoma O O
( O O
MYC O O
- O O
ECSE O O
) O O
are O O
physically O O
associated O O
with O O
the O O
MYC O O
promoter O O
and O O
correlate O O
with O O
MYC O O
overexpression O O
. O O

CRISPR O O
/ O O
Cas9 O O
- O O
mediated O O
repression O O
or O O
deletion O O
of O O
a O O
constituent O O
enhancer O O
within O O
the O O
MYC O O
- O O
LASE O O
region O O
led O O
to O O
significant O O
reductions O O
in O O
the O O
expression O O
of O O
MYC O O
and O O
its O O
target O O
genes O O
and O O
to O O
the O O
impairment O O
of O O
anchorage O O
- O O
independent O O
and O O
clonogenic O O
growth O O
, O O
consistent O O
with O O
an O O
oncogenic O O
function O O
. O O
CRISPR O O
/ O O
Cas9 O O
- O O
mediated O O
repression O O
or O O
deletion O O
of O O
a O O
constituent O O
enhancer O O
within O O
the O O
MYC O O
- O O
LASE O O
region O O
led O O
to O O
significant O O
reductions O O
in O O
the O O
expression O O
of O O
MYC O O
and O O
its O O
target O O
genes O O
and O O
to O O
the O O
impairment O O
of O O
anchorage O O
- O O
independent O O
and O O
clonogenic O O
growth O O
, O O
consistent O O
with O O
an O O
oncogenic O O
function O O
. O O

Our O O
results O O
suggest O O
that O O
genomic O O
amplification O O
of O O
super O O
- O O
enhancers O O
represents O O
a O O
common O O
mechanism O O
to O O
activate O O
cancer O O
driver O O
genes O O
in O O
multiple O O
cancer O O
types O O
. O O

Inhibition O O
of O O
growth O O
, O O
migration O O
and O O
invasion O O
of O O
human O O
bladder B-CellLine B-CellLine
cancer I-CellLine I-CellLine
cells I-CellLine I-CellLine
by O O
antrocin O O
, O O
a O O
sesquiterpene O O
lactone O O
isolated O O
from O O
Antrodia O O
cinnamomea O O
, O O
and O O
its O O
molecular O O
mechanisms O O
. O O
Bladder O O
cancer O O
is O O
the O O
ninth O O
most O O
common O O
cancer O O
around O O
the O O
world O O
, O O
and O O
is O O
a O O
severe O O
urological O O
cancer O O
irrespective O O
of O O
sex O O
. O O

Approximately O O
65 O O
% O O
of O O
the O O
bladder O O
cancers O O
will O O
recur O O
following O O
surgery O O
; O O
with O O
more O O
than O O
20 O O
% O O
of O O
those O O
patients O O
showing O O
an O O
advanced O O
and O O
metastatic O O
stage O O
, O O
with O O
reducing O O
prognosis O O
. O O

Metastasis O O
causes O O
the O O
most O O
death O O
of O O
bladder O O
cancer O O
yet O O
current O O
therapeutic O O
options O O
remain O O
limited O O
. O O

Antrocin O O
, O O
a O O
sesquiterpene O O
lactone O O
isolated O O
from O O
Antrodia O O
cinnamomea O O
, O O
has O O
been O O
identified O O
as O O
a O O
strong O O
cytotoxic O O
agent O O
against O O
lung B-CellLine B-CellLine
and O O
metastatic O B-CellLine
breast B-CellLine I-CellLine
cancer I-CellLine I-CellLine
cells I-CellLine I-CellLine
; O O
however O O
, O O
the O O
effects O O
and O O
mechanisms O O
of O O
antrocin O O
on O O
cancer O O
growth O O
and O O
metastasis O O
remain O O
largely O O
unclear O O
. O O

This O O
study O O
showed O O
that O O
treatment O O
with O O
cytotoxic O O
concentration O O
of O O
antrocin O O
induced O O
both O O
intrinsic O O
and O O
extrinsic O O
apoptotic O O
pathways O O
in O O
human O O
bladder B-CellLine B-CellLine
cancer I-CellLine I-CellLine
5637 I-CellLine I-CellLine
cells I-CellLine I-CellLine
, O O
evidenced O O
by O O
increase O O
of O O
Fas O O
, O O
DR5 O O
, O O
Bax O O
expression O O
and O O
caspase O O
- O O
3 O O
, O O
- O O
8 O O
and O O
- O O
9 O O
activation O O
. O O

Exposure O O
to O O
non O O
- O O
cytotoxic O O
concentrations O O
of O O
antrocin O O
significantly O O
inhibited O O
cell O O
growth O O
, O O
migration O O
, O O
and O O
invasion O O
, O O
which O O
was O O
associated O O
with O O
decreased O O
phosphorylation O O
of O O
focal O O
adhesion O O
kinase O O
( O O
FAK O O
) O O
and O O
paxillin O O
. O O

Antrocin O O
also O O
reduced O O
subcellular O O
distribution O O
of O O
FAK O O
and O O
paxillin O O
at O O
the O O
focal O O
adhesion O O
contacts O O
of O O
the O O
cell O O
periphery O O
site O O
, O O
and O O
disrupted O O
the O O
formation O O
of O O
filopodia O O
and O O
lamellipodia O O
. O O

Moreover O O
, O O
antrocin O O
increased O O
epithelial O O
- O O
to O O
- O O
mesenchymal O O
transition O O
- O O
related O O
gene O O
E O O
- O O
cadherin O O
and O O
decreased O O
vimentin O O
expression O O
. O O

Real O O
- O O
time O O
PCR O O
analysis O O
showed O O
that O O
antrocin O O
downregulated O O
the O O
expression O O
of O O
mRNA O O
of O O
several O O
MMPs O O
, O O
including O O
MMP O O
- O O
2 O O
. O O

Moreover O O
, O O
the O O
phosphorylation O O
of O O
ERK O O
and O O
c O O
- O O
Fos O O
were O O
also O O
attenuated O O
by O O
antrocin O O
. O O

Data O O
from O O
chromatin O O
immunoprecipitation O O
assay O O
demonstrated O O
that O O
antrocin O O
decreased O O
the O O
DNA O O
binding O O
activity O O
of O O
c O O
- O O
Fos O O
to O O
the O O
upstream O O
/ O O
enhancer O O
region O O
of O O
MMP O O
- O O
2 O O
promoter O O
, O O
an O O
action O O
likely O O
to O O
result O O
in O O
the O O
reducing O O
MMP O O
- O O
2 O O
expression O O
. O O
Data O O
from O O
chromatin O O
immunoprecipitation O O
assay O O
demonstrated O O
that O O
antrocin O O
decreased O O
the O O
DNA O O
binding O O
activity O O
of O O
c O O
- O O
Fos O O
to O O
the O O
upstream O O
/ O O
enhancer O O
region O O
of O O
MMP O O
- O O
2 O O
promoter O O
, O O
an O O
action O O
likely O O
to O O
result O O
in O O
the O O
reducing O O
MMP O O
- O O
2 O O
expression O O
. O O

Overall O O
, O O
this O O
is O O
the O O
first O O
study O O
which O O
demonstrates O O
that O O
antrocin O O
- O O
inhibited O O
migration O O
and O O
invasion O O
of O O
bladder B-CellLine B-CellLine
cancer I-CellLine I-CellLine
cells I-CellLine I-CellLine
is O O
partly O O
via O O
inactivation O O
of O O
FAK O O
- O O
paxillin O O
and O O
ERK O O
- O O
c O O
- O O
Fos O O
- O O
MMP2 O O
signaling O O
pathways O O
. O O

Both O O
antrocin O O
- O O
induced O O
intrinsic O O
and O O
extrinsic O O
apoptosis O O
is O O
through O O
upregulation O O
of O O
pro O O
- O O
apoptotic O O
proteins O O
, O O
including O O
Bax O O
, O O
Fas O O
, O O
and O O
DR5 O O
. O O

These O O
results O O
provide O O
insights O O
for O O
understanding O O
the O O
anti O O
- O O
cancer O O
effects O O
and O O
mechanisms O O
of O O
antrocin O O
in O O
human O O
bladder B-CellLine B-CellLine
cancer I-CellLine I-CellLine
cells I-CellLine I-CellLine
and O O
indicate O O
that O O
antrocin O O
may O O
be O O
a O O
potential O O
therapeutic O O
agent O O
for O O
invasive O O
bladder B-CellLine B-CellLine
cancer I-CellLine I-CellLine
cells I-CellLine I-CellLine
by O O
inhibition O O
of O O
metastasis O O
and O O
induction O O
of O O
apoptosis O O
. O O

Integrated O O
genome O O
- O O
scale O O
analysis O O
of O O
the O O
transcriptional O O
regulatory O O
landscape O O
in O O
a O O
blood B-CellLine B-CellLine
stem O I-CellLine
/ O I-CellLine
progenitor O I-CellLine
cell O I-CellLine
model O O
. O O

Comprehensive O O
study O O
of O O
transcriptional O O
control O O
processes O O
will O O
be O O
required O O
to O O
enhance O O
our O O
understanding O O
of O O
both O O
normal O O
and O O
malignant O O
hematopoiesis O O
. O O

Modern O O
sequencing O O
technologies O O
have O O
revolutionized O O
our O O
ability O O
to O O
generate O O
genome O O
- O O
scale O O
expression O O
and O O
histone O O
modification O O
profiles O O
, O O
transcription O O
factor O O
( O O
TF O O
) O O
- O O
binding O O
maps O O
, O O
and O O
also O O
comprehensive O O
chromatin O O
- O O
looping O O
information O O
. O O

Many O O
of O O
these O O
technologies O O
, O O
however O O
, O O
require O O
large O O
numbers O O
of O O
cells O O
, O O
and O O
therefore O O
cannot O O
be O O
applied O O
to O O
rare O O
hematopoietic B-CellLine B-CellLine
stem I-CellLine I-CellLine
/ I-CellLine I-CellLine
progenitor I-CellLine I-CellLine
cell I-CellLine I-CellLine
( O O
HSPC B-CellLine B-CellLine
) O O
populations O O
. O O

The O O
stem B-CellLine B-CellLine
cell I-CellLine I-CellLine
factor I-CellLine O
- I-CellLine O
dependent I-CellLine O
multipotent I-CellLine B-CellLine
progenitor I-CellLine I-CellLine
cell I-CellLine I-CellLine
line I-CellLine I-CellLine
HPC I-CellLine I-CellLine
- I-CellLine I-CellLine
7 I-CellLine I-CellLine
represents O O
a O O
well O O
- O O
recognized O O
cell O O
line O O
model O O
for O O
HSPCs B-CellLine B-CellLine
. O O

Here O O
we O O
report O O
genome O O
- O O
wide O O
maps O O
for O O
17 O O
TFs O O
, O O
3 O O
histone O O
modifications O O
, O O
DNase O O
I O O
hypersensitive O O
sites O O
, O O
and O O
high O O
- O O
resolution O O
promoter O O
- O O
enhancer O O
interactomes O O
in O O
HPC B-CellLine B-CellLine
- I-CellLine I-CellLine
7 I-CellLine I-CellLine
cells I-CellLine I-CellLine
. O O

Integrated O O
analysis O O
of O O
these O O
complementary O O
data O O
sets O O
revealed O O
TF O O
occupancy O O
patterns O O
of O O
genomic O O
regions O O
involved O O
in O O
promoter O O
- O O
anchored O O
loops O O
. O O

Moreover O O
, O O
preferential O O
associations O O
between O O
pairs O O
of O O
TFs O O
bound O O
at O O
either O O
ends O O
of O O
chromatin O O
loops O O
led O O
to O O
the O O
identification O O
of O O
4 O O
previously O O
unrecognized O O
protein O O
- O O
protein O O
interactions O O
between O O
key O O
blood B-CellLine B-CellLine
stem I-CellLine I-CellLine
cell I-CellLine I-CellLine
regulators O O
. O O

All O O
HPC B-CellLine O
- I-CellLine O
7 I-CellLine O
data O O
sets O O
are O O
freely O O
available O O
both O O
through O O
standard O O
repositories O O
and O O
a O O
user O O
- O O
friendly O O
Web O O
interface O O
. O O

Together O O
with O O
previously O O
generated O O
genome O O
- O O
wide O O
data O O
sets O O
, O O
this O O
study O O
integrates O O
HPC B-CellLine O
- I-CellLine O
7 I-CellLine O
data O O
into O O
a O O
genomic O O
resource O O
on O O
par O O
with O O
ENCODE O O
tier O B-CellLine
1 O I-CellLine
cell O I-CellLine
lines O I-CellLine
and O O
, O O
importantly O O
, O O
is O O
the O O
only O O
current O O
model O O
with O O
comprehensive O O
genome O O
- O O
scale O O
data O O
that O O
is O O
relevant O O
to O O
HSPC B-CellLine B-CellLine
biology O O
. O O

A O O
new O O
class O O
of O O
temporarily O O
phenotypic O O
enhancers O O
identified O O
by O O
CRISPR O O
/ O O
Cas9 O O
- O O
mediated O O
genetic O O
screening O O
. O O

With O O
< O O
2 O O
% O O
of O O
the O O
human O O
genome O O
coding O O
for O O
proteins O O
, O O
a O O
major O O
challenge O O
is O O
to O O
interpret O O
the O O
function O O
of O O
the O O
noncoding O O
DNA O O
. O O

Millions O O
of O O
regulatory O O
sequences O O
have O O
been O O
predicted O O
in O O
the O O
human O O
genome O O
through O O
analysis O O
of O O
DNA O O
methylation O O
, O O
chromatin O O
modification O O
, O O
hypersensitivity O O
to O O
nucleases O O
, O O
and O O
transcription O O
factor O O
binding O O
, O O
but O O
few O O
have O O
been O O
shown O O
to O O
regulate O O
transcription O O
in O O
their O O
native O O
contexts O O
. O O

We O O
have O O
developed O O
a O O
high O O
- O O
throughput O O
CRISPR O O
/ O O
Cas9 O O
- O O
based O O
genome O O
- O O
editing O O
strategy O O
and O O
used O O
it O O
to O O
interrogate O O
174 O O
candidate O O
regulatory O O
sequences O O
within O O
the O O
1 O O
- O O
Mbp O O
POU5F1 O O
locus O O
in O O
human B-CellLine B-CellLine
embryonic I-CellLine I-CellLine
stem I-CellLine I-CellLine
cells I-CellLine I-CellLine
( O O
hESCs B-CellLine B-CellLine
) O O
. O O

We O O
identified O O
two O O
classical O O
regulatory O O
elements O O
, O O
including O O
a O O
promoter O O
and O O
a O O
proximal O O
enhancer O O
, O O
that O O
are O O
essential O O
for O O
POU5F1 O O
transcription O O
in O O
hESCs B-CellLine B-CellLine
. O O

Unexpectedly O O
, O O
we O O
also O O
discovered O O
a O O
new O O
class O O
of O O
enhancers O O
that O O
contribute O O
to O O
POU5F1 O O
transcription O O
in O O
an O O
unusual O O
way O O
: O O
Disruption O O
of O O
such O O
sequences O O
led O O
to O O
a O O
temporary O O
loss O O
of O O
POU5F1 O O
transcription O O
that O O
is O O
fully O O
restored O O
after O O
a O O
few O O
rounds O O
of O O
cell O O
division O O
. O O

These O O
results O O
demonstrate O O
the O O
utility O O
of O O
high O O
- O O
throughput O O
screening O O
for O O
functional O O
characterization O O
of O O
noncoding O O
DNA O O
and O O
reveal O O
a O O
previously O O
unrecognized O O
layer O O
of O O
gene O O
regulation O O
in O O
human O O
cells O O
. O O

In O O
Vivo O O
Deletion O O
of O O
the O O
Cebpa O O
+ O O
37 O O
kb O O
Enhancer O O
Markedly O O
Reduces O O
Cebpa O O
mRNA O O
in O O
Myeloid B-CellLine B-CellLine
Progenitors I-CellLine I-CellLine
but O O
Not O O
in O O
Non O O
- O O
Hematopoietic O O
Tissues O O
to O O
Impair O O
Granulopoiesis O O
. O O
In O O
Vivo O O
Deletion O O
of O O
the O O
Cebpa O O
+ O O
37 O O
kb O O
Enhancer O O
Markedly O O
Reduces O O
Cebpa O O
mRNA O O
in O O
Myeloid B-CellLine B-CellLine
Progenitors I-CellLine I-CellLine
but O O
Not O O
in O O
Non O O
- O O
Hematopoietic O O
Tissues O O
to O O
Impair O O
Granulopoiesis O O
. O O

The O O
murine O O
Cebpa O O
gene O O
contains O O
a O O
+ O O
37 O O
kb O O
, O O
evolutionarily O O
conserved O O
440 O O
bp O O
enhancer O O
that O O
directs O O
high O O
- O O
level O O
expression O O
to O O
myeloid B-CellLine B-CellLine
progenitors I-CellLine I-CellLine
in O O
transgenic O O
mice O O
. O O

The O O
enhancer O O
is O O
bound O O
and O O
activated O O
by O O
Runx1 O O
, O O
Scl O O
, O O
GATA2 O O
, O O
C O O
/ O O
EBPalpha O O
, O O
c O O
- O O
Myb O O
, O O
Pu O O
. O O
1 O O
, O O
and O O
additional O O
Ets O O
factors O O
in O O
myeloid B-CellLine B-CellLine
cells I-CellLine I-CellLine
. O O

CRISPR O O
/ O O
Cas9 O O
- O O
mediated O O
replacement O O
of O O
the O O
wild O O
- O O
type O O
enhancer O O
with O O
a O O
variant O O
mutant O O
in O O
its O O
seven O O
Ets O O
sites O O
leads O O
to O O
20 O O
- O O
fold O O
reduction O O
of O O
Cebpa O O
mRNA O O
in O O
the O O
32Dcl3 B-CellLine B-CellLine
myeloid I-CellLine I-CellLine
cell I-CellLine I-CellLine
line I-CellLine I-CellLine
. O O

To O O
determine O O
the O O
effect O O
of O O
deleting O O
the O O
enhancer O O
in O O
vivo O O
, O O
we O O
now O O
characterize O O
C57BL O O
/ O O
6 O O
mice O O
in O O
which O O
loxP O O
sites O O
flank O O
a O O
688 O O
bp O O
DNA O O
segment O O
containing O O
the O O
enhancer O O
. O O

CMV O O
- O O
Cre O O
mediated O O
germline O O
deletion O O
resulted O O
in O O
diminution O O
of O O
the O O
expected O O
number O O
of O O
viable O O
Enh O O
( O O
f O O
/ O O
f O O
) O O
; O O
CMV O O
- O O
Cre O O
offspring O O
, O O
with O O
28 O O
- O O
fold O O
reduction O O
in O O
marrow B-CellLine O
Cebpa O O
mRNA O O
but O O
normal O O
levels O O
in O O
liver B-CellLine B-CellLine
, O O
lung B-CellLine B-CellLine
, O O
adipose B-CellLine B-CellLine
, O O
intestine B-CellLine B-CellLine
, O O
muscle B-CellLine B-CellLine
, O O
and O O
kidney B-CellLine B-CellLine
. O O

Cre O O
- O O
transduction O O
of O O
lineage O B-CellLine
- O I-CellLine
negative O I-CellLine
marrow B-CellLine I-CellLine
cells I-CellLine I-CellLine
in O O
vitro O O
reduced O O
Cebpa O O
mRNA O O
12 O O
- O O
fold O O
, O O
with O O
impairment O O
of O O
granulocytic O B-CellLine
maturation O O
, O O
morphologic O O
blast O O
accumulation O O
, O O
and O O
IL O O
- O O
3 O O
dependent O O
myeloid B-CellLine O
colony O O
replating O O
for O O
> O O
12 O O
generations O O
. O O

Exposure O O
of O O
Enh O O
( O O
f O O
/ O O
f O O
) O O
; O O
Mx1 O O
- O O
Cre O O
mice O O
to O O
pIpC O O
led O O
to O O
14 O O
- O O
fold O O
reduction O O
of O O
Cebpa O O
mRNA O O
in O O
GMP O O
or O O
CMP O O
, O O
30 O O
- O O
fold O O
reduction O O
in O O
LSK O B-CellLine
, O O
and O O
< O O
2 O O
- O O
fold O O
reduction O O
in O O
the O O
LSK O O
/ O O
SLAM O O
subset O O
. O O

FACS O O
analysis O O
of O O
marrow B-CellLine O
from O O
these O O
mice O O
revealed O O
10 O O
- O O
fold O O
reduced O O
neutrophils O B-CellLine
, O O
3 O O
- O O
fold O O
decreased O O
GMP O O
, O O
and O O
3 O O
- O O
fold O O
increased O O
LSK O B-CellLine
cells O I-CellLine
. O O

Progenitor O O
cell O O
cycle O O
progression O O
was O O
mildly O O
impaired O O
. O O
Granulocyte B-CellLine B-CellLine
and O O
B B-CellLine B-CellLine
lymphoid I-CellLine I-CellLine
colony O I-CellLine
forming O I-CellLine
units O I-CellLine
were O O
reduced O O
while O O
monocytic B-CellLine B-CellLine
and O O
erythroid B-CellLine B-CellLine
colonies I-CellLine I-CellLine
were O O
increased O O
, O O
with O O
reduced O O
Pu O O
. O O
1 O O
and O O
Gfi1 O O
and O O
increased O O
Egr1 O O
and O O
Klf4 O O
in O O
GMP O O
. O O

Finally O O
, O O
competitive O O
transplantation O O
indicated O O
preservation O O
of O O
functional O O
long O O
- O O
term O O
hematopoietic B-CellLine B-CellLine
stem I-CellLine I-CellLine
cells I-CellLine I-CellLine
upon O O
enhancer O O
deletion O O
and O O
confirmed O O
marrow B-CellLine O
- O O
intrinsic O O
impairment O O
of O O
granulopoiesis O O
and O O
B B-CellLine B-CellLine
cell I-CellLine I-CellLine
generation O O
with O O
LSK O B-CellLine
and O O
monocyte B-CellLine B-CellLine
lineage I-CellLine I-CellLine
expansion O O
. O O

These O O
findings O O
demonstrate O O
a O O
critical O O
role O O
for O O
the O O
+ O O
37 O O
kb O O
Cebpa O O
enhancer O O
for O O
hematopoietic O B-CellLine
- O O
specific O O
Cebpa O O
expression O O
, O O
with O O
enhancer O O
deletion O O
leading O O
to O O
impaired O O
myelopoiesis O O
and O O
potentially O O
preleukemic O B-CellLine
progenitor O I-CellLine
expansion O O
. O O
These O O
findings O O
demonstrate O O
a O O
critical O O
role O O
for O O
the O O
+ O O
37 O O
kb O O
Cebpa O O
enhancer O O
for O O
hematopoietic O B-CellLine
- O O
specific O O
Cebpa O O
expression O O
, O O
with O O
enhancer O O
deletion O O
leading O O
to O O
impaired O O
myelopoiesis O O
and O O
potentially O O
preleukemic O B-CellLine
progenitor O I-CellLine
expansion O O
. O O

Identification O O
of O O
a O O
novel O O
distal O O
regulatory O O
element O O
of O O
the O O
human O O
Neuroglobin O O
gene O O
by O O
the O O
chromosome O O
conformation O O
capture O O
approach O O
. O O
Neuroglobin O O
( O O
NGB O O
) O O
is O O
predominantly O O
expressed O O
in O O
the O O
brain B-CellLine B-CellLine
and O O
retina B-CellLine B-CellLine
. O O

Studies O O
suggest O O
that O O
NGB O O
exerts O O
protective O O
effects O O
to O O
neuronal B-CellLine B-CellLine
cells I-CellLine I-CellLine
and O O
is O O
implicated O O
in O O
reducing O O
the O O
severity O O
of O O
stroke O O
and O O
Alzheimer O O
' O O
s O O
disease O O
. O O

However O O
, O O
little O O
is O O
known O O
about O O
the O O
mechanisms O O
which O O
regulate O O
the O O
cell O O
type O O
- O O
specific O O
expression O O
of O O
the O O
gene O O
. O O

In O O
this O O
study O O
, O O
we O O
hypothesized O O
that O O
distal O O
regulatory O O
elements O O
( O O
DREs O O
) O O
are O O
involved O O
in O O
optimal O O
expression O O
of O O
the O O
NGB O O
gene O O
. O O

By O O
chromosome O O
conformation O O
capture O O
we O O
identified O O
two O O
novel O O
DREs O O
located O O
- O O
70 O O
kb O O
upstream O O
and O O
+ O O
100 O O
kb O O
downstream O O
from O O
the O O
NGB O O
gene O O
. O O

ENCODE O O
database O O
showed O O
the O O
presence O O
of O O
DNaseI O O
hypersensitive O O
and O O
transcription O O
factors O O
binding O O
sites O O
in O O
these O O
regions O O
. O O

Further O O
analyses O O
using O O
luciferase O O
reporters O O
and O O
chromatin O O
immunoprecipitation O O
suggested O O
that O O
the O O
- O O
70 O O
kb O O
region O O
upstream O O
of O O
the O O
NGB O O
gene O O
contained O O
a O O
neuronal O O
- O O
specific O O
enhancer O O
and O O
GATA O O
transcription O O
factor O O
binding O O
sites O O
. O O

Knockdown O O
of O O
GATA O O
- O O
2 O O
caused O O
NGB O O
expression O O
to O O
drop O O
dramatically O O
, O O
indicating O O
GATA O O
- O O
2 O O
as O O
an O O
essential O O
transcription O O
factor O O
for O O
the O O
activation O O
of O O
NGB O O
expression O O
. O O

The O O
crucial O O
role O O
of O O
the O O
DRE O O
in O O
NGB O O
expression O O
activation O O
was O O
further O O
confirmed O O
by O O
the O O
drop O O
in O O
NGB O O
level O O
after O O
CRISPR O O
- O O
mediated O O
deletion O O
of O O
the O O
DRE O O
. O O

Taken O O
together O O
, O O
we O O
show O O
that O O
the O O
NGB O O
gene O O
is O O
regulated O O
by O O
a O O
cell O O
type O O
- O O
specific O O
loop O O
formed O O
between O O
its O O
promoter O O
and O O
the O O
novel O O
DRE O O
. O O

A O O
Novel O O
Regulatory O O
Mechanism O O
of O O
Type O O
II O O
Collagen O O
Expression O O
via O O
a O O
SOX9 O O
- O O
dependent O O
Enhancer O O
in O O
Intron O O
6 O O
. O O
A O O
Novel O O
Regulatory O O
Mechanism O O
of O O
Type O O
II O O
Collagen O O
Expression O O
via O O
a O O
SOX9 O O
- O O
dependent O O
Enhancer O O
in O O
Intron O O
6 O O
. O O

Type O O
II O O
collagen O O
alpha1 O O
is O O
specific O O
for O O
cartilaginous O O
tissues O O
, O O
and O O
mutations O O
in O O
its O O
gene O O
are O O
associated O O
with O O
skeletal O O
diseases O O
. O O

Its O O
expression O O
has O O
been O O
shown O O
to O O
be O O
dependent O O
on O O
SOX9 O O
, O O
a O O
master O O
transcription O O
factor O O
required O O
for O O
chondrogenesis O O
that O O
binds O O
to O O
an O O
enhancer O O
region O O
in O O
intron O O
1 O O
. O O

However O O
, O O
ChIP O O
sequencing O O
revealed O O
that O O
SOX9 O O
does O O
not O O
strongly O O
bind O O
to O O
intron O O
1 O O
, O O
but O O
rather O O
it O O
binds O O
to O O
intron O O
6 O O
and O O
a O O
site O O
30 O O
kb O O
upstream O O
of O O
the O O
transcription O O
start O O
site O O
. O O

Here O O
, O O
we O O
aimed O O
to O O
determine O O
the O O
role O O
of O O
the O O
novel O O
SOX9 O O
- O O
binding O O
site O O
in O O
intron O O
6 O O
. O O
Here O O
, O O
we O O
aimed O O
to O O
determine O O
the O O
role O O
of O O
the O O
novel O O
SOX9 O O
- O O
binding O O
site O O
in O O
intron O O
6 O O
. O O

We O O
prepared O O
reporter O O
constructs O O
that O O
contain O O
a O O
Col2a1 O O
promoter O O
, O O
intron O O
1 O O
with O O
or O O
without O O
intron O O
6 O O
, O O
and O O
the O O
luciferase O O
gene O O
. O O
We O O
prepared O O
reporter O O
constructs O O
that O O
contain O O
a O O
Col2a1 O O
promoter O O
, O O
intron O O
1 O O
with O O
or O O
without O O
intron O O
6 O O
, O O
and O O
the O O
luciferase O O
gene O O
. O O

Although O O
the O O
reporter O O
constructs O O
were O O
not O O
activated O O
by O O
SOX9 O O
alone O O
, O O
the O O
construct O O
that O O
contained O O
both O O
introns O O
1 O O
and O O
6 O O
was O O
activated O O
5 O O
- O O
10 O O
- O O
fold O O
by O O
the O O
SOX9 O O
/ O O
SOX5 O O
or O O
the O O
SOX9 O O
/ O O
SOX6 O O
combination O O
in O O
transient O O
- O O
transfection O O
assays O O
in O O
293T B-CellLine B-CellLine
cells I-CellLine I-CellLine
. O O

This O O
enhancement O O
was O O
also O O
observed O O
in O O
rat O O
chondrosarcoma B-CellLine B-CellLine
cells I-CellLine I-CellLine
that O O
stably O O
expressed O O
the O O
construct O O
. O O

CRISPR O O
/ O O
Cas9 O O
- O O
induced O O
deletion O O
of O O
intron O O
6 O O
in O O
RCS B-CellLine B-CellLine
cells O I-CellLine
revealed O O
that O O
a O O
10 O O
- O O
bp O O
region O O
of O O
intron O O
6 O O
is O O
necessary O O
both O O
for O O
Col2a1 O O
expression O O
and O O
SOX9 O O
binding O O
. O O

Furthermore O O
, O O
SOX9 O O
, O O
but O O
not O O
SOX5 O O
, O O
binds O O
to O O
this O O
region O O
as O O
demonstrated O O
in O O
an O O
electrophoretic O O
mobility O O
shift O O
assay O O
, O O
although O O
both O O
SOX9 O O
and O O
SOX5 O O
bind O O
to O O
a O O
larger O O
325 O O
- O O
bp O O
fragment O O
of O O
intron O O
6 O O
containing O O
this O O
small O O
sequence O O
. O O

These O O
findings O O
suggest O O
a O O
novel O O
mechanism O O
of O O
action O O
of O O
SOX5 O O
/ O O
6 O O
; O O
namely O O
, O O
the O O
SOX9 O O
/ O O
5 O O
/ O O
6 O O
combination O O
enhances O O
Col2a1 O O
transcription O O
through O O
a O O
novel O O
enhancer O O
in O O
intron O O
6 O O
together O O
with O O
the O O
enhancer O O
in O O
intron O O
1 O O
. O O

Renal O O
Anemia O O
Model O O
Mouse O O
Established O O
by O O
Transgenic O O
Rescue O O
with O O
an O O
Erythropoietin O O
Gene O O
Lacking O O
Kidney B-CellLine B-CellLine
- O O
Specific O O
Regulatory O O
Elements O O
. O O

The O O
erythropoietin O O
( O O
Epo O O
) O O
gene O O
is O O
under O O
tissue O O
- O O
specific O O
inducible O O
regulation O O
. O O

Because O O
the O O
kidney B-CellLine B-CellLine
is O O
the O O
primary O O
EPO O O
- O O
producing O O
tissue O O
in O O
adults O O
, O O
impaired O O
EPO O O
production O O
in O O
chronic O O
kidney O O
disorders O O
results O O
in O O
serious O O
renal O O
anemia O O
. O O

The O O
Epo O O
gene O O
contains O O
a O O
liver B-CellLine B-CellLine
- O O
specific O O
enhancer O O
in O O
the O O
3 O O
' O O
region O O
, O O
but O O
the O O
kidney B-CellLine B-CellLine
- O O
specific O O
enhancer O O
for O O
gene O O
expression O O
in O O
renal B-CellLine B-CellLine
EPO I-CellLine I-CellLine
- I-CellLine I-CellLine
producing I-CellLine I-CellLine
( I-CellLine I-CellLine
REP I-CellLine I-CellLine
) I-CellLine I-CellLine
cells I-CellLine I-CellLine
remains O O
elusive O O
. O O
The O O
Epo O O
gene O O
contains O O
a O O
liver B-CellLine B-CellLine
- O O
specific O O
enhancer O O
in O O
the O O
3 O O
' O O
region O O
, O O
but O O
the O O
kidney B-CellLine B-CellLine
- O O
specific O O
enhancer O O
for O O
gene O O
expression O O
in O O
renal B-CellLine B-CellLine
EPO I-CellLine I-CellLine
- I-CellLine I-CellLine
producing I-CellLine I-CellLine
( I-CellLine I-CellLine
REP I-CellLine I-CellLine
) I-CellLine I-CellLine
cells I-CellLine I-CellLine
remains O O
elusive O O
. O O

Here O O
, O O
we O O
examined O O
a O O
conserved O O
upstream O O
element O O
for O O
renal O O
Epo O O
regulation O O
( O O
CURE O O
) O O
region O O
that O O
spans O O
17 O O
. O O
4 O O
kb O O
to O O
3 O O
. O O
6 O O
kb O O
upstream O O
of O O
the O O
Epo O O
gene O O
and O O
harbors O O
several O O
phylogenetically O O
conserved O O
elements O O
. O O

We O O
prepared O O
various O O
Epo O O
gene O O
- O O
reporter O O
constructs O O
utilizing O O
a O O
bacterial O O
artificial O O
chromosome O O
and O O
generated O O
a O O
number O O
of O O
transgenic O O
- O O
mouse O O
lines O O
. O O

We O O
observed O O
that O O
deletion O O
of O O
the O O
CURE O O
region O O
( O O
deltaCURE O O
) O O
abrogated O O
Epo O O
gene O O
expression O O
in O O
REP B-CellLine B-CellLine
cells I-CellLine I-CellLine
. O O

Although O O
transgenic O O
expression O O
of O O
the O O
deltaCURE O O
construct O O
rescued O O
Epo O O
- O O
deficient O O
mice O O
from O O
embryonic O O
lethality O O
, O O
the O O
rescued O O
mice O O
had O O
severe O O
EPO O O
- O O
dependent O O
anemia O O
. O O

These O O
mouse O O
lines O O
serve O O
as O O
an O O
elaborate O O
model O O
for O O
the O O
search O O
for O O
erythroid B-CellLine B-CellLine
stimulatory O O
activity O O
and O O
are O O
referred O O
to O O
as O O
AnRED O O
( O O
anemic O O
model O O
with O O
renal O O
EPO O O
deficiency O O
) O O
mice O O
. O O

We O O
also O O
dissected O O
the O O
CURE O O
region O O
by O O
exploiting O O
a O O
minigene O O
harboring O O
four O O
phylogenetically O O
conserved O O
elements O O
in O O
reporter O O
transgenic O O
- O O
mouse O O
analyses O O
. O O

Our O O
analyses O O
revealed O O
that O O
Epo O O
gene O O
regulation O O
in O O
REP B-CellLine B-CellLine
cells I-CellLine I-CellLine
is O O
a O O
complex O O
process O O
that O O
utilizes O O
multiple O O
regulatory O O
influences O O
. O O

Mapping O O
cell O O
type O O
- O O
specific O O
transcriptional O O
enhancers O O
using O O
high O O
affinity O O
, O O
lineage O O
- O O
specific O O
Ep300 O O
bioChIP O O
- O O
seq O O
. O O

Understanding O O
the O O
mechanisms O O
that O O
regulate O O
cell O O
type O O
- O O
specific O O
transcriptional O O
programs O O
requires O O
developing O O
a O O
lexicon O O
of O O
their O O
genomic O O
regulatory O O
elements O O
. O O

We O O
developed O O
a O O
lineage O O
- O O
selective O O
method O O
to O O
map O O
transcriptional O O
enhancers O O
, O O
regulatory O O
genomic O O
regions O O
that O O
activate O O
transcription O O
, O O
in O O
mice O O
. O O

Since O O
most O O
tissue O O
- O O
specific O O
enhancers O O
are O O
bound O O
by O O
the O O
transcriptional O O
co O O
- O O
activator O O
Ep300 O O
, O O
we O O
used O O
Cre O O
- O O
directed O O
, O O
lineage O O
- O O
specific O O
Ep300 O O
biotinylation O O
and O O
pulldown O O
on O O
immobilized O O
streptavidin O O
followed O O
by O O
next O O
generation O O
sequencing O O
of O O
co O O
- O O
precipitated O O
DNA O O
to O O
identify O O
lineage O O
- O O
specific O O
enhancers O O
. O O

By O O
driving O O
this O O
system O O
with O O
lineage O O
- O O
specific O O
Cre O O
transgenes O O
, O O
we O O
mapped O O
enhancers O O
active O O
in O O
embryonic B-CellLine B-CellLine
endothelial I-CellLine I-CellLine
cells I-CellLine I-CellLine
/ O O
blood B-CellLine B-CellLine
or O O
skeletal B-CellLine B-CellLine
muscle I-CellLine I-CellLine
. O O

Analysis O O
of O O
these O O
enhancers O O
identified O O
new O O
transcription O O
factor O O
heterodimer O O
motifs O O
that O O
likely O O
regulate O O
transcription O O
in O O
these O O
lineages O O
. O O

Furthermore O O
, O O
we O O
identified O O
candidate O O
enhancers O O
that O O
regulate O O
adult O O
heart B-CellLine B-CellLine
- O O
or O O
lung B-CellLine B-CellLine
- O O
specific O O
endothelial B-CellLine B-CellLine
cell I-CellLine I-CellLine
specialization O O
. O O

Our O O
strategy O O
for O O
tissue O O
- O O
specific O O
protein O O
biotinylation O O
opens O O
new O O
avenues O O
for O O
studying O O
lineage O O
- O O
specific O O
protein O O
- O O
DNA O O
and O O
protein O O
- O O
protein O O
interactions O O
. O O

Identification O O
and O O
characterization O O
of O O
variants O O
and O O
a O O
novel O O
4 O O
bp O O
deletion O O
in O O
the O O
regulatory O O
region O O
of O O
SIX6 O O
, O O
a O O
risk O O
factor O O
for O O
primary O O
open O O
- O O
angle O O
glaucoma O O
. O O

BACKGROUND O O
: O O
Primary O O
open O O
- O O
angle O O
glaucoma O O
( O O
POAG O O
) O O
is O O
a O O
complex O O
disease O O
of O O
multigenic O O
inheritance O O
and O O
the O O
most O O
common O O
subtype O O
of O O
glaucoma O O
. O O
SIX6 O O
encodes O O
a O O
transcription O O
factor O O
involved O O
in O O
retina B-CellLine B-CellLine
, O O
optic B-CellLine B-CellLine
nerve I-CellLine I-CellLine
, O O
and O O
pituitary B-CellLine B-CellLine
development O O
. O O

Previous O O
studies O O
showed O O
a O O
genetic O O
association O O
between O O
the O O
SIX6 O O
locus O O
and O O
POAG O O
, O O
identifying O O
risk O O
alleles O O
. O O

Whether O O
these O O
alleles O O
are O O
present O O
also O O
in O O
the O O
south O O
Indian O O
population O O
is O O
unclear O O
. O O

METHODS O O
: O O
To O O
address O O
this O O
question O O
, O O
the O O
SIX6 O O
gene O O
and O O
an O O
already O O
characterized O O
and O O
highly O O
conserved O O
SIX6 O O
enhancer O O
( O O
Ch14 O O
: O O
60974427 O O
- O O
60974430 O O
) O O
were O O
sequenced O O
in O O
two O O
south O O
Indian O O
cohorts O O
, O O
respectively O O
, O O
composed O O
of O O
65 O O
/ O O
65 O O
and O O
200 O O
/ O O
200 O O
POAG O O
cases O O
/ O O
age O O
- O O
matched O O
controls O O
. O O
METHODS O O
: O O
To O O
address O O
this O O
question O O
, O O
the O O
SIX6 O O
gene O O
and O O
an O O
already O O
characterized O O
and O O
highly O O
conserved O O
SIX6 O O
enhancer O O
( O O
Ch14 O O
: O O
60974427 O O
- O O
60974430 O O
) O O
were O O
sequenced O O
in O O
two O O
south O O
Indian O O
cohorts O O
, O O
respectively O O
, O O
composed O O
of O O
65 O O
/ O O
65 O O
and O O
200 O O
/ O O
200 O O
POAG O O
cases O O
/ O O
age O O
- O O
matched O O
controls O O
. O O

We O O
next O O
used O O
Taqman O O
- O O
based O O
allelic O O
discrimination O O
assay O O
to O O
genotype O O
a O O
common O O
variant O O
( O O
rs33912345 O O
: O O
c O O
. O O
421A O O
> O O
C O O
) O O
and O O
the O O
rs1048372 O O
SNP O O
in O O
two O O
cohorts O O
, O O
respectively O O
, O O
composed O O
of O O
557 O O
/ O O
387 O O
and O O
590 O O
/ O O
448 O O
POAG O O
cases O O
/ O O
age O O
- O O
matched O O
controls O O
. O O

An O O
additional O O
cohort O O
of O O
153 O O
POAG O O
cases O O
was O O
subsequently O O
recruited O O
to O O
assess O O
the O O
association O O
of O O
the O O
rs33912345 O O
: O O
c O O
. O O
421A O O
> O O
C O O
and O O
rs10483727 O O
variants O O
with O O
more O O
prominent O O
changes O O
in O O
two O O
POAG O O
diagnostic O O
parameters O O
: O O
retinal B-CellLine B-CellLine
nerve I-CellLine I-CellLine
fiber I-CellLine I-CellLine
layer I-CellLine O
thickness O O
and O O
vertical O O
cup B-CellLine O
/ O O
disc B-CellLine O
ratio O O
, O O
using O O
spectral O O
domain O O
optical O O
coherence O O
tomography O O
. O O

The O O
activity O O
of O O
the O O
newly O O
identified O O
enhancer O O
variants O O
was O O
assessed O O
by O O
transgenesis O O
in O O
zebrafish O O
and O O
luciferase O O
assays O O
. O O

RESULTS O O
: O O
We O O
identified O O
two O O
known O O
rare O O
and O O
two O O
common O O
variants O O
in O O
the O O
SIX6 O O
locus O O
and O O
a O O
novel O O
4 O O
bp O O
deletion O O
in O O
the O O
analyzed O O
enhancer O O
. O O

Contrary O O
to O O
previous O O
studies O O
, O O
we O O
could O O
not O O
establish O O
a O O
significant O O
association O O
between O O
the O O
rs10483727 O O
and O O
rs33912345 O O
: O O
c O O
. O O
421A O O
> O O
C O O
variants O O
and O O
PAOG O O
in O O
the O O
south O O
Indian O O
ethnicity O O
but O O
patients O O
carrying O O
the O O
corresponding O O
C O O
or O O
T O O
risk O O
alleles O O
exhibited O O
a O O
dose O O
- O O
dependent O O
reduction O O
of O O
the O O
thickness O O
of O O
the O O
retinal B-CellLine B-CellLine
nerve I-CellLine I-CellLine
fiber I-CellLine I-CellLine
layer I-CellLine O
and O O
a O O
significant O O
increase O O
in O O
the O O
vertical O O
cup B-CellLine O
/ O O
disc B-CellLine O
ratio O O
. O O

Transgenesis O O
in O O
zebrafish O O
and O O
luciferase O O
assays O O
demonstrated O O
that O O
the O O
newly O O
identified O O
4 O O
bp O O
deletion O O
significantly O O
reduced O O
reporter O O
expression O O
in O O
cells O O
of O O
the O O
retinal B-CellLine O
ganglion I-CellLine B-CellLine
and O O
amacrine B-CellLine B-CellLine
layers I-CellLine I-CellLine
, O O
where O O
human O O
SIX6 O O
is O O
expressed O O
. O O

CONCLUSION O O
: O O
Altogether O O
, O O
our O O
data O O
further O O
support O O
the O O
implication O O
of O O
SIX6 O O
variants O O
as O O
POAG O O
risk O O
factors O O
and O O
implicates O O
SIX6 O O
haploinsufficiency O O
in O O
POAG O O
pathogenesis O O
. O O

NFATc2 O O
enhances O O
tumor O O
- O O
initiating O O
phenotypes O O
through O O
the O O
NFATc2 O O
/ O O
SOX2 O O
/ O O
ALDH O O
axis O O
in O O
lung O O
adenocarcinoma O O
. O O
Tumor B-CellLine B-CellLine
- I-CellLine I-CellLine
initiating I-CellLine I-CellLine
cells I-CellLine I-CellLine
( O O
TIC B-CellLine B-CellLine
) O O
are O O
dynamic O O
cancer B-CellLine B-CellLine
cell I-CellLine I-CellLine
subsets O O
that O O
display O O
enhanced O O
tumor O O
functions O O
and O O
resilience O O
to O O
treatment O O
but O O
the O O
mechanism O O
of O O
TIC B-CellLine O
induction O O
or O O
maintenance O O
in O O
lung O O
cancer O O
is O O
not O O
fully O O
understood O O
. O O

In O O
this O O
study O O
, O O
we O O
show O O
the O O
calcium O O
pathway O O
transcription O O
factor O O
NFATc2 O O
is O O
a O O
novel O O
regulator O O
of O O
lung B-CellLine B-CellLine
TIC I-CellLine I-CellLine
phenotypes O O
, O O
including O O
tumorspheres O O
, O O
cell O O
motility O O
, O O
tumorigenesis O O
, O O
as O O
well O O
as O O
in O O
vitro O O
and O O
in O O
vivo O O
responses O O
to O O
chemotherapy O O
and O O
targeted O O
therapy O O
. O O

In O O
human O O
lung O O
cancers O O
, O O
high O O
NFATc2 O O
expression O O
predicted O O
poor O O
tumor O O
differentiation O O
, O O
adverse O O
recurrence O O
- O O
free O O
and O O
cancer O O
- O O
specific O O
overall O O
survivals O O
. O O

Mechanistic O O
investigations O O
identified O O
NFATc2 O O
response O O
elements O O
in O O
the O O
3 O O
' O O
enhancer O O
region O O
of O O
SOX2 O O
, O O
and O O
NFATc2 O O
/ O O
SOX2 O O
coupling O O
upregulates O O
ALDH1A1 O O
by O O
binding O O
to O O
its O O
5 O O
' O O
enhancer O O
. O O
Mechanistic O O
investigations O O
identified O O
NFATc2 O O
response O O
elements O O
in O O
the O O
3 O O
' O O
enhancer O O
region O O
of O O
SOX2 O O
, O O
and O O
NFATc2 O O
/ O O
SOX2 O O
coupling O O
upregulates O O
ALDH1A1 O O
by O O
binding O O
to O O
its O O
5 O O
' O O
enhancer O O
. O O

Through O O
this O O
axis O O
, O O
oxidative O O
stress O O
induced O O
by O O
cancer O O
drug O O
treatment O O
is O O
attenuated O O
, O O
leading O O
to O O
increased O O
resistance O O
in O O
a O O
mutation O O
- O O
independent O O
manner O O
. O O

Targeting O O
this O O
axis O O
provides O O
a O O
novel O O
approach O O
for O O
the O O
long O O
- O O
term O O
treatment O O
of O O
lung O O
cancer O O
through O O
TIC B-CellLine O
elimination O O
. O O

A O O
lipodystrophy O O
- O O
causing O O
lamin O O
A O O
mutant O O
alters O O
conformation O O
and O O
epigenetic O O
regulation O O
of O O
the O O
anti O O
- O O
adipogenic O O
MIR335 O O
locus O O
. O O

Mutations O O
in O O
the O O
Lamin O O
A O O
/ O O
C O O
( O O
LMNA O O
) O O
gene O O
- O O
encoding O O
nuclear O O
LMNA O O
cause O O
laminopathies O O
, O O
which O O
include O O
partial O O
lipodystrophies O O
associated O O
with O O
metabolic O O
syndromes O O
. O O

The O O
lipodystrophy O O
- O O
associated O O
LMNA O O
p O O
. O O
R482W O O
mutation O O
is O O
known O O
to O O
impair O O
adipogenic O O
differentiation O O
, O O
but O O
the O O
mechanisms O O
involved O O
are O O
unclear O O
. O O

We O O
show O O
in O O
this O O
study O O
that O O
the O O
lamin O O
A O O
p O O
. O O
R482W O O
hot O O
spot O O
mutation O O
prevents O O
adipogenic O O
gene O O
expression O O
by O O
epigenetically O O
deregulating O O
long O O
- O O
range O O
enhancers O O
of O O
the O O
anti O O
- O O
adipogenic O O
MIR335 O O
microRNA O O
gene O O
in O O
human O O
adipocyte B-CellLine B-CellLine
progenitor I-CellLine I-CellLine
cells I-CellLine I-CellLine
. O O
We O O
show O O
in O O
this O O
study O O
that O O
the O O
lamin O O
A O O
p O O
. O O
R482W O O
hot O O
spot O O
mutation O O
prevents O O
adipogenic O O
gene O O
expression O O
by O O
epigenetically O O
deregulating O O
long O O
- O O
range O O
enhancers O O
of O O
the O O
anti O O
- O O
adipogenic O O
MIR335 O O
microRNA O O
gene O O
in O O
human O O
adipocyte B-CellLine B-CellLine
progenitor I-CellLine I-CellLine
cells I-CellLine I-CellLine
. O O

The O O
R482W O O
mutation O O
results O O
in O O
a O O
loss O O
of O O
function O O
of O O
differentiation O O
- O O
dependent O O
lamin O O
A O O
binding O O
to O O
the O O
MIR335 O O
locus O O
. O O

This O O
impairs O O
H3K27 O O
methylation O O
and O O
instead O O
favors O O
H3K27 O O
acetylation O O
on O O
MIR335 O O
enhancers O O
. O O
This O O
impairs O O
H3K27 O O
methylation O O
and O O
instead O O
favors O O
H3K27 O O
acetylation O O
on O O
MIR335 O O
enhancers O O
. O O

The O O
lamin O O
A O O
mutation O O
further O O
promotes O O
spatial O O
clustering O O
of O O
MIR335 O O
enhancer O O
and O O
promoter O O
elements O O
along O O
with O O
overexpression O O
of O O
the O O
MIR355 O O
gene O O
after O O
adipogenic O O
induction O O
. O O
The O O
lamin O O
A O O
mutation O O
further O O
promotes O O
spatial O O
clustering O O
of O O
MIR335 O O
enhancer O O
and O O
promoter O O
elements O O
along O O
with O O
overexpression O O
of O O
the O O
MIR355 O O
gene O O
after O O
adipogenic O O
induction O O
. O O

Our O O
results O O
link O O
a O O
laminopathy O O
- O O
causing O O
lamin O O
A O O
mutation O O
to O O
an O O
unsuspected O O
deregulation O O
of O O
chromatin O O
states O O
and O O
spatial O O
conformation O O
of O O
an O O
miRNA O O
locus O O
critical O O
for O O
adipose B-CellLine B-CellLine
progenitor I-CellLine I-CellLine
cell I-CellLine I-CellLine
fate O O
. O O

A O O
novel O O
HER2 O O
gene O O
body O O
enhancer O O
contributes O O
to O O
HER2 O O
expression O O
. O O
A O O
novel O O
HER2 O O
gene O O
body O O
enhancer O O
contributes O O
to O O
HER2 O O
expression O O
. O O

The O O
transcriptional O O
regulation O O
of O O
the O O
human O O
epidermal O O
growth O O
factor O O
receptor O O
- O O
2 O O
( O O
HER2 O O
) O O
contributes O O
to O O
an O O
enhanced O O
HER2 O O
expression O O
in O O
HER2 O O
- O O
positive O O
breast O O
cancers O O
with O O
HER2 O O
gene O O
amplification O O
and O O
HER2 O O
- O O
low O O
or O O
HER2 O O
- O O
negative O O
breast O O
cancers O O
following O O
radiotherapy O O
or O O
endocrine O O
therapy O O
, O O
and O O
this O O
drives O O
tumorigenesis O O
and O O
the O O
resistance O O
to O O
therapy O O
. O O

Epigenetic O O
mechanisms O O
are O O
critical O O
for O O
transcription O O
regulation O O
, O O
however O O
, O O
such O O
mechanisms O O
in O O
the O O
transcription O O
regulation O O
of O O
HER2 O O
are O O
limited O O
to O O
the O O
involvement O O
of O O
tri O O
- O O
methylated O O
histone O O
3 O O
lysine O O
4 O O
( O O
H3K4me3 O O
) O O
and O O
acetylated O O
histone O O
3 O O
lysine O O
9 O O
( O O
H3K9ac O O
) O O
at O O
the O O
HER2 O O
promoter O O
region O O
. O O
Epigenetic O O
mechanisms O O
are O O
critical O O
for O O
transcription O O
regulation O O
, O O
however O O
, O O
such O O
mechanisms O O
in O O
the O O
transcription O O
regulation O O
of O O
HER2 O O
are O O
limited O O
to O O
the O O
involvement O O
of O O
tri O O
- O O
methylated O O
histone O O
3 O O
lysine O O
4 O O
( O O
H3K4me3 O O
) O O
and O O
acetylated O O
histone O O
3 O O
lysine O O
9 O O
( O O
H3K9ac O O
) O O
at O O
the O O
HER2 O O
promoter O O
region O O
. O O

Here O O
, O O
we O O
report O O
the O O
identification O O
of O O
a O O
novel O O
enhancer O O
in O O
the O O
HER2 O O
3 O O
' O O
gene O O
body O O
, O O
which O O
we O O
have O O
termed O O
HER2 O O
gene O O
body O O
enhancer O O
( O O
HGE O O
) O O
. O O
Here O O
, O O
we O O
report O O
the O O
identification O O
of O O
a O O
novel O O
enhancer O O
in O O
the O O
HER2 O O
3 O O
' O O
gene O O
body O O
, O O
which O O
we O O
have O O
termed O O
HER2 O O
gene O O
body O O
enhancer O O
( O O
HGE O O
) O O
. O O

The O O
HGE O O
starts O O
from O O
the O O
3 O O
' O O
end O O
of O O
intron O O
19 O O
and O O
extends O O
into O O
intron O O
22 O O
, O O
possesses O O
enhancer O O
histone O O
modification O O
marks O O
in O O
specific O O
cells O O
and O O
enhances O O
the O O
transcriptional O O
activity O O
of O O
the O O
HER2 O O
promoters O O
. O O

We O O
also O O
found O O
that O O
TFAP2C O O
, O O
a O O
known O O
regulator O O
of O O
HER2 O O
, O O
binds O O
to O O
HGE O O
and O O
is O O
required O O
for O O
its O O
enhancer O O
function O O
and O O
that O O
DNA O O
methylation O O
in O O
the O O
HGE O O
region O O
inhibits O O
the O O
histone O O
modifications O O
characterizing O O
enhancer O O
and O O
is O O
inversely O O
correlated O O
with O O
HER2 O O
expression O O
in O O
breast O O
cancer O O
samples O O
. O O

The O O
identification O O
of O O
this O O
novel O O
enhancer O O
sheds O O
a O O
light O O
on O O
the O O
roles O O
of O O
epigenetic O O
mechanisms O O
in O O
HER2 O O
transcription O O
, O O
in O O
both O O
HER2 O O
- O O
positive O O
breast O O
cancer O O
samples O O
and O O
individuals O O
with O O
HER2 O O
- O O
low O O
or O O
HER2 O O
- O O
negative O O
breast O O
cancers O O
undergoing O O
radiotherapy O O
or O O
endocrine O O
therapy O O
. O O

STAT5 O O
- O O
mediated O O
chromatin O O
interactions O O
in O O
superenhancers O O
activate O O
IL O O
- O O
2 O O
highly O O
inducible O O
genes O O
: O O
Functional O O
dissection O O
of O O
the O O
Il2ra O O
gene O O
locus O O
. O O

Cytokines O O
critically O O
control O O
immune O O
responses O O
, O O
but O O
how O O
regulatory O O
programs O O
are O O
altered O O
to O O
allow O O
T B-CellLine B-CellLine
cells I-CellLine I-CellLine
to O O
differentially O O
respond O O
to O O
distinct O O
cytokine O O
stimuli O O
remains O O
poorly O O
understood O O
. O O

Here O O
, O O
we O O
have O O
globally O O
analyzed O O
enhancer O O
elements O O
bound O O
by O O
IL O O
- O O
2 O O
- O O
activated O O
STAT5 O O
and O O
IL O O
- O O
21 O O
- O O
activated O O
STAT3 O O
in O O
T B-CellLine B-CellLine
cells I-CellLine I-CellLine
and O O
identified O O
Il2ra O O
as O O
the O O
top O O
- O O
ranked O O
gene O O
regulated O O
by O O
an O O
IL O O
- O O
2 O O
- O O
activated O O
STAT5 O O
- O O
bound O O
superenhancer O O
and O O
one O O
of O O
the O O
top O O
genes O O
regulated O O
by O O
STAT3 O O
- O O
bound O O
superenhancers O O
. O O
Here O O
, O O
we O O
have O O
globally O O
analyzed O O
enhancer O O
elements O O
bound O O
by O O
IL O O
- O O
2 O O
- O O
activated O O
STAT5 O O
and O O
IL O O
- O O
21 O O
- O O
activated O O
STAT3 O O
in O O
T B-CellLine B-CellLine
cells I-CellLine I-CellLine
and O O
identified O O
Il2ra O O
as O O
the O O
top O O
- O O
ranked O O
gene O O
regulated O O
by O O
an O O
IL O O
- O O
2 O O
- O O
activated O O
STAT5 O O
- O O
bound O O
superenhancer O O
and O O
one O O
of O O
the O O
top O O
genes O O
regulated O O
by O O
STAT3 O O
- O O
bound O O
superenhancers O O
. O O

Moreover O O
, O O
we O O
found O O
that O O
STAT5 O O
binding O O
was O O
rapidly O O
superenriched O O
at O O
genes O O
highly O O
induced O O
by O O
IL O O
- O O
2 O O
and O O
that O O
IL O O
- O O
2 O O
- O O
activated O O
STAT5 O O
binding O O
induces O O
new O O
and O O
augmented O O
chromatin O O
interactions O O
within O O
superenhancer O O
- O O
containing O O
genes O O
. O O

Based O O
on O O
chromatin O O
interaction O O
analysis O O
by O O
paired O O
- O O
end O O
tag O O
( O O
ChIA O O
- O O
PET O O
) O O
sequencing O O
data O O
, O O
we O O
used O O
CRISPR O O
- O O
Cas9 O O
gene O O
editing O O
to O O
target O O
three O O
of O O
the O O
STAT5 O O
binding O O
sites O O
within O O
the O O
Il2ra O O
superenhancer O O
in O O
mice O O
. O O
Based O O
on O O
chromatin O O
interaction O O
analysis O O
by O O
paired O O
- O O
end O O
tag O O
( O O
ChIA O O
- O O
PET O O
) O O
sequencing O O
data O O
, O O
we O O
used O O
CRISPR O O
- O O
Cas9 O O
gene O O
editing O O
to O O
target O O
three O O
of O O
the O O
STAT5 O O
binding O O
sites O O
within O O
the O O
Il2ra O O
superenhancer O O
in O O
mice O O
. O O

Each O O
mutation O O
decreased O O
STAT5 O O
binding O O
and O O
altered O O
IL O O
- O O
2 O O
- O O
induced O O
Il2ra O O
gene O O
expression O O
, O O
revealing O O
that O O
individual O O
elements O O
within O O
the O O
superenhancer O O
were O O
not O O
functionally O O
redundant O O
and O O
that O O
all O O
were O O
required O O
for O O
normal O O
gene O O
expression O O
. O O

Thus O O
, O O
we O O
demonstrate O O
cooperative O O
utilization O O
of O O
superenhancer O O
elements O O
to O O
optimize O O
gene O O
expression O O
and O O
show O O
that O O
STAT5 O O
mediates O O
IL O O
- O O
2 O O
- O O
induced O O
chromatin O O
looping O O
at O O
superenhancers O O
to O O
preferentially O O
regulate O O
highly O O
inducible O O
genes O O
, O O
thereby O O
providing O O
new O O
insights O O
into O O
the O O
mechanisms O O
underlying O O
cytokine O O
- O O
dependent O O
superenhancer O O
function O O
. O O

Low O O
- O O
Grade O O
Astrocytoma O O
Mutations O O
in O O
IDH1 O O
, O O
P53 O O
, O O
and O O
ATRX O O
Cooperate O O
to O O
Block O O
Differentiation O O
of O O
Human O B-CellLine
Neural B-CellLine I-CellLine
Stem I-CellLine I-CellLine
Cells I-CellLine I-CellLine
via O O
Repression O O
of O O
SOX2 O O
. O O
Low O O
- O O
grade O O
astrocytomas O O
( O O
LGAs O O
) O O
carry O O
neomorphic O O
mutations O O
in O O
isocitrate O O
dehydrogenase O O
( O O
IDH O O
) O O
concurrently O O
with O O
P53 O O
and O O
ATRX O O
loss O O
. O O

To O O
model O O
LGA O O
formation O O
, O O
we O O
introduced O O
R132H O O
IDH1 O O
, O O
P53 O O
shRNA O O
, O O
and O O
ATRX O O
shRNA O O
into O O
human O B-CellLine
neural B-CellLine I-CellLine
stem I-CellLine I-CellLine
cells I-CellLine I-CellLine
( O O
NSCs B-CellLine B-CellLine
) O O
. O O

These O O
oncogenic O O
hits O O
blocked O O
NSC B-CellLine B-CellLine
differentiation O O
, O O
increased O O
invasiveness O O
in O O
vivo O O
, O O
and O O
led O O
to O O
a O O
DNA O O
methylation O O
and O O
transcriptional O O
profile O O
resembling O O
IDH1 O O
mutant O O
human O O
LGAs O O
. O O

The O O
differentiation O O
block O O
was O O
caused O O
by O O
transcriptional O O
silencing O O
of O O
the O O
transcription O O
factor O O
SOX2 O O
secondary O O
to O O
disassociation O O
of O O
its O O
promoter O O
from O O
a O O
putative O O
enhancer O O
. O O

This O O
occurred O O
because O O
of O O
reduced O O
binding O O
of O O
the O O
chromatin O O
organizer O O
CTCF O O
to O O
its O O
DNA O O
motifs O O
and O O
disrupted O O
chromatin O O
looping O O
. O O

Our O O
human O O
model O O
of O O
IDH O O
mutant O O
LGA O O
formation O O
implicates O O
impaired O O
NSC B-CellLine B-CellLine
differentiation O O
because O O
of O O
repression O O
of O O
SOX2 O O
as O O
an O O
early O O
driver O O
of O O
gliomagenesis O O
. O O

Functional O O
assessment O O
of O O
human O O
enhancer O O
activities O O
using O O
whole O O
- O O
genome O O
STARR O O
- O O
sequencing O O
. O O

BACKGROUND O O
: O O
Genome O O
- O O
wide O O
quantification O O
of O O
enhancer O O
activity O O
in O O
the O O
human O O
genome O O
has O O
proven O O
to O O
be O O
a O O
challenging O O
problem O O
. O O

Recent O O
efforts O O
have O O
led O O
to O O
the O O
development O O
of O O
powerful O O
tools O O
for O O
enhancer O O
quantification O O
. O O

However O O
, O O
because O O
of O O
genome O O
size O O
and O O
complexity O O
, O O
these O O
tools O O
have O O
yet O O
to O O
be O O
applied O O
to O O
the O O
whole O O
human O O
genome O O
. O O

RESULTS O O
: O O
In O O
the O O
current O O
study O O
, O O
we O O
use O O
a O O
human O O
prostate B-CellLine B-CellLine
cancer I-CellLine I-CellLine
cell I-CellLine I-CellLine
line I-CellLine I-CellLine
, O O
LNCaP B-CellLine B-CellLine
as O O
a O O
model O O
to O O
perform O O
whole O O
human O O
genome O O
STARR O O
- O O
seq O O
( O O
WHG O O
- O O
STARR O O
- O O
seq O O
) O O
to O O
reliably O O
obtain O O
an O O
assessment O O
of O O
enhancer O O
activity O O
. O O

This O O
approach O O
builds O O
upon O O
previously O O
developed O O
STARR O O
- O O
seq O O
in O O
the O O
fly O O
genome O O
and O O
CapSTARR O O
- O O
seq O O
techniques O O
in O O
targeted O O
human O O
genomic O O
regions O O
. O O

With O O
an O O
improved O O
library O O
preparation O O
strategy O O
, O O
our O O
approach O O
greatly O O
increases O O
the O O
library O O
complexity O O
per O O
unit O O
of O O
starting O O
material O O
, O O
which O O
makes O O
it O O
feasible O O
and O O
cost O O
- O O
effective O O
to O O
explore O O
the O O
landscape O O
of O O
regulatory O O
activity O O
in O O
the O O
much O O
larger O O
human O O
genome O O
. O O

In O O
addition O O
to O O
our O O
ability O O
to O O
identify O O
active O O
, O O
accessible O O
enhancers O O
located O O
in O O
open O O
chromatin O O
regions O O
, O O
we O O
can O O
also O O
detect O O
sequences O O
with O O
the O O
potential O O
for O O
enhancer O O
activity O O
that O O
are O O
located O O
in O O
inaccessible O O
, O O
closed O O
chromatin O O
regions O O
. O O

When O O
treated O O
with O O
the O O
histone O O
deacetylase O O
inhibitor O O
, O O
Trichostatin O O
A O O
, O O
genes O O
nearby O O
this O O
latter O O
class O O
of O O
enhancers O O
are O O
up O O
- O O
regulated O O
, O O
demonstrating O O
the O O
potential O O
for O O
endogenous O O
functionality O O
of O O
these O O
regulatory O O
elements O O
. O O

CONCLUSION O O
: O O
WHG O O
- O O
STARR O O
- O O
seq O O
provides O O
an O O
improved O O
approach O O
to O O
current O O
pipelines O O
for O O
analysis O O
of O O
high O O
complexity O O
genomes O O
to O O
gain O O
a O O
better O O
understanding O O
of O O
the O O
intricacies O O
of O O
transcriptional O O
regulation O O
. O O

Genomic O O
dissection O O
of O O
enhancers O O
uncovers O O
principles O O
of O O
combinatorial O O
regulation O O
and O O
cell O O
type O O
- O O
specific O O
wiring O O
of O O
enhancer O O
- O O
promoter O O
contacts O O
. O O

Genomic O O
binding O O
of O O
transcription O O
factors O O
, O O
like O O
the O O
glucocorticoid O O
receptor O O
( O O
GR O O
) O O
, O O
is O O
linked O O
to O O
the O O
regulation O O
of O O
genes O O
. O O

However O O
, O O
as O O
we O O
show O O
here O O
, O O
GR O O
binding O O
is O O
a O O
poor O O
predictor O O
of O O
GR O O
- O O
dependent O O
gene O O
regulation O O
even O O
when O O
taking O O
the O O
3D O O
organization O O
of O O
the O O
genome O O
into O O
account O O
. O O

To O O
connect O O
GR O O
binding O O
sites O O
to O O
the O O
regulation O O
of O O
genes O O
in O O
the O O
endogenous O O
genomic O O
context O O
, O O
we O O
turned O O
to O O
genome O O
editing O O
. O O
To O O
connect O O
GR O O
binding O O
sites O O
to O O
the O O
regulation O O
of O O
genes O O
in O O
the O O
endogenous O O
genomic O O
context O O
, O O
we O O
turned O O
to O O
genome O O
editing O O
. O O

By O O
deleting O O
GR O O
binding O O
sites O O
, O O
individually O O
or O O
in O O
combination O O
, O O
we O O
uncovered O O
how O O
cooperative O O
interactions O O
between O O
binding O O
sites O O
contribute O O
to O O
the O O
regulation O O
of O O
genes O O
. O O
By O O
deleting O O
GR O O
binding O O
sites O O
, O O
individually O O
or O O
in O O
combination O O
, O O
we O O
uncovered O O
how O O
cooperative O O
interactions O O
between O O
binding O O
sites O O
contribute O O
to O O
the O O
regulation O O
of O O
genes O O
. O O

Specifically O O
, O O
for O O
the O O
GR O O
target O O
gene O O
GILZ O O
, O O
we O O
show O O
that O O
the O O
simultaneous O O
presence O O
of O O
a O O
cluster O O
of O O
GR O O
binding O O
sites O O
is O O
required O O
for O O
the O O
activity O O
of O O
an O O
individual O O
enhancer O O
and O O
that O O
the O O
GR O O
- O O
dependent O O
regulation O O
of O O
GILZ O O
depends O O
on O O
multiple O O
GR O O
- O O
bound O O
enhancers O O
. O O
Specifically O O
, O O
for O O
the O O
GR O O
target O O
gene O O
GILZ O O
, O O
we O O
show O O
that O O
the O O
simultaneous O O
presence O O
of O O
a O O
cluster O O
of O O
GR O O
binding O O
sites O O
is O O
required O O
for O O
the O O
activity O O
of O O
an O O
individual O O
enhancer O O
and O O
that O O
the O O
GR O O
- O O
dependent O O
regulation O O
of O O
GILZ O O
depends O O
on O O
multiple O O
GR O O
- O O
bound O O
enhancers O O
. O O

Further O O
, O O
by O O
deleting O O
GR O O
binding O O
sites O O
that O O
are O O
shared O O
between O O
different O O
cell O O
types O O
, O O
we O O
show O O
how O O
cell O O
type O O
- O O
specific O O
genome O O
organization O O
and O O
enhancer O O
- O O
blocking O O
can O O
result O O
in O O
cell O O
type O O
- O O
specific O O
wiring O O
of O O
promoter O O
- O O
enhancer O O
contacts O O
. O O
Further O O
, O O
by O O
deleting O O
GR O O
binding O O
sites O O
that O O
are O O
shared O O
between O O
different O O
cell O O
types O O
, O O
we O O
show O O
how O O
cell O O
type O O
- O O
specific O O
genome O O
organization O O
and O O
enhancer O O
- O O
blocking O O
can O O
result O O
in O O
cell O O
type O O
- O O
specific O O
wiring O O
of O O
promoter O O
- O O
enhancer O O
contacts O O
. O O

This O O
rewiring O O
allows O O
an O O
individual O O
GR O O
binding O O
site O O
shared O O
between O O
different O O
cell O O
types O O
to O O
direct O O
the O O
expression O O
of O O
distinct O O
transcripts O O
and O O
thereby O O
contributes O O
to O O
the O O
cell O O
type O O
- O O
specific O O
consequences O O
of O O
glucocorticoid O O
signaling O O
. O O
This O O
rewiring O O
allows O O
an O O
individual O O
GR O O
binding O O
site O O
shared O O
between O O
different O O
cell O O
types O O
to O O
direct O O
the O O
expression O O
of O O
distinct O O
transcripts O O
and O O
thereby O O
contributes O O
to O O
the O O
cell O O
type O O
- O O
specific O O
consequences O O
of O O
glucocorticoid O O
signaling O O
. O O

Selective O O
dissociation O O
between O O
LSD1 O O
and O O
GFI1B O O
by O O
a O O
LSD1 O O
inhibitor O O
NCD38 O O
induces O O
the O O
activation O O
of O O
ERG O O
super O O
- O O
enhancer O O
in O O
erythroleukemia B-CellLine B-CellLine
cells I-CellLine I-CellLine
. O O
Lysine O O
- O O
specific O O
demethylase O O
1 O O
( O O
LSD1 O O
) O O
is O O
a O O
histone O O
modifier O O
for O O
transcriptional O O
repression O O
involved O O
in O O
the O O
regulation O O
of O O
hematopoiesis O O
. O O
Selective O O
dissociation O O
between O O
LSD1 O O
and O O
GFI1B O O
by O O
a O O
LSD1 O O
inhibitor O O
NCD38 O O
induces O O
the O O
activation O O
of O O
ERG O O
super O O
- O O
enhancer O O
in O O
erythroleukemia B-CellLine B-CellLine
cells I-CellLine I-CellLine
. O O
Lysine O O
- O O
specific O O
demethylase O O
1 O O
( O O
LSD1 O O
) O O
is O O
a O O
histone O O
modifier O O
for O O
transcriptional O O
repression O O
involved O O
in O O
the O O
regulation O O
of O O
hematopoiesis O O
. O O

We O O
previously O O
reported O O
that O O
a O O
LSD1 O O
inhibitor O O
NCD38 O O
induces O O
transdifferentiation O O
from O O
erythroid B-CellLine B-CellLine
lineage I-CellLine I-CellLine
to O O
granulomonocytic B-CellLine B-CellLine
lineage I-CellLine I-CellLine
and O O
exerts O O
anti O O
- O O
leukemia O O
effect O O
through O O
de O O
- O O
repression O O
of O O
the O O
specific O O
super O O
- O O
enhancers O O
of O O
hematopoietic O B-CellLine
regulators O O
including O O
ERG O O
in O O
a O O
human B-CellLine B-CellLine
erythroleukemia I-CellLine I-CellLine
cell I-CellLine I-CellLine
line I-CellLine I-CellLine
, O O
HEL B-CellLine B-CellLine
. O O

However O O
, O O
the O O
mechanistic O O
basis O O
for O O
this O O
specificity O O
of O O
NCD38 O O
has O O
remained O O
unclear O O
. O O

Herein O O
, O O
we O O
report O O
major O O
partners O O
associated O O
with O O
LSD1 O O
and O O
clarify O O
the O O
mechanism O O
in O O
HEL B-CellLine B-CellLine
cells I-CellLine I-CellLine
. O O

Proteome O O
analysis O O
identified O O
54 O O
candidate O O
proteins O O
associated O O
with O O
LSD1 O O
, O O
including O O
several O O
transcription O O
factors O O
such O O
as O O
GFI1B O O
and O O
RUNX1 O O
as O O
well O O
as O O
BRAF O O
- O O
histone O O
deacetylase O O
complex O O
( O O
BHC O O
) O O
components O O
such O O
as O O
CoREST O O
, O O
HDAC1 O O
, O O
and O O
HDAC2 O O
. O O

NCD38 O O
selectively O O
disrupted O O
the O O
interaction O O
of O O
LSD1 O O
with O O
GFI1B O O
but O O
not O O
with O O
RUNX1 O O
, O O
CoREST O O
, O O
HDAC1 O O
and O O
HDAC2 O O
. O O
Erg O O
was O O
downregulated O O
in O O
murine O O
erythroid B-CellLine B-CellLine
progenitors I-CellLine I-CellLine
with O O
prominent O O
upregulation O O
of O O
Gfi1b O O
. O O

NCD38 O O
induced O O
ERG O O
and O O
attenuated O O
an O O
erythroid B-CellLine B-CellLine
marker O O
CD235a O O
in O O
HEL B-CellLine B-CellLine
while O O
this O O
attenuation O O
was O O
mimicked O O
by O O
the O O
lentiviral O O
overexpression O O
of O O
ERG O O
. O O

The O O
ERG O O
super O O
- O O
enhancer O O
contained O O
the O O
conserved O O
binding O O
motif O O
of O O
GFI1B O O
and O O
was O O
actually O O
occupied O O
by O O
GFI1B O O
. O O
The O O
ERG O O
super O O
- O O
enhancer O O
contained O O
the O O
conserved O O
binding O O
motif O O
of O O
GFI1B O O
and O O
was O O
actually O O
occupied O O
by O O
GFI1B O O
. O O

NCD38 O O
dissociated O O
LSD1 O O
and O O
CoREST O O
but O O
not O O
GFI1B O O
from O O
the O O
ERG O O
super O O
- O O
enhancer O O
. O O
NCD38 O O
dissociated O O
LSD1 O O
and O O
CoREST O O
but O O
not O O
GFI1B O O
from O O
the O O
ERG O O
super O O
- O O
enhancer O O
. O O

Collectively O O
, O O
the O O
selective O O
separation O O
of O O
LSD1 O O
from O O
GFI1B O O
by O O
NCD38 O O
restores O O
the O O
ERG O O
super O O
- O O
enhancer O O
activation O O
and O O
consequently O O
upregulates O O
ERG O O
expression O O
, O O
inducing O O
the O O
transdifferentiation O O
linked O O
to O O
the O O
anti O O
- O O
leukemia O O
effect O O
. O O
Collectively O O
, O O
the O O
selective O O
separation O O
of O O
LSD1 O O
from O O
GFI1B O O
by O O
NCD38 O O
restores O O
the O O
ERG O O
super O O
- O O
enhancer O O
activation O O
and O O
consequently O O
upregulates O O
ERG O O
expression O O
, O O
inducing O O
the O O
transdifferentiation O O
linked O O
to O O
the O O
anti O O
- O O
leukemia O O
effect O O
. O O

SP8 O O
and O O
SP9 O O
coordinately O O
promote O O
D2 O O
- O O
type O O
medium B-CellLine O
spiny I-CellLine O
neuron I-CellLine B-CellLine
production O O
by O O
activating O O
Six3 O O
expression O O
. O O

Dopamine O O
receptor O O
DRD1 O O
- O O
expressing O O
medium B-CellLine B-CellLine
spiny I-CellLine I-CellLine
neurons I-CellLine I-CellLine
( O O
D1 O B-CellLine
MSNs B-CellLine I-CellLine
) O O
and O O
dopamine O O
receptor O O
DRD2 O O
- O O
expressing O O
medium O B-CellLine
spiny O I-CellLine
neurons O I-CellLine
( O O
D2 O B-CellLine
MSNs B-CellLine I-CellLine
) O O
are O O
the O O
principal O O
projection O B-CellLine
neurons B-CellLine I-CellLine
in O O
the O O
striatum B-CellLine B-CellLine
, O O
which O O
is O O
divided O O
into O O
dorsal B-CellLine B-CellLine
striatum I-CellLine I-CellLine
( O O
caudate B-CellLine B-CellLine
nucleus I-CellLine I-CellLine
and O O
putamen B-CellLine B-CellLine
) O O
and O O
ventral B-CellLine B-CellLine
striatum I-CellLine I-CellLine
( O O
nucleus B-CellLine B-CellLine
accumbens I-CellLine I-CellLine
and O O
olfactory B-CellLine B-CellLine
tubercle I-CellLine I-CellLine
) O O
. O O

Progenitors O O
of O O
these O O
neurons B-CellLine B-CellLine
arise O O
in O O
the O O
lateral B-CellLine B-CellLine
ganglionic I-CellLine I-CellLine
eminence I-CellLine I-CellLine
( O O
LGE B-CellLine B-CellLine
) O O
. O O

Using O O
conditional O O
deletion O O
, O O
we O O
show O O
that O O
mice O O
lacking O O
the O O
transcription O O
factor O O
genes O O
Sp8 O O
and O O
Sp9 O O
lose O O
virtually O O
all O O
D2 O B-CellLine
MSNs B-CellLine I-CellLine
as O O
a O O
result O O
of O O
reduced O O
neurogenesis O O
in O O
the O O
LGE B-CellLine B-CellLine
, O O
whereas O O
D1 O O
MSNs B-CellLine O
are O O
largely O O
unaffected O O
. O O
SP8 O O
and O O
SP9 O O
together O O
drive O O
expression O O
of O O
the O O
transcription O O
factor O O
Six3 O O
in O O
a O O
spatially O O
restricted O O
domain O O
of O O
the O O
LGE B-CellLine B-CellLine
subventricular O I-CellLine
zone O I-CellLine
. O O

Conditional O O
deletion O O
of O O
Six3 O O
also O O
prevents O O
the O O
formation O O
of O O
most O O
D2 O O
MSNs B-CellLine O
, O O
phenocopying O O
the O O
Sp8 O O
/ O O
9 O O
mutants O O
. O O

Finally O O
, O O
ChIP O O
- O O
Seq O O
reveals O O
that O O
SP9 O O
directly O O
binds O O
to O O
the O O
promoter O O
and O O
a O O
putative O O
enhancer O O
of O O
Six3 O O
Thus O O
, O O
this O O
study O O
defines O O
components O O
of O O
a O O
transcription O O
pathway O O
in O O
a O O
regionally O O
restricted O O
LGE B-CellLine O
progenitor O O
domain O O
that O O
selectively O O
drives O O
the O O
generation O O
of O O
D2 O O
MSNs B-CellLine B-CellLine
. O O
Finally O O
, O O
ChIP O O
- O O
Seq O O
reveals O O
that O O
SP9 O O
directly O O
binds O O
to O O
the O O
promoter O O
and O O
a O O
putative O O
enhancer O O
of O O
Six3 O O
Thus O O
, O O
this O O
study O O
defines O O
components O O
of O O
a O O
transcription O O
pathway O O
in O O
a O O
regionally O O
restricted O O
LGE B-CellLine B-CellLine
progenitor O O
domain O O
that O O
selectively O O
drives O O
the O O
generation O O
of O O
D2 O B-CellLine
MSNs B-CellLine I-CellLine
. O O

Identification O O
of O O
a O O
Novel O O
Enhancer O O
/ O O
Chromatin O O
Opening O O
Element O O
Associated O O
with O O
High O O
- O O
Level O O
gamma O O
- O O
Globin O O
Gene O O
Expression O O
. O O

The O O
organization O O
of O O
the O O
five O O
beta O O
- O O
type O O
globin O O
genes O O
on O O
chromosome O O
11 O O
reflects O O
the O O
timing O O
of O O
expression O O
during O O
erythroid B-CellLine B-CellLine
cell I-CellLine I-CellLine
development O O
, O O
with O O
the O O
embryonic O O
epsilon O O
- O O
globin O O
gene O O
being O O
located O O
at O O
the O O
5 O O
' O O
end O O
, O O
followed O O
by O O
the O O
two O O
fetal O O
gamma O O
- O O
globin O O
genes O O
, O O
and O O
with O O
the O O
adult O O
beta O O
- O O
and O O
delta O O
- O O
globin O O
genes O O
being O O
located O O
at O O
the O O
3 O O
' O O
end O O
. O O

Here O O
, O O
we O O
functionally O O
characterized O O
a O O
DNase O O
I O O
- O O
hypersensitive O O
site O O
( O O
HS O O
) O O
located O O
4 O O
kb O O
upstream O O
of O O
the O O
Ggamma O O
- O O
globin O O
gene O O
( O O
HBG O O
- O O
4kb O O
HS O O
) O O
. O O
Here O O
, O O
we O O
functionally O O
characterized O O
a O O
DNase O O
I O O
- O O
hypersensitive O O
site O O
( O O
HS O O
) O O
located O O
4 O O
kb O O
upstream O O
of O O
the O O
Ggamma O O
- O O
globin O O
gene O O
( O O
HBG O O
- O O
4kb O O
HS O O
) O O
. O O

This O O
site O O
is O O
occupied O O
by O O
transcription O O
factors O O
USF1 O O
, O O
USF2 O O
, O O
EGR1 O O
, O O
MafK O O
, O O
and O O
NF O O
- O O
E2 O O
in O O
the O O
human B-CellLine O
erythroleukemia I-CellLine B-CellLine
cell I-CellLine I-CellLine
line I-CellLine I-CellLine
K562 I-CellLine I-CellLine
and O O
exhibits O O
histone O O
modifications O O
typical O O
for O O
enhancers O O
. O O

We O O
generated O O
a O O
synthetic O O
zinc O O
finger O O
( O O
ZF O O
) O O
DNA O O
- O O
binding O O
domain O O
targeting O O
the O O
HBG O O
- O O
4kb O O
HS O O
( O O
HBG O O
- O O
4kb O O
ZF O O
) O O
. O O

The O O
HBG O O
- O O
4kb O O
ZF O O
interacted O O
with O O
the O O
target O O
site O O
in O O
vitro O O
and O O
in O O
the O O
context O O
of O O
cells O O
with O O
a O O
high O O
affinity O O
and O O
specificity O O
. O O

Direct O O
delivery O O
of O O
the O O
HBG O O
- O O
4kb O O
ZF O O
to O O
K562 B-CellLine B-CellLine
and O O
primary O O
human O O
erythroid B-CellLine B-CellLine
cells I-CellLine I-CellLine
caused O O
a O O
reduction O O
in O O
gamma O O
- O O
globin O O
gene O O
expression O O
which O O
was O O
associated O O
with O O
decreased O O
binding O O
of O O
transcription O O
factors O O
and O O
active O O
histone O O
marks O O
at O O
and O O
downstream O O
of O O
the O O
HS O O
. O O

The O O
data O O
demonstrate O O
that O O
the O O
HBG O O
- O O
4kb O O
HS O O
is O O
important O O
for O O
fetal O O
globin O O
production O O
and O O
suggest O O
that O O
it O O
may O O
act O O
by O O
opening O O
chromatin O O
in O O
a O O
directional O O
manner O O
. O O

Functional O O
CRISPR O O
screen O O
identifies O O
AP1 O O
- O O
associated O O
enhancer O O
regulating O O
FOXF1 O O
to O O
modulate O O
oncogene O O
- O O
induced O O
senescence O O
. O O
Functional O O
CRISPR O O
screen O O
identifies O O
AP1 O O
- O O
associated O O
enhancer O O
regulating O O
FOXF1 O O
to O O
modulate O O
oncogene O O
- O O
induced O O
senescence O O
. O O

BACKGROUND O O
: O O
Functional O O
characterization O O
of O O
non O O
- O O
coding O O
elements O O
in O O
the O O
human O O
genome O O
is O O
a O O
major O O
genomic O O
challenge O O
and O O
the O O
maturation O O
of O O
genome O O
- O O
editing O O
technologies O O
is O O
revolutionizing O O
our O O
ability O O
to O O
achieve O O
this O O
task O O
. O O

Oncogene O O
- O O
induced O O
senescence O O
, O O
a O O
cellular O O
state O O
of O O
irreversible O O
proliferation O O
arrest O O
that O O
is O O
enforced O O
following O O
excessive O O
oncogenic O O
activity O O
, O O
is O O
a O O
major O O
barrier O O
against O O
cancer O O
transformation O O
; O O
therefore O O
, O O
bypassing O O
oncogene O O
- O O
induced O O
senescence O O
is O O
a O O
critical O O
step O O
in O O
tumorigenesis O O
. O O

Here O O
, O O
we O O
aim O O
at O O
further O O
identification O O
of O O
enhancer O O
elements O O
that O O
are O O
required O O
for O O
the O O
establishment O O
of O O
this O O
state O O
. O O

RESULTS O O
: O O
We O O
first O O
apply O O
genome O O
- O O
wide O O
profiling O O
of O O
enhancer O O
- O O
RNAs O O
( O O
eRNAs O O
) O O
to O O
systematically O O
identify O O
enhancers O O
that O O
are O O
activated O O
upon O O
oncogenic O O
stress O O
. O O

DNA O O
motif O O
analysis O O
of O O
these O O
enhancers O O
indicates O O
AP O O
- O O
1 O O
as O O
a O O
major O O
regulator O O
of O O
the O O
transcriptional O O
program O O
induced O O
by O O
oncogene O O
- O O
induced O O
senescence O O
. O O

We O O
thus O O
constructed O O
a O O
CRISPR O O
- O O
Cas9 O O
sgRNA O O
library O O
designed O O
to O O
target O O
senescence O O
- O O
induced O O
enhancers O O
that O O
are O O
putatively O O
regulated O O
by O O
AP O O
- O O
1 O O
and O O
used O O
it O O
in O O
a O O
functional O O
screen O O
. O O

We O O
identify O O
a O O
critical O O
enhancer O O
that O O
we O O
name O O
EnhAP1 O O
- O O
OIS1 O O
and O O
validate O O
that O O
mutating O O
the O O
AP O O
- O O
1 O O
binding O O
site O O
within O O
this O O
element O O
results O O
in O O
oncogene O O
- O O
induced O O
senescence O O
bypass O O
. O O
We O O
identify O O
a O O
critical O O
enhancer O O
that O O
we O O
name O O
EnhAP1 O O
- O O
OIS1 O O
and O O
validate O O
that O O
mutating O O
the O O
AP O O
- O O
1 O O
binding O O
site O O
within O O
this O O
element O O
results O O
in O O
oncogene O O
- O O
induced O O
senescence O O
bypass O O
. O O

Furthermore O O
, O O
we O O
identify O O
FOXF1 O O
as O O
the O O
gene O O
regulated O O
by O O
this O O
enhancer O O
and O O
demonstrate O O
that O O
FOXF1 O O
mediates O O
EnhAP1 O O
- O O
OIS1 O O
effect O O
on O O
the O O
senescence O O
phenotype O O
. O O

CONCLUSIONS O O
: O O
Our O O
study O O
elucidates O O
a O O
novel O O
cascade O O
mediated O O
by O O
AP O O
- O O
1 O O
and O O
FOXF1 O O
that O O
regulates O O
oncogene O O
- O O
induced O O
senescence O O
and O O
further O O
demonstrates O O
the O O
power O O
of O O
CRISPR O O
- O O
based O O
functional O O
genomic O O
screens O O
in O O
deciphering O O
the O O
function O O
of O O
non O O
- O O
coding O O
regulatory O O
elements O O
in O O
the O O
genome O O
. O O

STAT5 O O
- O O
Driven O O
Enhancers O O
Tightly O O
Control O O
Temporal O O
Expression O O
of O O
Mammary O O
- O O
Specific O O
Genes O O
. O O
STAT5 O O
- O O
Driven O O
Enhancers O O
Tightly O O
Control O O
Temporal O O
Expression O O
of O O
Mammary O O
- O O
Specific O O
Genes O O
. O O

The O O
de O O
novo O O
formation O O
of O O
milk O O
- O O
secreting O O
mammary B-CellLine B-CellLine
epithelium I-CellLine I-CellLine
during O O
pregnancy O O
is O O
regulated O O
by O O
prolactin O O
through O O
activation O O
of O O
the O O
transcription O O
factor O O
STAT5 O O
, O O
which O O
stimulates O O
the O O
expression O O
of O O
several O O
hundred O O
mammary O O
- O O
specific O O
genes O O
. O O

In O O
addition O O
to O O
its O O
key O O
role O O
in O O
activating O O
gene O O
expression O O
in O O
mammary O O
tissue O O
, O O
STAT5 O O
, O O
which O O
is O O
ubiquitously O O
expressed O O
in O O
most O O
cell O O
types O O
, O O
implements O O
T B-CellLine B-CellLine
cell I-CellLine I-CellLine
- O O
specific O O
programs O O
controlled O O
by O O
interleukins O O
. O O

However O O
, O O
the O O
mechanisms O O
by O O
which O O
STAT5 O O
controls O O
cell O O
- O O
specific O O
genetic O O
programs O O
activated O O
by O O
distinct O O
cytokines O O
remain O O
relatively O O
unknown O O
. O O

Integration O O
of O O
data O O
from O O
genome O O
- O O
wide O O
surveys O O
of O O
chromatin O O
markers O O
and O O
transcription O O
factor O O
binding O O
at O O
regulatory O O
elements O O
may O O
shed O O
light O O
on O O
the O O
mechanisms O O
that O O
drive O O
cell O O
- O O
specific O O
programs O O
. O O

Here O O
, O O
we O O
have O O
illustrated O O
how O O
STAT5 O O
controls O O
cell O O
- O O
specific O O
gene O O
expression O O
through O O
its O O
concentration O O
and O O
an O O
auto O O
- O O
regulatory O O
enhancer O O
supporting O O
its O O
high O O
levels O O
in O O
mammary O O
tissue O O
. O O

The O O
unique O O
genomic O O
features O O
of O O
STAT5 O O
- O O
driven O O
enhancers O O
or O O
super O O
- O O
enhancers O O
that O O
regulate O O
mammary O O
- O O
specific O O
genes O O
and O O
their O O
dynamic O O
remodeling O O
in O O
response O O
to O O
pregnancy O O
hormone O O
levels O O
are O O
described O O
. O O
The O O
unique O O
genomic O O
features O O
of O O
STAT5 O O
- O O
driven O O
enhancers O O
or O O
super O O
- O O
enhancers O O
that O O
regulate O O
mammary O O
- O O
specific O O
genes O O
and O O
their O O
dynamic O O
remodeling O O
in O O
response O O
to O O
pregnancy O O
hormone O O
levels O O
are O O
described O O
. O O

We O O
have O O
further O O
provided O O
biological O O
evidence O O
supporting O O
the O O
in O O
vivo O O
function O O
of O O
a O O
STAT5 O O
- O O
driven O O
super O O
- O O
enhancer O O
with O O
the O O
aid O O
of O O
CRISPR O O
/ O O
Cas9 O O
genome O O
editing O O
. O O
We O O
have O O
further O O
provided O O
biological O O
evidence O O
supporting O O
the O O
in O O
vivo O O
function O O
of O O
a O O
STAT5 O O
- O O
driven O O
super O O
- O O
enhancer O O
with O O
the O O
aid O O
of O O
CRISPR O O
/ O O
Cas9 O O
genome O O
editing O O
. O O

Finally O O
, O O
we O O
discuss O O
how O O
the O O
functions O O
of O O
mammary O O
- O O
specific O O
super O O
- O O
enhancers O O
are O O
confined O O
by O O
the O O
zinc O O
finger O O
protein O O
, O O
CTCF O O
, O O
to O O
allow O O
exclusive O O
activation O O
of O O
mammary O O
- O O
specific O O
genes O O
without O O
affecting O O
common O O
neighboring O O
genes O O
. O O

This O O
review O O
comprehensively O O
summarizes O O
the O O
molecular O O
pathways O O
underlying O O
differential O O
control O O
of O O
cell O O
- O O
specific O O
gene O O
sets O O
by O O
STAT5 O O
and O O
provides O O
novel O O
insights O O
into O O
STAT5 O O
- O O
dependent O O
mammary O O
physiology O O
. O O

